

EVER 2014 NICE

Science for Sight

PROGRAMME BOOK

October 1-4


www.ever.be



EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH

21 CME credits

TARGETING THE MEDIATORS OF INFLAMMATION¹



Delivering efficacy in the clinical setting²⁻⁵

Ozurdex[®]
(dexamethasone intravitreal
implant) 0.7mg

These images are for illustrative purposes only and do not represent inflammatory mediator levels in the eye.

OZURDEX[®] (Dexamethasone 700 micrograms intravitreal implant in applicator)

Abbreviated Prescribing Information

Presentation: Intravitreal implant in applicator. One implant contains 700 micrograms of dexamethasone. Disposable injection device, containing a rod-shaped implant which is not visible. The implant is approximately 0.46 mm in diameter and 6 mm in length. **Indications:** Treatment of adult patients with macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). Treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis. **Dosage and Administration:** Please refer to the Summary of Product Characteristics before prescribing for full information. OZURDEX must be administered by a qualified ophthalmologist experienced in intravitreal injections. The recommended dose is one OZURDEX implant to be administered intravitreally to the affected eye. Administration to both eyes concurrently is not recommended. Repeat doses should be considered when a patient experiences a response to treatment followed subsequently by a loss in visual acuity and in the physician's opinion may benefit from retreatment without being exposed to significant risk. Patients who experience and retain improved vision should not be retreated. Patients who experience a deterioration in vision, which is not slowed by OZURDEX, should not be retreated. There is only very limited information on repeat dosing intervals less than 6 months. There is currently no experience of repeat administrations in posterior segment non-infectious uveitis or beyond 2 implants in Retinal Vein Occlusion. Patients should be monitored following the injection to permit early treatment if an infection or increased intraocular pressure occurs. Single-use intravitreal implant in applicator for intravitreal use only. The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). The patient should be instructed to self-administer broad spectrum antimicrobial drops daily for 3 days before and after each injection. Before the injection, the periorbital skin, eyelid and ocular surface should be disinfected and adequate local anaesthesia should be administered. Remove the foil pouch from the carton and examine for damage. In a sterile field, open the foil pouch and gently place the applicator on a sterile tray. Carefully remove the cap from the applicator. Once the foil pouch is opened the applicator should be used immediately. Hold the applicator in one hand and pull the safety tab straight off the applicator. Do not twist or flex the tab. With the bevel of the needle up away

from the sclera, advance the needle about 1 mm into the sclera then redirect toward the centre of the eye into the vitreous cavity until the silicone sleeve is against the conjunctiva. Slowly press the actuator button until an audible click is noted. Before withdrawing the applicator from the eye, make sure that the actuator button is fully pressed and has locked flush with the applicator surface. Remove the needle in the same direction as used to enter the vitreous. Immediately after injecting OZURDEX, use indirect ophthalmoscopy in the quadrant of injection to confirm successful implantation. Visualisation is possible in the large majority of cases. In cases in which the implant cannot be visualised, take a sterile cotton bud and lightly depress over the injection site to bring the implant into view. Following the intravitreal injection patients should continue to be treated with a broad spectrum antimicrobial. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Active or suspected ocular or periocular infection including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases. Advanced glaucoma which cannot be adequately controlled by medicinal products alone. Aphakic eyes with rupture of the posterior lens capsule. Eyes with Anterior Chamber Intraocular Lens (ACIOL) and rupture of the posterior lens capsule. **Warnings/Precautions:** Intravitreal injections, including OZURDEX can be associated with endophthalmitis, intraocular inflammation, increased intraocular pressure and retinal detachment. Proper aseptic injection techniques must always be used. Patients should be monitored following the injection to permit early treatment if an infection or increased intraocular pressure occurs. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients must be instructed to report any symptoms suggestive of endophthalmitis or any of the above mentioned events without delay. All patients with posterior capsule tear, e.g. those with a posterior lens, and/or those who have an iris defect (e.g. due to iridectomy) with or without a history of vitrectomy, are at risk of implant migration into the anterior chamber. Other than those patients contraindicated where OZURDEX should not be used, OZURDEX should be used with caution and only following a careful risk/benefit assessment. These patients should be closely monitored for any signs of implant migration. Corticosteroids should be used cautiously in patients with a history of ocular herpes simplex and not be used in active ocular herpes simplex. The safety and efficacy of OZURDEX administered to both eyes concurrently have not been studied and is not recommended. OZURDEX is not recommended in patients with

macular oedema secondary to RVO with significant retinal ischemia. OZURDEX should be used with caution in patients taking anti-coagulant or anti-platelet medicinal products. **Interactions:** No interaction studies have been performed. Systemic absorption is minimal and no interactions are anticipated. **Pregnancy:** There are no adequate data from the use of intravitreally administered dexamethasone in pregnant women. OZURDEX is not recommended during pregnancy unless the potential benefit justifies the potential risk to the foetus. **Lactation:** Dexamethasone is excreted in breast milk. No effects on the child are anticipated due to the route of administration and the resulting systemic levels. However OZURDEX is not recommended during breast feeding unless clearly necessary. **Driving/Use of Machines:** Patients may experience temporarily reduced vision after receiving OZURDEX by intravitreal injection. They should not drive or use machines until this has resolved. **Adverse Effects:** RVO In clinical trials the most frequently reported adverse events were increased intraocular pressure (IOP) (24.0%) and conjunctival haemorrhage (14.7%). Increased IOP with OZURDEX peaked at day 60 and returned to baseline levels by day 180. Elevations of IOP either did not require treatment or were managed with the temporary use of topical IOP-lowering medicinal products. The following adverse events were reported: Very common ($\geq 1/10$): IOP increased, conjunctival haemorrhage* Common ($\geq 1/100$ to $< 1/10$): Ocular hypertension, vitreous detachment, cataract, subcapsular cataract, vitreous haemorrhage*, visual disturbance, vitreous opacities* (including vitreous floaters), eye pain*, photopsia*, conjunctival oedema*, anterior chamber cell*, conjunctival hyperaemia*, headache Uncommon ($\geq 1/1,000$ to $< 1/100$): Retinal tear*, anterior chamber flare* Headache. **Uveitis** In clinical trials the most frequently reported adverse events in the study eye were conjunctival haemorrhage (30.3%), increased IOP (25.0%) and cataract (11.8%). The following adverse events were reported: Very common: Increased IOP, cataract, conjunctival haemorrhage* Common: Retinal detachment, Myodesopsia, vitreous opacities, blepharitis, sclera hyperaemia*, visual impairment, abnormal sensation in the eye*, eyelid pruritus, migraine. (*Adverse reactions considered to be related to the intravitreal injection procedure rather than the dexamethasone implant). Please refer to Summary of Product Characteristics for full information on side effects. **Basic NHS Price:** £870 (ex VAT) per pack containing 1 implant. **Marketing Authorisation number:** EU/1/10/638/001 **Marketing Authorisation Holder:** Allergan Pharmaceuticals Ireland, Castlebar Road, Westport, Co. Mayo, Ireland. **Legal Category:** POM. **Date of Preparation:** May 2013.

Adverse events should be reported to your local Allergan office and to your Regulatory Authority

References: 1. Nehme A & Edelman J. Invest Ophthalmol Vis Sci. 2008;49(5):2030-2038. 2. Capone Jr A, et al. Monotherapy vs Combination Therapy With Dexamethasone Intravitreal Implant (DEX Implant) in Retinal Vein Occlusion (SHASTA study). Presented at the American Academy of Ophthalmology 2013 Annual Meeting; November 16-19, 2013; New Orleans, LA, US. 3. Papathomas T, Kamal A et al. Presented at ARVO 2013, May 5-9; Seattle, USA. 4. Berthon L et al. Long-term use of OZURDEX[®] in macular oedema from retinal vein occlusions. CERK/RVO Study. Les Cahiers d'Ophthalmologie 2013; 15:25-27. 5. Tomkins-Netzer O, et al. Treatment with Repeat Dexamethasone Implants Results in Long-Term Disease Control in Eyes with Noninfectious Uveitis. Ophthalmology 2014 doi; 10.1016/j.ophtha.2014.02.003. [Epub ahead of print].

Date of Preparation: July 2014 EU/0281/2014b

ALLERGAN
ophthalmology

WORD FROM THE EVER 2014 PRESIDENT

Constantin J POURNARAS



Dear EVER members, colleagues and friends,

As the 2014 EVER President, it is my great pleasure to welcome you to the 2014 EVER meeting in Nice, France.

A significant rise in EVER Congress participation has been seen since the meeting moved to the attractive city of Nice on the French Riviera. The ease of access, the excellent support from the local authorities and the pleasant environment, have all contributed to the maturation of new ideas.

Thanks to your contributions and under the guidance of the Program Secretary, the Sections Chairs and the Sections secretaries, we succeed to prepare a well-balanced scientific program which includes plenary lectures, special interest symposia, free papers, posters and courses.

These events promote the interaction between clinicians and researchers which leads to new research directions, as well as opportunities to renew friendships and to establish collaborations. In addition, the organization of the 2014 EUPO course in collaboration with EVER, will provide the opportunity to younger residences to present their data.

We look forward to the challenge of the 2014 EVER meeting, as significant advances in Ophthalmology and new insights into basic mechanisms of ocular diseases, as well as improvement in diagnosis and treatment of the ocular pathologies, are forthcoming.

Wide participation from the ophthalmic and vision science communities ensures a mixture of high standard clinical and basic science. We believe that this participation should be extended by attracting additional groups and opinion leaders to our meeting.

In this context, changes have been made to the organization of the special interest symposia, asking a higher involvement of the Section chairs and the free registration of the SIS invited speakers.

The EVER conference would not be possible without the generous support of our sponsors. Their increasing support is probably an acknowledgment of the tremendous progress achieved the last few years in the treatment of eye pathologies.


I am really looking forward to seeing you in Nice in October. I would like to express one more time my gratitude to all the people who have contributed to the success of this meeting, not only related to the scientific program, but also to the social activities associated with the congress.

Constantin J Pournaras
President EVER 2014

Your partner for clinical research and regulatory affairs in Europe



- + Multinational clinical trials phases I – IV
- + Medical device pre- and post marketing studies
- + Project management and consulting
- + Regulatory affairs
- + Biostatistics and data management
- + Locally present in 11 European countries
- + 300 projects performed
- + Global drug and device regulatory services



Appletree CI Group AG
Rudolf-Diesel-Strasse 3
8404 Winterthur
Switzerland
P+41 52 209 06 55
F+41 52 209 06 50
contact@appletree-cig.com
www.appletree-cig.com

TABLE OF CONTENTS

Word from the President	1
About EVER	4
Board 2014.....	8
Congress Information.....	10
Grants.....	12
Floor plan	14
Exhibitors.....	15
Partners of EVER	16
About the Programme Book	18
Programme Committee 2014.....	19
Industry Sponsored Symposia.....	20
Courses	21
Wednesday, October 1	23
Lunchtime session: Industry-sponsored symposium 1	24
First afternoon session.....	25
Opening Ceremony	29
EVER Past President lecture	30
Second afternoon session.....	31
European Ophthalmology Heritage Lecture.....	34
EVER/Acta lecture.....	35
Welcome reception.....	37
Thursday, October 2.....	39
Breakfast session: Industry-sponsored breakfast	40
First morning session.....	41
Keynote Lecture: Austin ROORDA	44
Second morning session	45
Lunchtime session: Industry-sponsored symposium 2.....	48
Ophthalmic Research Lecture: Bahram BODAGHI.....	49
First afternoon session.....	50
Poster session 1.....	53
Second afternoon session.....	58
Evening session: Industry-sponsored symposium 3.....	61
Friday, October 3	63
First morning session.....	64
Keynote Lecture: David SULLIVAN.....	67
Second morning session	68
Lunchtime session: Industry-sponsored symposium 4.....	71
First afternoon session.....	72
Poster session 2.....	75
Business Meetings of the Scientific Sections.....	80
Second afternoon session.....	81
Congress Dinner.....	85
Saturday, October 4.....	87
First morning session.....	88
Keynote Lecture: Jay NEITZ	91
Second morning session	92
Lunchtime session: Industry-sponsored symposium 5.....	95
First afternoon session.....	98
Poster session 3.....	101
Second afternoon session.....	106
EVER General Assembly and Prize Giving.....	109
Presenting first authors	119
All authors index.....	125
Presenting first authors by country	135
Time Schedule.....	136
Sponsors	back cover

The European Association for Vision and Eye Research, EVER, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress.

MEMBERSHIP

EVER currently has members from 50 countries all over the world and represented by 11 scientific sections.

Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research.


Applications for membership - available on www.ever.be - may be submitted at any time, membership is on calendar year basis and starts on January 1.

Every member must select one of the 11 Scientific Sections that best represents his or her primary area of interest.


The benefits of EVER membership are:

- submission of abstracts to EVER annual meeting
- reduced registration fee for EVER annual meeting
- organizing Special Interest Symposia (SIS) and courses during the EVER annual meeting
- participating in the EBO review courses
- EACCME granted 21 European CME credits (ECMEC) recognized by the American Medical Association- for the EVER annual meetings
- voting rights for the election of the Board Members (except members-in-training and emeritus members)
- EVER section travel grants
- EVER section paper abstract prizes
- EVER poster prizes
- free electronic subscription to the EVER journal, Acta Ophthalmologica (IF 2.345)
- quarterly E-Newsletter

AFFILIATION TO SCIENTIFIC SECTIONS



CONGRESS PARTICIPANTS:



Clinical with or without research: 73 %
Research only: 27 %

ELECTIONS

In 2014 new representatives of the scientific sections

- ACB - Anatomy / Cell Biology
- EOVS - Electrophysiology, physiological Optics, Vision Sciences
- MBGE - Molecular Biology / Genetics / Epidemiology

will be elected through electronic voting. Voting 2014 will close on October 3, midnight.

The result of the elections will be announced at the General Assembly on Saturday October 4, 2014.

The scientific sections will hold their Business Meetings on Friday, Oct 3, 2014 from 15:45 - 16:25. The agenda is available on page 80.

The following 2 sections will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2015:

- NSPH - Neuro-ophthalmology / Strabismology / Paediatric Ophthalmology / History of Ophthalmology
- PO - Pathology / Oncology

The statutes and by-laws are available on the website:

www.ever.be » about » statutes.



EVER - European Association for Vision and Eye Research

www.ever.be

We aim to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information. EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. EVER currently has members from over 50 countries and is represented by 11 scientific sections. One of the main activities of EVER is the organizing of a high quality research meeting every October at a location chosen for its access and its agreeable autumn climate. EVER collaborates closely with other societies and encourages them to convene annually with EVER.



EVER f - EVER Foundation

www.ever-f.eu

In 2010, the EVER Foundation was created to raise money to organize EVER f Research Fellowships to offer to young ophthalmologists or young vision scientists, especially from Eastern Europe or from developing countries outside Europe, the opportunity to gain experience in laboratory techniques and scientific research in leading European Departments for Vision and Eye Research. The duration of the fellowship is limited to 6 months.

Fellowships 2013:

1. Dr. Reka ALBERT, Hungary - host institute: Queens Medical Centre, Nottingham, UK
2. Dr. Minika JASIELSKA, Poland - host institute: Department of Experimental Ophthalmology at the Charite Univeristy Medicine in Berlin, Germany

Fellowships 2014:


1. Dr. Ganne PRATYUSHA, India - host institute : Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK
2. Dr. Mohamed Shafik Mohamed ELALFY, Egypt - host institute : Queens Medical Centre, Nottingham, UK

Acta Ophthalmologica

ACTA OPHTHALMOLOGICA - EVER's journal

eu.wiley.com

Acta Ophthalmologica is the official scientific publication of the European Association for Vision and Eye Research (EVER) and of the five Nordic ophthalmological societies. Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses. (IF 2.345)



**Constantin
POURNARAS**

• President



**Catherine
CREUZOT**

• Secretary
General



**Jean-Jacques
GICQUEL**

• Treasurer



**Marcela
VOTRUBA**

• Programme
Secretary



**Alfred
WEGENER**

• Vice President



**Bart
LEROY**

• President Elect



**Nadja
KNOP**

• Vice-President
Elect



**Werner
SPILEERS**

• Vice-President
Elect



**Philippe
KESTELYN**

• Past President



**Leopold
SCHMETTERER**

• EVER / liaison



**Marlene
VERLAECKT**

• Executive Officer



**Lies
VAN EYCKEN**

• Design & Publishing



**Dew
DRIESSEN**

• Executive Assistant



**Paul
MOERS**

• Webmaster

OFFICE



**Nadja
KNÖP**

- Anatomy / Cell Biology



**Thomas
FUCHSLUGER**

- Cornea / Ocular Surface



**Werner
SPILEERS**

- Electrophysiology, physiological Optics, Vision Sciences



**Alain
BRON**

- Glaucoma



**Andrew
DICK**

- Immunology / Microbiology



**Rafael
BARRAQUER**

- Lens / Cataract



**Bart
LEROY**

- Molecular Biology / Genetics / Epidemiology



**Aki
KAWASAKI**

- Neuro-ophthalmology / Strabismology / Paediatric / History



**Laurence
DESJARDINS**

- Pathology / Oncology



**Gerhard
GARHÖFER**

- Physiology / Biochemistry / Pharmacology



**Peter
WIEDEMANN**

- Retina / Vitreous



**Bozena
ROMANOWSKA-
DIXON**

- East Europe

REGIONAL
REPRESENTATIVE



**Jean-Pierre
CAUJOLLE**

- Nice, France

LOCAL
REPRESENTATIVE

Venue

EVER 2014 will be held at the Acropolis Convention Center in Nice, France

→ visit the website on www.nice-acropolis.com

The scientific programme of the EVER congress starts on Wednesday, October 1 at 12:30 and concludes on Saturday, October 4 at 19:15.

Registration

Everyone attending the scientific sessions - whether or not an EVER member - must register and pay the registration fee.

On-site registration starts on Wednesday, Oct 1, 10:00.

Please note that:

- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- if you register as an Eye-care, Technician or Nurse, you need to prove your status with a document signed by the Head of your Department

Registration fees on-site

	EUR	EUR
EVER member	455	390 *
Course invited speakers		
Member-in-training	250	200 *
Non-member	800	645 *
Non-member-in-training	400	310 *
Eye-Care / Technician / Nurse	200	180 *
Congress Dinner (member / non-member)	90	90
Congress Dinner (in training)	60	60

* Citizens of these listed countries only: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Congo, Egypt, Georgia, Iran, Libya, Macedonia, Moldova, Montenegro, Morocco, Ouzbekistan, Pakistan, Serbia, Tunisia, Ukraine

Cancellation policy

Refunds - up to 75% of the advance registration fee will be granted for cancellation received in writing prior to Sept 15, 2014. Refunds will not be granted for later cancellations or no-shows.

Website

The EVER website www.ever.be has a central role in the EVER organisation. At this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2014 meeting and view the status (session, hour, place) of your presentation
- pay on-line and obtain an overview of past payments
- look for other EVER members
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- cast your vote for officers
- print CME certificate after each congress you attended

Housing

ADVANCEDFAIR

AdvancedFair has negotiated special rates for accommodation in several categories of hotels.

Contact: Guillaume ANCIAUX - ga@advancedfair.com

Travel

The Nice Côte d'Azur Airport is located 15 minutes from the Acropolis, at 7 km from the city centre.

The tramway line connects most of the hotels with the Acropolis Convention Center.

Weather

Nice sees on average 6 hours of sunshine per day during October so it remains warm and pleasant.

It is a perfect time of year to go and explore the city and discover for yourself the many fantastic historic and cultural landmarks Nice has.

There are also a variety of museums and art galleries that can be a worthwhile way to while away a day in the city.

The average temperature of the sea is 19°C.



Welcome Reception

The Welcome Reception is open for all participants

- **Wednesday 19:00 - 21:00**
in the Exhibition area, Acropolis Convention Center

Congress Dinner

Registration for the Congress Dinner is required.

Members / non-members: 90 EUR

Members in training: 60 EUR

Space is limited.

- **Friday 20:00 in Hotel NEGRESCO**
37, promenade des Anglais, Nice

Coffee / tea / refreshments

Included in the registration fee are the coffee / tea and soft drinks offered throughout the whole meeting.

Internet access

Wi-Fi internet access is available in the Convention Center.

Photographs



It is strictly forbidden to take photographs or videos of the presentations in all lecture halls.

Publication of the abstracts

The abstracts of the EVER 2014 congress are published on-line in a special issue of Acta Ophthalmologica, the EVER journal. Access for members-only through EVER homepage.

Business Meetings

EVER Business Meetings of the scientific sections
Friday, 15:45 - 16:25

- ACB Gallieni 1 & 2
- COS Rhodes 2
- EOVS Rhodes 1
- G Rhodes 1
- IM Rhodes 4
- LC Rhodes 2
- MBGE Gallieni 5
- NSHP Rhodes 4
- PO Rhodes 3
- PBP Hermes
- RV Hermes

Agenda see page 80

EVER General Assembly and Prize Giving

Saturday, 17:45 - 19:15 in room Hermes

Agenda see page 109

No-shows

Please note that any first author, whose paper or poster has been accepted, will be prohibited from presenting papers at EVER for the next two years if a valid reason is not sent to the EVER office in writing.

CME - Continued Medical Education credits

The European Accreditation Council for Continuing Medical Education Institution of the UEMS, EACCME has granted 21 European CME credits (ECMEC) to the EVER 2014 congress on Oct 1-4 in Nice, France.

CME credit certificates can be printed from the EVER website after the congress.

Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants must make their own arrangements with respect to health and travel insurance.

EVER 2014 congress App



Download: App store

All you need to know about the EVER 2014 congress:

- About EVER
- Floorplan and sponsors
- My congress bag
- My schedule
- News Feeds
- Photo sharing
- Session rating
- etc.



EVER section travel award

We are pleased to announce that the following 11 members have received an EVER section travel award of 750 EUR each, from each of the EVER sections:

- **ACB - Lyubomyr LYTVYNCHUK - Ukraine**
1672 - Study of anti-proliferative activity of ranibizumab, bevacizumab, pegaptanib and aflibercept on fibroblast-like cell strain in vitro
- **COS - Binh Minh HA THI - France**
1724 - Corneal endothelial cells from old donors: differentiation, senescence, proliferative capacities and optimized culture conditions
- **EOVS - Julia DONALD - Australia**
2441 - Developing a clinically viable protocol for measuring and analysing the human contrast sensitivity function on a standard computerised chart
- **G - Henrietta HO - Singapore**
3425 - Angle closure glaucoma in Asians: comparison of biometric and anterior segment parameters between Japanese and Chinese subjects
- **IM - Luis MUNOZ-ERAZO - Australia**
2641 - Cytokine gene expression and protein production in West Nile virus-infected retinal pigment epithelium
- **LC - Alexandros PENNOS - Spain**
S097 - Comparison of optical and psychophysical methods to measure intraocular straylight
- **MBGE -Helder ANDRE - Sweden**
T068 - Exogenous regulation of the HIF pathway in RPE cells
- **NSPH - Guzel BIKBOVA - Japan**
2651 - Advanced glycation end-products induced activation of NFkB and its suppression by different neurotrophic factors
- **PBP - Houda TAHIRI - Canada**
F012 - Lymphocytic microparticles modulate macrophages function in experimental choroidal neovascularization
- **PO - Emine KILIC - The Netherlands**
4246 - SF3B1 and EIF1AX mutations in uveal melanoma: a protective factor, or not?
- **RV - Elizabeth STEWART - United Kingdom**
4742 - Apoptosis and proliferation in diabetic eyes



Alta Eficacia Tecnología SL, Spain, travel grant

Alta Eficacia Tecnología is pleased to announce a travel grant of 750 EUR for the best paper in the EOVS section

- **EOVS - Ieva SLIESORAITYTE**
2446 - Chromatic pupillometry for assessment functional rod and cone patterns in Usher syndrome patients

The prize will be presented by Professor Celia SANCHEZ RAMOS at the General Assembly.



quartett diagnostica Research Award

3 grants supported by quartett for best paper in COS

- **Translational Research Award**
- **Basic Science Research Award**
- **Clinical Research Award**

The papers will be chosen during the congress and the grants will be handed over during quartett diagnostica Research Award Session on Saturday 4 October 2014 from 08:30 till 10:00 in room Gallieni 5.



EVER section paper abstract prize

We are pleased to announce that the following 11 members have received an EVER section paper abstract prize of 500 EUR each, from each of the EVER sections:

- **ACB - Maria TOTH - Hungary**
1671 - Human retinal pigment epithelial cells dying through autophagy are engulfed by professional and non-professional phagocytes
- **COS - Samantha WILSON - United Kingdom**
1723 - Corneal decellularisation: recycling tissue for transplantation
- **EOVS - Markku LEINONEN - Finland**
2444 - Visual Search Test (VST) - reaction time perimetry with fixation objects detectable only by foveal vision
- **G - Francisco JUNOY MONTOLIO - The Netherlands**
3424 - Lateral inhibition in the human visual system in healthy subjects and in patients with glaucoma
- **IM - Alexandra MOUALLEM - France**
3443 - Diagnostic and prognostic value of cerebrospinal fluid analysis in Vogt-Koyanagi-Harada syndrome
- **LC -Guillaume DEBELLEMANIERE - France**
1771 - Optical and morphological characterization of a 3D printed intraocular lens
- **MBGE - M. Laura GARCIA GARCIA - Spain**
1764 - Use of antibiotic-resistance-free plasmids for non-viral transfection of pigment epithelium-derived factor in rat primary cells
- **NSPH - Vincent DAIEN - France**
2654 - Incidence and characteristics of congenital cataract surgery in France from 2010 to 2012
- **PBP - Marialaura AMADIO - Italy**
3475 - Silencing HuR: a new potential pharmacological strategy to target VEGF
- **PO - Joni TURUNEN - Finland**
4242 - BAP1 germline mutations in Finnish uveal melanoma patients
- **RV - Olivier FLECK - France**
1664 - Macular pigment optical density in a French population over 75 years old (MONTRACHET's study: Maculopathy, Optic Nerve, nuTRition, neurovAsCular and HEarT diseases)



EVER Poster Prizes

Poster prizes of 500 EUR will be awarded for the best posters across all sections.


The winners will be chosen by the poster moderators and will be announced in the General Assembly and followed by the prize giving ceremony on Saturday October 4.

Please make sure to attend.

No prize will be given after the congress.



LEVEL 2
RHODES



101 - Alimera Sciences

110 - Allergan

103 - Charles River

102 - Iris Pharma

111 - Horus Pharma

109 - Nicox

108 - Novartis France

112 - Ocuspecto Oy

104 - Théa

105 - Wisepress

Non profit

107 - ARVO

106 - ISOPT





ARVO - Association for Research in Vision and Ophthalmology

www.arvo.org

In many senses the counterpart of EVER in North America, the purposes of ARVO are to encourage and assist research, training, publication, and dissemination of knowledge in vision and ophthalmology. EVER and ARVO are collaborating in many fields, including an ARVO symposium held every year in EVER and an EVER symposium held in ARVO since 2005. See page 83.



EBO - European Board of Ophthalmology

ebo-online.org

The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology in the countries of the European Union by ensuring that the training is raised to the best possible level. It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section of Ophthalmology of the European Union of Medical Specialists (UEMS). Since 2007, EBO has organized review courses open to all delegates during the EVER congress. See pages 26, 32.



EEBA - European Eye Bank Association

www.europeaneyebanks.org

The EEBA is a technical-scientific organization comprising individual members from 83 eye banks from 25 European countries. Founded with the simple objective of sharing information regarding eye-banking, the Association is today the leading pan-national association in Europe dedicated to the advancement of eye-banking and an authoritative reference point for eye banks wishing to work according to quality standards. The EEBA is collaborating with EVER since 2012. See page 106.



EUPO - European University Professors of Ophthalmology

www.eupo.eu

EUPO is the organizer of the annual structured subspecialty course for residents in training in Europe since 1988. Most of the ophthalmology curriculum is covered over a 4 year period to allow residents to get an overview of theoretical knowledge during their residency rotation. EUPO courses are held in different places in Europe.

EUPO 2014 is organized with EVER. The EUPO 2015 course on UVEITIS and GLAUCOMA will be organized prior the SOE congress in Vienna, Austria on June 5 - 6, 2015.



EURETINA - European Society of Retina Specialists

www.euretina.org

The aims of EURETINA are to establish personal contacts and to promote the exchange of knowledge between vitreoretinal and macula specialists in Europe, and encourage vitreoretinal and macula research in Europe, promote the diffusion of specific knowledge to the general ophthalmologists in Europe and to keep contact with similar groups in other continents. EURETINA has organised a symposium during EVER paralleled with an EVER symposium in EURETINA since 2002, see page 81.



FAN - European Fluorescein Angiography Club

www.fan-int.org

The FAN Club started as a friendly reunion of pioneers of Medical Retina, in the early days of fluorescein angiography and lasercoagulation of the retina. The FAN received a semi-official status, being invited to organize a session of Medical Retina Case Presentations during large meetings in Ophthalmology. The Club runs itself without official status, there is no membership fee, and no registration fee for the meetings. Upcoming meetings are decided within the group, trying to change the location from country to country, and offering all members the opportunity to organize at least once a full day reunion in their hospital. Since 2012, FAN has organised joint meetings open to all delegates during the EVER congress. See page 98, 106.



FRO - Belgian Fund for Research in Ophthalmology

www.fro-online.org

The aim of the FRO association is to stimulate research in ophthalmology and in visual function by awarding grants to research projects carried out under order of Belgian institutions. The FRO candidates have presented their research work to an international jury during the EVER congress since 2002. See pages 100, 108.



GOA - Groupe Ophthalmologie Allergo

In ocular surface pathologies the cooperation between clinical ophthalmology and allergology created the GOA. The GOA allowed the development of clinical research in ocular allergic disease. Vernal keratoconjunctivitis and atopic keratoconjunctivitis create severe ocular impairment that must be recognized and treated. See page 66.



KPro Study Group

www.kpro.org

The KPro Study Group was established in 1990 to foster clinical and basic research on keratoprosthesis, synthetic corneas and artificial corneal implants. This International Group aims to foster the development and improvement of keratoprosthesis worldwide for the benefit of eyecare and patients. The KPro Study Group is collaborating with EVER since 2004. See pages 92 and 98.



OOG - The Ophthalmic Oncology Group

www.oog.eu

OOG is an independent scientific workgroup devoted to basic and clinical ophthalmic oncology. It has convened with EVER since 1998. The aims of the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based databases to share scientific information, organise multicenter studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowledge about them. OOG encourages all EVER delegates to take part in its sessions. See pages 89, 93 and 99.



SOE - Societas Ophthalmologica Europea



www.soevision.org

SOE aims to promote ophthalmology in Europe and to stimulate co-operation between European ophthalmologists and between their National Societies. Today, its mission is to become a central point in European ophthalmology through education and by fostering collaboration with subspecialty societies and supranational organisations both within Europe and beyond.

The 2015 SOE Congress will take place from 6-9 June, 2015 in Vienna, Austria.

ABOUT THE PROGRAMME BOOK

This programme book is organised chronologically



The sessions are colour-coded

Special Interest Symposium (SIS)

Keynote Lecture

Poster Session

Free Papers (FP)



General Assembly & Business Meeting

Social

Joint Meeting (Joint M)

Course

Industry Sponsored Symposium (CIS)

- FP = Free Paper session
- SIS = Special Interest Symposium
- CIS = Industry Sponsored Symposium
-  = EVER section travel award recipient
-  = EVER section paper abstract prize recipient
- rf* = Rapid Fire presentation
- ★ = Conflict of interest disclosed

Scientific sections

- ACB = Anatomy/Cell Biology
- COS = Cornea/Ocular Surface
- EOVS = Electrophysiology, Physiological Optics, Vision Sciences
- G = Glaucoma
- IM = Immunology/Microbiology
- LC = Lens and Cataract
- MBGE = Molecular Biology/Genetics/ Epidemiology
- NSPH = Neuro-ophthalmology/Strabismology/Paediatric Ophthalmology/History of Ophthalmology
- PBP = Physiology/Biochemistry/Pharmacology
- PO = Pathology/Oncology
- RV = Retina/Vitreous



June 2014

Programme secretary, Marcela VOTRUBA

Section programme secretaries

ACB	Anatomy/Cell Biology	Goran PETROVSKI
COS	Cornea/Ocular Surface	Jean-Jacques GICQUEL
EOVS	Electrophysiology, Physiological Optics, Vision Sciences	Miguel CASTELO-BRANCO
G	Glaucoma	Sayeh POURJAVAN
IM	Immunology/Microbiology	Piergiorgio NERI
LC	Lens and Cataract	Stefan LÖFGREN
MBGE	Molecular Biology/Genetics/Epidemiology	Petra LISKOVA
NSPH	Neuro-ophthalmology/Strabismus/Paediatric Ophthalmology/ History of Ophthalmology	Dominique BREMOND-GIGNAC
PBP	Physiology/Biochemistry/Pharmacology	Alexandre MOULIN
PO	Pathology/Oncology	Neville OSBORNE
RV	Retina/Vitreous	Stephanie BAILLIF
EVER	President Elect	Leopold SCHMETTERER
EVER	Executive Officer	Marlene VERLAECKT

The Industry Sponsored Symposia throughout the EVER 2014 congress:



Allergan Industry-sponsored lunchtime symposium

Wednesday, Oct 1, 12:30 - 13:25 24



Horus and innovation

Thursday, Oct 2, 7:30 - 8:30 40



What's new in micronutrition for AMD patients?

Thursday, Oct 2, 12:35 - 13:30 48

What's new in ocular surface disorders?

Thursday, Oct 2, 18:00 - 19:30 61



Aflibercept: Setting its sight on DME

Friday, Oct 3, 12:35 - 13:30 71





Changing Perspectives in DME: Recognising & Understanding Chronic DME

Saturday, Oct 4, 12:35 - 13:30 95

The 12 courses throughout the EVER 2014 congress:

Wednesday, October 1

Course 1	13:30 - 15:00	PO: Don't panic: a survival course in statistics	25
Course 2	13:30 - 15:00	COS: Corneal Dystrophies – from molecular basis to therapeutic approach	25
Course 3	13:30 - 15:00	IM: EBO course: Intraocular inflammation and infection (Part I) 	26
Course 4	13:30 - 15:00	NSPH: Differential diagnosis and evaluation of acute optic neuropathies and other neuro-ophthalmic causes of acute visual loss	26
Course 5	16:00 - 17:30	IM: EBO course: Intraocular Inflammation and Infection (Part II) 	32

Thursday, October 2

Course 6	08:30 - 10:00	COS: Corneal infectious diseases	42
Course 7	14:20 - 15:50	RV: Diabetic retinopathy	50
Course 8	14:20 - 15:50	COS: Why do you need wavefront aberrometry and straylight measurement in your daily practice?	50
Course 9	16:30 - 18:00	PO: Radiotherapy in ophthalmology.....	59

Friday, October 3

Course 10	13:30 - 15:00	General: How to get your research published?	72
------------------	----------------------	--	----

Saturday, October 4

Course 11	11:00 - 12:30	NSPH: Examination of eye movements and common peripheral and central oculomotility disorders.....	94
Course 12	13:35 - 15:05	NSPH: What's new in visual development and binocular vision.....	98



**WEDNESDAY
OCTOBER 1
2014**

INDUSTRY-SPONSORED SYMPOSIUM 1



Industry-sponsored lunchtime symposium

SIS
RV**Retinal imaging**

Leopold SCHMETTERER

Hermes

13:30	1611	Challenges for interpreting retinal morphology BEKT–Aarhus C
13:50	1612	Doppler OCT WERKMEISTER R–Vienna
14:10	1613	OCT elastography LEITGEB R–Vienna
14:30	1614	Choroidal thickness SOUBRANE G–Paris
14:50		Conclusions

Course 1 Don't panic: a survival course in statistics

PO

Tero KIVELÄ

Rhodes 1

Advanced

Without doubt, survival analysis is one of the most versatile statistical methods with a wide range of applications in eye and vision research. More generally known as time-to-event analysis, it is the least biased way of presenting data from longitudinal follow-up studies. However, because this type of analysis was first developed for research on metastatic cancer, the basic methods take assumptions that are often violated in assessing other outcome times than time to death of cancer. In such situations the analysis needs to be adjusted. This course highlights pearls not to be missed and pitfalls to be circumvented in applying time-to-event analysis. Topics that will be covered include basics like Kaplan-Meier analysis and proportional hazards regression, plus advanced alternatives such as relative survival, cumulative incidences, competing risks regression, and interval censoring. The course is spiced with good and not-so-good examples from the published literature and from the work of the faculty.

13:30	1621	Kaplan-Meier analysis and Cox regression KIVELÄ T–Helsinki
13:52	1622	Relative survival DAMATO B–San Francisco, CA
14:14	1623	Cumulative incidence and interval censoring KIVELÄ T–Helsinki
14:36		Cases from the literature

Course 2 Corneal Dystrophies – from molecular basis to therapeutic approach

COS

Edward WYLEGALA, Anna NOWINSKA

Rhodes 2

Intermediate

Corneal dystrophies are the group of hereditary disorders affecting all corneal layers. Since 2008 when IC3D classification was published there are new advances in diagnosis and treatment. During this course we would like to present the current methods of diagnosis including genetic testing and different treatment options.

13:30	1631	Anterior corneal dystrophies JANISZEWSKA D–Sosnowiec
13:48	1632	Stromal corneal dystrophies NOWINSKA A–Bytom
14:06	1633	Posterior corneal dystrophies LISKOVA P–Prague
14:24	1634	Advantages and disadvantages of PTK DOBROWOLSKI D–Katowice
14:42	1635	Surgical treatment options for corneal dystrophies WYLEGALA E–Katowice

FIRST AFTERNOON SESSION | 13:30 - 15:00

Course 3 EBO course: Intraocular inflammation and infection (Part I)

IM

Bahram BODAGHI, Carl P HERBORT

Rhodes 3

Intermediate



The aim of this course is to review major topics of intraocular inflammation and infection. MCQs will be proposed online before the course to evaluate the basic knowledge of the participants. The test will be followed by 6 consecutive general presentations for the understanding of different uveitis features. The course will be interactive allowing general discussion and the participation of the audience. MCQs will be discussed during each presentation. At the end of this course, participants will be prepared for the MCQ part of the EBO examination in uveitis.

13:30	1641	Pathophysiology of uveitis DICK A–Bristol
13:45	1642	Classification of uveitis ANDROUDI S–Thessaloniki
14:00	1643	Signs and symptoms of uveitis NERI P, ARAPI I, PIRANI V, ZUCCHI M, PRIMAVERA L–Ancona
14:15	1644	Laboratory work-up and specialized investigations PLEYER U–Berlin
14:30	1645	Imaging in uveitis: techniques and indications HERBORT C–Lausanne
14:45	1646	Therapeutic management of uveitis DICK A–Bristol

Course 4 Differential diagnosis and evaluation of acute optic neuropathies and other neuro-ophthalmic causes of acute visual loss

NSPH

Gabriella SZATMARY, Aki KAWASAKI

Rhodes 4

Beginners

Orbital, and intracranial pre- and retro-chiasmal causes of acute visual loss will be presented according to underlying pathophysiology. Relevant symptomatology, signs, generated working diagnosis and differential diagnostic possibilities will be discussed. Recommended diagnostic investigations, including laboratory, imaging, and pathologic findings will be detailed. The learning objectives of the course are to recognize clinical features, determine the usefulness and limitations of diagnostic tests, understand underlying mechanisms, and discuss therapeutic possibilities of neuro-ophthalmic causes of acute visual loss.

13:30	1651	Genetic causes of acute visual loss YU-WAI-MAN P–Newcastle upon Tyne
13:52	1652	Inflammatory and infectious causes of acute visual loss SZATMARY G, POLGAR T–Hattiesburg
14:14	1653	Neoplastic causes of acute visual loss BOSCHI A–Brussels
14:36	1654	Vascular causes of acute visual loss KAWASAKI A–Lausanne

FP

RV 1/6 : Cell biology and macular pigment in AMD

Gallieni 1 & 2

Anita LEYS, Carl ARNDT

13:30	1661	The effect of a rock inhibitor ama0428 in a model of wet age-related macular degeneration HOLLANDERS K, VAN BERGEN T, VANDEWALLE E, STALMANS I—Leuven
13:42	1662	Evaluation of potential retinal toxicity after intravitreal administration of a novel neuroprotective agent, synthetic analog of dehydroepinandrosterone (DHEA) TSIKA C, NIAVI S, GRAVANIS A, TSILIMBARIS M—Heraklion
13:54	1663 <i>rf</i>	Variations and repeatability of macular pigment and its spatial profiles in south Asian and white subjects HUNTJENS B, CTORI I—London
14:00	1664	Macular pigment optical density in a French population over 75 years old (MONTRACHET's study: Maculopathy, Optic Nerve, nuTRition, neurovAsCular and HEarT diseases) FLECK O, KOEHRER P, DANIEL S, BINQUET C, BRETILLON L, ACAR N, TZOURIO C, BRON AM, CREUZOT-GARCHER C—Dijon, Bordeaux
14:12	1665	Does foveal anatomy influence macular pigment and its spatial profile? A bi-racial study CTORI I, HUNTJENS B—London
14:24	1666 <i>rf</i>	Macular response to a carotenoid supplement in healthy eyes MARQUINA I, BRAUTASET R, NILSSON M—Stockholm
14:30	1667	Relation between the retinal reflectivity on SD-OCT and the cone density measured using adaptive optics FLORES M, DEBELLEMANIERE G, TUMAHAI P, KOEHL A, MEILLAT M, SCHWARTZ C, DELBOSC B, SALEH M—Besançon

FP

ACB 1/2 : Retinal and glial cell biology

Gallieni 5

Goran PETROVSKI, Beatriz I GALLEGRO

13:30	1671	Human retinal pigment epithelial cells dying through autophagy are engulfed by professional and non-professional phagocytes TÓTH M, KRISTÓF E, DORÓ Z, VERÉB Z, ALBERT R, FÉSÜS L, PETROVSKI G—Debrecen, Szeged
13:42	1672	Study of anti-proliferative activity of ranibizumab, bevacizumab, pegaptanib and aflibercept on fibroblast-like cell strain in vitro LYTVYNCHUK L, S A—Kyiv
13:54	1673	Microglia in mice retina contralateral to experimental glaucoma exhibit qualitative signs of activation in all retinal layers GALLEGO B, SALAZAR JJ, DE HOZ R, ROJAS B, RAMIREZ AI, VALIENTE-SORIANO FJ, AVILÉS-TRIGUEROS M, VILLEGAS PEREZ MP, VIDAL-SANZ M, TRIVINO A, RAMIREZ JM—Madrid, Murcia
14:06	1674	Energy supply is critical for Müller cells ability to transport glutamate KOLKO M—Hellerup
14:18	1675	Activation of cannabinoid receptor CB2 in ARPE-19 cells stimulates the release of inflammatory cytokines via activation of the ERK pathway HYTTI M, PIIPPO N, KORHONEN E, SALMINEN A, KAARNIRANTA K, KAUPPINEN A—Kuopio
14:30	1676	The best corrected visual acuity and retinal thickness are associated with improved cortical visual processing in treated wet-AMD patients VOTTONEN P, KAARNIRANTA K, TARKKA I, PÄÄKKÖNEN A—Kuopio, Jyväskylä



15:10 - 15:20 Welcome by the President EVER 2014
Constantin POURNARAS



15:20 - 15:30 EVER *f* highlights
Harminder S DUA, Leopold SCHMETTERER





Philippe KESTELYN
Ghent

AIDS thirty years later, lessons from a pandemic

Introduction by Constantin POURNARAS

At the start of the AIDS epidemic in the early eighties panic, fear and disbelief prevailed. A new "Great Plague" had arrived! Now, thirty years later, we know the enemy, we have devised effective weapons that transform a deadly disease into a chronic condition, and very recently we made our first attempts at engineering cellular resistance to HIV. This lecture will explore the many new insights we gained during our fight against AIDS, with some emphasis on the ophthalmic aspects of the disease.

SIS
RV

Retinal vein occlusion: treatments in 2014

Hermes

Constantin POURNARAS, Agnes GLACET-BERNARD

16:00	1711	Pathophysiologic mechanisms based treatment for RVO related macular edema POURNARAS C–Geneva
16:18 ★	1712	CRVO treatments in 2014 GLACET-BERNARD A–Creteil
16:36	1713	BRVO treatments in 2014 PETROPOULOS IK–Geneva
16:54	1714	The (new) place of laser treatment in RVO PUCHE N–Montbonnot/Grenoble
17:12	1715	RVO related macular edema: Rules for the patients follow up; how to choose the applied treatment? LOEWENSTEIN A–Tel Aviv

FP

COS 1/5: Corneal bioengineering

Rhodes 1

Andrew HOPKINSON, Gilles THURET

16:00	1721	A standardised 'off the shelf' substrate for enhanced tissue engineering HOPKINSON A, BRANCH MJ, DUA A–Nottingham
16:12	1722	Human induced pluripotent stem cells (hiPSC)-derived endothelial cells: new opportunity for corneal bioengineering THURET G, HE Z, SUFFEE N, FOREST F, BERNARD A, PISELLI S, PERRACHE C, DUMOLLARD JM, PEOC'H M, GAIN P–Saint-Etienne
16:24	1723	Corneal decellularisation: recycling tissue for transplantation WILSON SL–Nottingham
16:36	1724	Corneal endothelial cells from old donors: differentiation, senescence, proliferative capacities and optimized culture conditions HA THI B, HE Z, FOREST F, THURET JY, PISELLI S, PERRACHE C, PEOC'H M, DUMOLLARD JM, ACQUART S, GAIN P, THURET G–Saint-Etienne, Gif sur Yvette
16:48	1725 <i>rf</i>	Influence of pressure on in vitro human corneal endothelial cells derived from human induced pluripotent stem cell (hiPSC) JUMELLE C, SUFFEE N, FOREST F, HE Z, BERNARD A, NANGOUM-FOSSO T, NAIGEON N, PERRACHE C, PEOC'H M, GAIN P, THURET G–Saint-Etienne
16:54	1726 <i>rf</i>	Development of an ECM hydrogel for corneal tissue engineering AHEARNE M–Dublin
17:00	1727 <i>rf</i>	Ocular chronic graft versus host disease after allogeneic hematopoietic stem cell transplantation – preliminary data JEPPESEN H, LINDEGAARD J, SENGELOEV H, JULIAN HO, PRAUSE J, HEEGAARD S–Copenhagen, Glostrup
17:06	1728 <i>rf</i>	Positive cultures in corneas stored with cold storage technique to be used for corneal grafting JULIAN HO, LINDEGAARD J, HØJGAARD-OLSEN K, HEEGAARD S–Copenhagen

SECOND AFTERNOON SESSION | 16:00 - 17:30

FP	G 1/2 : Surgery	Rhodes 2
	Alain BRON, K. Sheng LIM	
16:00	1731	What is driving the decision to perform a filtering procedure BRON AM, DE LAZZER A, KOEHRER P, BONNABEL A, AHO S, CREUZOT-GARCHER C—Dijon
16:12	1732	Rho Kinase Inhibitor AMA0526 improves surgical outcome in a rabbit model of glaucoma filtration surgery VAN DE VELDE S, VAN BERGEN T, VANDEWALLE E, STALMANS I—Leuven
16:24	1733	Inhibition of $\alpha 5\beta 1$ -integrin significantly improves the surgical outcome of glaucoma surgery in mice compared to MMC VAN BERGEN T, ZAHN G, CALDIROLA P, FSADNI M, CARAM-LELHAM N, VANDEWALLE E, STALMANS I—Leuven, Stockholm
16:36	1734	Selective laser trabeculoplasty in pseudophakic eyes with glaucoma MAGOURITSAS G, PORTALIOU DM, MOSCHONAS K, GEORGOPOULOS V—Athens
16:48	1735 <i>rf</i>	Filtering blebs functionality after trabeculectomy: a clinical and in vivo confocal microscopy study VIEIRA L, SANTOS A, LISBOA M, AMARAL A, CUNHA JP, MADURO V, REINA M—Lisbon
16:54	1736 <i>rf</i>	Self-tonometry is useful to detect IOP elevations in DALK patients with apparently normal intraocular pressures SMEDOWSKI A, TARNAWSKA D, WYLEGALA E—Katowice
17:00 *	1737 <i>rf</i>	Different aspects of IOP measurements with GAT versus DCT in glaucoma patients MEIER-GIBBONS F—Rapperswil

Course 5 IM EBO course: Intraocular inflammation and infection (Part II) Rhodes 3

Bahram BODAGHI, Carl P HERBORT

Intermediate



The first part on general aspects of uveitis will be followed by case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be intermediate and present entities that are frequently observed in routine. At the end of this course, participants will be prepared for the viva voce part of the EBO examination in uveitis.

16:00	1741	B27-associated uveitis, Fuchs uveitis WILLERMAIN F—Bruxelles
16:18	1742	Infectious uveitis PLEYER U—Berlin
16:36	1743	Behçet's disease, VKH, sarcoidosis KHAIRALLAH M, KAHLOUN R, BEN YAHIA S—Monastir
16:54	1744	White dot syndromes HERBORT C—Lausanne
17:12	1745	Pediatric uveitis BODAGHI B—Paris

SIS PBP The role of mononuclear phagocytes in age related macular degeneration (AMD) Rhodes 4

Florian SENNLAUB

16:00	1751	A transcriptional network underlies the identity and diversity of tissue macrophages GAUTIER E—Paris
16:18	1752	The aging phenotype of microglia in the retina and its relationship to AMD WONG W—Bethesda
16:36	1753	Damaged photoreceptor cells initiate microglial activation in a mouse model of retinal degeneration MAEDA A—Cleveland
16:54	1754	Photoreceptor toxicity of subretinal Mononuclear Phagocytes GUILLONNEAU X, HU S, CALIPPE B, LAVALETTE S, SENNLAUB F—Paris
17:12	1755	Subretinal Mononuclear Phagocyte survival and accumulation in AMD SENNLAUB F—Paris

FP

MBGE 1/1

Gallieni 1 & 2

Marzena GAJECKA, Marcela VOTRUBA

16:00	1761	The KORA-AGE Eye Study: Genetic Susceptibility GRAW J, MOLNOS S, HEIER M, LINKOHR B, BREIER M, HOLLE R, GRILL E, GRALLERT H, PETERS A–Neuherberg, Munich
16:12	1762	Assessment of ocular surface microbiota in keratoconus patients – a pilot study GAJECKA M, MATYSIAK A, KUBICKA M, SZAFLIK JP–Poznan, Warsaw
16:24	1763	Ocular biometry and its relationship to incident myopia and hyperopia in children ROSE K–Sydney
16:36	1764	Use of antibiotic-resistance-free plasmids for non-viral transfection of pigment epithelium-derived factor in rat primary cells GARCIA GARCIA L, RECALDE S, FERNÁNDEZ-ROBREDO P, HERNÁNDEZ M, RODRIGUEZ JR, BEZUNARTEA J, MARIE C, SCHERMAN D, IZSVÁK Z, JOHNNEN S, THUMANN G, GARCIA-LAYANA A–Pamplona, Paris, Berlin, Aachen, Genève
16:48	1765 <i>rf</i>	Biomarkers of Age-Related Macular Degeneration (AMD): Four new obesity-related genetic loci are associated with advanced AMD PATERNO JJ, HELISALMI S, TOKARZ P, BLASIAK J, HILTUNEN M, UUSITUPA M, KAARNIRANTA K–Kuopio, Lodz
16:54	1766 <i>rf</i>	Analysis of Keratoconus genetic factors within Keratoconus Loci and mtDNA NOWAK DM, KAROLAK JA, KUBICKA M, KULINSKA K, POLAKOWSKI P, SZAFLIK JP, GAJECKA M–Poznan, Warsaw
17:00	1767 <i>rf</i>	Visual dysfunction and pupillary responses are dissociated in the Opa3 mutant mouse with retinal degeneration VOTRUBA M, DAVIES JR, DOUGLAS RH, DAVIES VJ–Cardiff, London
17:06	1768 <i>rf</i>	BAX and BCL-2 genes in patients with Retinal Detachment with and without Proliferative Vitreoretinopathy. The Retina 4 project GONZALEZ-BUENDIA L, PASTOR-IDOATE S, RODRIGUEZ-HERNANDEZ I, ROJAS J, GONZALEZ-SARMIENTO R, PASTOR JC–Valladolid, Salamanca

FP

LC 1/1

Gallieni 5

Deborah VANDERVEEN, Aif NYSTRÖM

16:00	1771	Optical and morphological characterization of a 3D printed intraocular lens DEBELLEMANIERE G, FLORES M, MONTARD M, DELBOSC B, SALEH M–Besançon
16:12	1772	Radiation effects on light scattering and cataract formation in the lenses of interventional radiologist and cardiologists WEGENER A, HÖCK A, SCHEIDEMANN-WESP U, CÁMARA R, HAMMER GP, VOßMERBÄUMER U, LASER-JUNGA H, SINGER S–Bonn, Mainz, Luxembourg
16:24	1773	Strategies to reduce cytokine levels could suppress PCO progression ELDRED JA, SPALTON DJ, WORMSTONE IM–Norwich, London
16:36	1774	Safety and efficacy of intra-operative sub-Tenon injection of 2% lidocaine in cases of unexpected intra-operative floppy iris syndrome (IFIS) KLYSIK A, KORZYCKA D–Lodz
16:48	1775	Topical caffeine induces mydriasis in animals under ketamine-xylaxine anesthesia SÖDERBERG P, YU Z, TALEBIZADEH N, KRONSCHLÄGER M–Uppsala
17:00	1776 <i>rf</i>	Change in intraocular pressure in the early period after cataract phacoemulsification YUGAY MARIA, RYABTSEVA ALLA–Moscow
17:06	1777 <i>rf</i>	Comparison of optical and psychophysical methods to measure intraocular straylight PENNOS A, GINIS HS, ARTAL P–Murcia



Daniel SCHORDERET

Institute for Research in Ophthalmology (Sion)
Faculty of Life Sciences, Ecole polytechnique fédérale de Lausanne (Lausanne)
Faculty of Biology and Medicine (Lausanne)

Eye and genes: the new ophthalmology

Introduction by Marcela VOTRUBA

For many years, ophthalmology has based its practice on observing, trying, deducing and remembering. For many pioneers, this approach was not sufficient and tools were designed to improve the diagnostic and intervention capacities for these ocular diseases. Although inheritable eye disorders have been identified many years ago—Dalton described color blindness in 1798 – it is only in the second part of the 20th century that genetics flourished. Franceschetti and Klein from Geneva published numerous reports on dysmorphology, and were part of a great effort to categorize all syndromes so that nature’s experiments were not lost. Although both were ophthalmologists, they founded the first Institute of Medical Genetics in Switzerland and made significant contributions to the field. I was blessed to discover genetics through David Klein and to further do my doctoral thesis with Eric Engel, his successor, in Geneva. Fifteen years later, the identification of the genes responsible for inherited diseases was done either by karyotyping or by linkage analysis followed by physical mapping. The former was based on luck, and often, we didn’t have any. For the latter, we needed large families and new technologies, like autoradiograms or automated.



Russell G FOSTER
University of Oxford (Oxford)

Regulating the body clock
The unrecognised role of the eye

Introduction by Einar STEFANSSON

Little more than a decade ago discussion that the eye might contain another photoreceptor, different from the rods and cones, generated either polite amusement or a hostile rebuttal. The dogma was that all light detection took place by these photoreceptors whilst the other cells of the retina act only to process visual signals. However, several lines of research led to the discovery that the vertebrate eye, including humans, contains another class of photoreceptor based upon a small number of photosensitive retinal ganglion cells (pRGCs). These specialised neurons detect environmental irradiance and regulate a wide range of physiology and behaviour including the regulation of 24h body clocks, sleep, alertness, mood and even pupil size. Furthermore, the pRGCs have been shown to utilize a novel light signalling pathway based upon the photopigment melanopsin. Collectively these findings have transformed our understanding of how the eye detects light and are redefining our assessment, treatment and care of individuals with eye disease. The discovery and current understanding of this "third" class of ocular photoreceptor will be reviewed in this presentation.

Award presentation



Reception opened by Constantin POURNARAS
EVER 2014 President





**THURSDAY
OCTOBER 2
2014**

INDUSTRY-SPONSORED BREAKFAST



Horus and Innovation

SIS
RV**Contribution of "en face" SD-OCT in retinal and choroidal pathologies**

Hermes

Martine MAUGET-FAYSSE

08:30	2211	Contribution of "en face" SD-OCT in inflammatory diseases WOLFF B, VASSEUR V, BASDEKIDOU C, DE BATS F, SAHEL J, MAUGET-FAYSSE M—Paris, Lyon
08:48	2212	Contribution of "en face" SD-OCT in MacTel type 2 BASDEKIDOU C—Paris
09:06	2213	Contribution of "en face" SD-OCT in retinal and choroidal vascular abnormalities SCEMAMA TIMSIT C, MANASSEH N, MAUGET-FAYSSE M, VASSEUR V, WOLFF B, SAHEL J—Paris
09:24	2214	Contribution of "en face" SD-OCT in retinal surgical diseases CHIQUET C, GALLICE M—Grenoble
09:42	2215	Contribution of "en face" SD-OCT in retinal toxicity CAHUZAC A, VASSEUR V, PAQUES M, WOLFF B, MAUGET-FAYSSE M—Paris

SIS
G**Ocular blood flow and glaucoma**

Rhodes 1

Gerhard GARHOFER, Leopold SCHMETTERER

08:30	2221	The role of ocular perfusion pressure in glaucoma TOPOUZIS F—Thessaloniki
08:52 ★	2222	The coupling between neuronal activity and blood flow – What can we learn about glaucoma? GARHOFER G—Vienna
09:14	2223	Plasmalogens, astrocytes, and retinal vascular development ACAR N, SAAB S, CREUZOT-GARCHER C, BRON AM, BRETILLON L—Dijon
09:36	2224	Ocular rigidity: Biological importance and clinical implications SCHMETTERER L—Vienna

Course 6 Corneal infectious diseases COS

Jean-Jacques GICQUEL

Rhodes 2

Intermediate

Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged as important types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery such as radial keratotomy or penetrating keratoplasty and with the uncontrolled use of topical steroids. The clinical setting of each of these infections is important in alerting the clinician to the possible diagnosis. There have been improvements in rapid diagnostic techniques for such infections in the last years. Treatment has also improved, but remains a difficult problem, especially for Acanthamoeba. In this course, we'll give you an overview of recent developments in the clinical and histopathologic methods for diagnosis and treatment options of these corneal infections. We will also see how new techniques such as Amniotic Membrane Transplantation and Crosslinking can help the clinician, when facing severe cases.

08:30	2231	An update on corneal bacterial infections GICQUEL J—Poitiers
08:52 ★	2232	Corneal infectious diseases in children BREMONT-GIGNAC D—Amiens
09:14	2233	Herpes and Zoster corneal infections LABETOULLE M—Le Kremlin Bicêtre
09:36	2234	Acanthamoeba keratitis: a modern approach YEUNG A—Nottingham

SIS PBP Retinal glial in the healthy and unhealthy retina

Neville OSBORNE, Manuel VIDAL-SANZ

Rhodes 3

08:30	2241	Types and functions of retinal glial OSBORNE NN—Oxford
08:48	2242	Müller cells - structural and physiological functions REICHENBACH A—Leipzig
09:06	2243	Microglial cell reaction after optic nerve lesions VILLEGAS PEREZ MP, GALINDO-ROMERO C, VALIENTE-SORIANO FJ, JIMENEZ-LOPEZ M, SOBRADO-CALVO P, AGUDO-BARRIUOSO M, VIDAL-SANZ M—Murcia
09:24 ★	2244	Retinal astrocytes -characteristics and role in retinal blood vessel development FRUTTIGER M—London
09:42	2245	The influence of ocular hypertension on retinal glial cells ROJAS B, GALLEGGO B, DE HOZ R, RAMIREZ AI, SALAZAR JJ, TRIVINO A, RAMIREZ JM—Madrid

SIS IM Future of vitreoretinal Surgery in uveitis-diagnosis and management: the next steps

Piergiorgio NERI

Rhodes 4

08:30	2251	Ocular immunology and vitreoretinal surgery "face to face" NERI P, ARAPI I, PIRANI V, CARBONARI G—Agugliano, Ancona
08:52	2252	Vitreotomy in uveitis MARIOTTI C, SAIITA A, NICOLAI M—Ancona
09:14	2253	The state of the art of diagnostic vitrectomy DICK A—Bristol
09:36	2254	The role of retinal and choroidal biopsy DA CRUZ L—London

SIS
NSPH**Neuromyelitis optica (NMO): the expanding spectrum of antibody-mediated optic neuropathy**

Gallieni 1 & 2

Aki KAWASAKI, Jérôme DE SEZE

08:30	2261	Clinical manifestations of NMO YU-WAI-MAN P—Newcastle upon Tyne
08:52	2262	Antibodies, MRI and unusual clinical features of NMO DE SEZE J—Strasbourg
09:14 ★	2263	Using OCT to distinguish NMO and other types of optic neuropathy KARDON R—Iowa City
09:36 ★	2264	Overview of treatment of NMO DE SEZE J—Strasbourg

SIS
ACB**Inflammasomes in the pathogenesis of AMD - ten year anniversary for EVER RPE SIS**

Gallieni 5

Kai KAARNIRANTA, Hannu UUSITALO



08:30	2271	From protein aggregation to inflammasome activation in RPE cells KAUPPINEN A—Kuopio
08:52 ★	2272	Investigating AMD mechanisms using primary RPE cultures and donor tissue FERRINGTON D, TERLUK M, EBELING M, ROEHRICH H, MONTEZUMA S—Minneapolis
09:14	2273	Tale of lysosome in RPE cells and in the pathogenesis of AMD SINHA D—Baltimore
09:36	2274	Dysregulated para-inflammation in the pathogenesis of AMD XU H—Belfast



Austin ROORDA

UC Berkeley School of Optometry (Berkeley)

Testing vision: one cone at a time

Introduction by Marcela VOTRUBA

In humans, gaining experimental access to single sensory receptors - photoreceptors specifically - is a challenge, yet it is crucial for learning how the signals arising from each receptor are transformed into perception. By combining adaptive-optics microstimulation with high-speed eye tracking, we show that retinal function can be probed at the level of the individual cone photoreceptor in living eyes. This talk will describe the development and applications of our adaptive optics confocal imaging system which we use to track, target and deliver visible light stimuli to single cones or selections of cones. Highlighted applications will include our ongoing efforts to learn about the neural circuits that underlie human spatial and color vision.

Award of the EVER Certificate of Honour

SIS RV	Polypoidal choroidal vasculopathies		Hermes
	Gabriel COSCAS, Constantin POURNARAS		
11:05	2411	Classification, clinical pattern, multimodal imaging COSCAS G—Creteil	
11:20	2412	Secondary polypoidal choroidal vasculopathy (PCV) DONATI G, POURNARAS C—Geneva	
11:35	2413	Genetics in polypoidal choroidal vasculopathy ZERBIB J, SEMOUN O, LALLOUM F, SIKORAV A, TILLEUL J, COSCAS G, SOUIED E—Créteil	
11:50	2414	Therapeutic approaches- aflibercept first french results of intravitreal aflibercept for active naïve polypoidal choroidal vasculopathy-6 months follow up DIRANI A, COSCAS F, COSCAS G, SEMOUN O, SOUIED E—Beirut, Creteil	
12:05	2415	Therapeutic approaches 2: Ranibizumab SEMOUN O, ZERBIB J, LALLOUM F, SIKORAV A, COSCAS F, COSCAS G, SOUIED E—Créteil	
12:20 ★	2416	Therapeutic approaches 3: PDT , Laser and combined treatments UZZAN J, COSCAS G—Rouen, Paris	

SIS G	Autoimmune mechanisms and neuroinflammation in glaucoma		Rhodes 1
	Franz GRUS		
11:05	2421	Modulators for autophagy: implications for ageing and neurodegeneration BEHL C—Mainz	
11:27	2422	Autophagy in retina and axonal degeneration BOYA P—Madrid	
11:49	2423	Autoimmunity and neuroprotection in glaucoma GRUS F—Mainz	
12:11	2424	Reactive gliosis along the visual system in rodent models of ocular hypertension VIDAL-SANZ M, GALINDO-ROMERO C, SALINAS-NAVARRO M, VALIENTE-SORIANO FJ, GALLEGO B, ROJAS B, DE HOZ R, RAMIREZ AI, SALAZAR JJ, AVILES M, TRIVINO A, RAMIREZ JM, AGUDO M, VILLEGAS PEREZ MP—Murcia, Madrid	

FP **COS 2/5 : Corneal Imaging** **Rhodes 2**
Jean-Jacques GICQUEL

11:05	2431	Electron microscopic evaluation of the surfaces of variable depth lenticules in SMILE cases OSMAN I—Alexandria
11:17	2432	Handheld reflectance in vivo confocal microscopy for the diagnosis of conjunctival tumors GRIVET D, HAOUAS M, JULIENNE R, PERROT JL, LABEILLE B, CAMBAZARD F, FOREST F, DUMOLLARD JM, PEOC'H M, GAIN P, THURET G, CINOTTI E—Saint-Etienne
11:29	2433	Peripheral neuropathy in Parkinson disease: An in vivo confocal microscopy study ANJOS R, VIEIRA L, SOUSA A, MADURO V, ALVES N, CANDELARIA P—Lisboa
11:41	2434 <i>rf</i>	Reproducibility of keratometric measurements obtained with OCULUS® Pentacam® HR in the evaluation of keratoconus progression SILVA N, VIEIRA L, ANJOS R, ALVES N, MADURO V, FEIJAO J, CANDELARIA P—Lisboa
11:47	2435 <i>rf</i>	Peripheral neuropathy in chronic renal failure: an in vivo confocal microscopy study VIEIRA L, ANJOS R, SOUSA H, SOUSA A, BORGES A, BRANCO P, ALVES N, MADURO V, CANDELARIA P—Lisboa
11:53	2436 <i>rf</i>	Mathematical model of corneal reendothelialization after inadvertent descemetorhexis TRONE M, JULIENNE R, RANNOU K, BERNARD A, HE Z, GAVET Y, THURET G, GAIN P—Saint-Etienne
11:59	2437 <i>rf</i>	Investigation of anterior chamber flare and corneal Langerhans cells in rheumatoid arthritis and in dry eye MARSOVSZKY L, BAUSZ M, NÉMETH J, RESCH M—Budapest

FP **EOVS 1/1 : Visual function and physiology** **Rhodes 3**
Miguel CASTELO-BRANCO, Werner SPILEERS

11:05	2441	Developing a clinically viable protocol for measuring and analysing the human contrast sensitivity function on a standard computerised chart DONALD J, LI J, SAROSSY M, WEYMOUTH A—Parkville
11:17	2442	Flash visual evoked potentials (FVEP) in various stimulation conditions POJDA-WILCZEK D—Katowice
11:29	2443	Simulation of DME changes on OCT CORREIA A, ARAÚJO A, BARBEIRO S, CAMELO F, SERRANHO P, MORGADO M, BERNARDES R—Coimbra, Lisboa
11:41	2444	Visual Search Test (VST) - reaction time perimetry with fixation objects detectable only by foveal vision LEINONEN M, KNAAPI L—Turku, Pori
11:53	2445	Visual impairment in diabetic patients with and without established blood-retinal barrier leakage and relation with the status of the blood-brain barrier QUENDERA B, AMORIM A, CORDEIRO M, FERREIRA C, MARQUES J, BERNARDES R, REIS A, RIBEIRO L, CASTELO-BRANCO M—Coimbra
12:05	2446	Chromatic pupillometry for assessment functional rod and cone patterns in Usher syndrome patients SLIESORAITYTE I, MACHIN C, MAKOWIECKA K, MOHAND-SAID S, SAHEL J—Paris

SIS NSPH **New developments in paediatric strabismus and amblyopia** **Rhodes 4**
Marcel TEN TUSSCHER, Jonathan M. HOLMES

11:05	2451	New concepts concerning the neural mechanisms of infantile strabismus and amblyopia TEN TUSSCHER M–Brussels
11:27	2452	Curable forms of childhood strabismus MOHNEY B–Rochester
11:49	2453	Assessing stereopsis in preverbal children HOUTMAN AC–Brussels
12:11	2454	Amblyopia treatment trials HOLMES JM–Rochester MN

SIS MBGE **The genetics of keratoconus** **Gallieni 1 & 2**
Petra LISKOVA

11:05	2461	What genetics has taught us about keratoconus VINCENT AL–Auckland
11:35	2462	Genome-wide association studies for the identification of keratoconus susceptibility regions HYSI P–London
12:05	2463	Twin studies in keratoconus LISKOVA P–Prague

SIS ACB **You don't always need a knife ... - scleral lenses in ocular surface disease** **Gallieni 5**
Nadja KNOP, Rene MELY

11:05	2471	Ocular surface anatomy and physiology underlying scleral lens application KNOP E, KNOP N–Berlin, Hannover
11:23	2472	Coming back to the basics – overview on therapeutic contact lenses and scleral lenses MELY R–Valmont
11:41	2473	Scleral Lenses in the United States JACOBS D–Needham
11:59	2474	The rebirth of scleral lenses in Europe – 20 years of experience in treating ocular surface disease with scleral lenses MANCZAK H–Poznan
12:17 ★	2475	Scleral lenses as a high tech, versatile and cost efficient tool for the treatment of ocular surface disease in less developed countries MEKKI MB, YAHIAOUI S, BELAOUDMOU R, MOKHTARI MA–Algiers

INDUSTRY-SPONSORED SYMPOSIUM 2



What's new in micronutrition for AMD patients?

Moderator: Jean François KOROBELNIK

12:35		Introduction
12:40	2531	Effect of resveratrol on RPE cells and its potential role in AMD prevention KAARNIRANTA K–Kuopio
12:55	2532	New evidence from French investigation KOROBELNIK J–Bordeaux
13:10	2533	How to identify patients with nutritional risk factors for AMD? ASLAM T–Manchester
13:25		Conclusions



Bahram BODAGHI
University of Pierre and Marie Curie (Paris)

Revisiting infectious triggers of chronic intraocular immunity

Introduction by Uwe PLEYER

The pathogenesis of intraocular inflammation has been extensively revisited on the basis of different sophisticated experimental models but also new molecular tools applied to ocular fluids or tissues. Experimental ocular inflammation may not be induced in germ-free animal facilities. Moreover, an infectious agent has been identified in patients presenting with different uveitis entities, previously considered as autoimmune and therefore treated with corticosteroids and aggressive immunosuppressive agents. Molecular mimicry or expression of foreign antigens may trigger an inflammatory reaction, masquerading as an autoimmune uveitis. Fuchs cyclitis, Posner-Schlossman syndrome, serpiginous choroiditis, nonnecrotizing herpetic retinopathies have been recently characterized, expanding the spectrum of infectious uveitis. Microbiological identification remains the first step prior to initiation of a specific therapy, reducing the risk of relapse and achieving a better visual outcome in challenging situations.

Award presentation

FIRST AFTERNOON SESSION | 14:20 - 15:50

Course 7 Diabetic retinopathy RV

Catherine CREUZOT, Pascale MASSIN

Hermes

Beginners

The aim of this course is to help students to understand the different features occurring during diabetic retinopathy. Based on the pathophysiology, speakers will present the abnormalities linked to diabetes and the consequences observed in clinical practice. These aspect will concern diabetic retinopathy, macular edema and the different therapeutic options. Finally, clinical cases will be presented.

14:20	2611	Classification of DR MASSIN P-Paris
14:38	2612	Macular edema LOEWENSTEIN A-Tel Aviv
14:56	2613	Anti VEGF POURNARAS C-Genève
15:14	2614	Steroids KODJIKIAN L-Lyon
15:32	2615	Clinical cases CREUZOT-GARCHER C-Dijon

SIS Neuroprotection in European glaucoma G

M Francesca CORDEIRO, Miriam KOLKO

Rhodes 1

14:20	2621	Neuroprotection in the real world KURYSHEVA N-Moscow
14:42	2622	Current and emerging concepts in neuroprotection CORDEIRO M-London
15:04	2623	Possible future strategies in Neuroprotection PICAUD S, FROGER N, MATONTI F, FORSTER V, IVKOVIC I, BRUNEL N, SAHEL J-Paris
15:26	2624	NP in glaucoma – pitfalls and promises? SCHMETTERER L-Vienna

Course 8 Why do you need wavefront aberrometry and straylight COS measurement in your daily practice ?

Jean-Jacques GICQUEL, Pierre Jean PISELLA

Rhodes 2

Beginners

Quality of vision is a new comprehensive set of measures that determines visual performance at near, far and in variable light conditions. Good vision is no longer defined by 20/20 vision. The necessity of evaluating vision beyond Snellen acuity has led clinicians and vision scientists to utilize contrast sensitivity, wavefront aberrometry and straylight measurement in most clinical trials related to vision. Recently, the advent of 3D movies and 3D TVs brought us new challenges regarding 3 3 Dimensional Quality of Vision. In this course, experts will share with you their experience on this new frontier of modern ophthalmology.

14:20	2631	Wavefront Aberrometry: from basics to daily practice GICQUEL J-Poitiers
14:50	2632	Customization of Intraocular Lenses: a practical approach PISELLA P-Tours
15:20 *	2633	Straylight for dummies: applications in your daily practice VAN DEN BERG T-Amsterdam

FP **IM 1/2 : Advances in pathophysiology and diagnostics of ocular inflammatory diseases** **Rhodes 3**

Ahmed ABU EL ASRAR, Heping XU

14:20	2641	Cytokine gene expression and protein production in West Nile virus-infected retinal pigment epithelium MUNOZ-ERAZO L, MADIGAN M, KING NJC—Sydney
14:32	2642	Aqueous humor cytokine profile of patients with primary or recurrent ocular toxoplasmosis THIEME C, PLEYER U, METZNER S, DAMES C, SCHLICKEISER S, DOBNER B, VOLK HD—Berlin
14:44	2643	A new and standardized method to sample and analyse vitreous biopsies in unsolved uveitis by the Cellient® automated cell block system VAN CALSTER J, VAN GINDERDEUREN R—Leuven
14:56	2644	Specifics of viral entry in epidemic keratoconjunctivitis RAJAIYA J, YOUSUF MA, MUKHERJEE S, LEE JS, ZHOU X, RAMKE M, LEE JY, CHODOSH J—Boston
15:08	2645 <i>rf</i>	FGFβ and TGFβ contribute to tissue remodeling, fibrosis and inflammation in the orbital tissue of severe Grav PAWLOWSKI P, RESZEC J, ECKSTEIN A, JOHNSON K, GRZYBOWSKI A, CHYCZEWSKI L, MYSLIWIEC J—Bialystok, Essen, Poznan
15:14	2646 <i>rf</i>	Study of TOXO KO vaccine efficiency on the ophthalmological damage bound to Toxoplasma gondii, on a mouse model of ocular toxoplasmosis LEMEÉ G, MORISSE S, TARFAOUI N, DIMIER-POISSON I, SECHE E, PISELLA P—Tours
15:20	2647 <i>rf</i>	Eswab® transport media and 16S RNA PCR in the microbiological diagnosis of infectious keratitis BAUDONNET R, GARNIER F, ROBERT PY—Limoges
15:26	2648 <i>rf</i>	Infectious keratitis: 4 years in a tertiary hospital ANJOS R, VICENTE A, BORGES B, VIEIRA L, PINTO M, MADURO V, ALVES N, CANDELARIA P—Lisboa

FP **NSPH 1/2 - Pediatric session** **Rhodes 4**

Dominique BREMOND-GIGNAC, Cameron PARSA

14:20	2651	Advanced glycation end-products induced activation of NFκB and its suppression by different neurotrophic factors BIKBOVA G, OSHITARI T, YAMAMOTO S—Chiba
14:32	2652	Retinal vessel pathologies in a rat model of periventricular leucomalacia LORENZ B, STECK J, BLUEML C, KAMPMANN S, GERSTNER B, MAIER RF, STIEGER K—Giessen, Marburg
14:44	2653	Focal venous hypertension as a pathophysiologic mechanism for port-wine stains and the Sturge-Weber syndrome PARSA C—Paris
14:56	2654	Incidence and characteristics of congenital cataract surgery in France from 2010 to 2012 DAIEN V, ELIAOU-MALRIEU C, LEPAPE A, HEVE D, VILLAIN M—Montpellier
15:08	2655 <i>rf</i>	A new pediatric vision screener employing polarization-modulated, retinal-birefringence-scanning-based strabismus detection and bull's eye focus detection IRSCH K, GAMATIKOV B, WU YK, GUYTON D—Baltimore
15:14	2656 <i>rf</i>	Neosynephrine and tropicamide eyedrops for pupil dilation in premature infants is almost twice as efficient as tropicamide eyedrops alone LUX AL, GUILLOIS B, DEGOUMOIS A, MOURIAUX F, DENION E—Caen
15:20	2657 <i>rf</i>	3D shape perception in strabismus subjects SAWAMURA H, GILBERT C, TODD JT, VANDENBERGHE R, ORBAN GA—Tokyo, Oxford, Columbus, Leuven, Parma
15:26 ★	2658 <i>rf</i>	Clinical experience with Raxone® (Idebenone) in the treatment of patients with Leber's hereditary optic neuropathy (LHON) METZ G, GALLENMÜLLER C, VON LIVONIUS B, LOB F, COPPARD N, MEIER T, KLOPSTOCK T—Liestal, Munich

FIRST AFTERNOON SESSION | 14:20 - 15:50

SIS MBGE Clinical & molecular aspects of albinism Gallieni 1 & 2

Bart LEROY, Benoit ARVEILER

14:20	2661	Normal pigment production ARVEILER B–Bordeaux
14:42	2662	The array of clinical albinism subtypes LEROY BP–Ghent
15:04	2663	Genotypes & molecular strategies in albinism ARVEILER B, LASSEAUX E, MORICE-PICARD F–Bordeaux
15:26	2664	Electrophysiology in the diagnosis of albinism HOLDER GE, NEVEU MM–London

SIS ACB When the oil runs dry - Innovative treatment options for MGD Gallieni 5

Erich KNOP, David A. SULLIVAN

14:20	2671	Innovative treatments for MGD - EVER more important for ocular surface disease KNOP N, KNOP E–Hannover, Berlin
14:35	2672	Individual physical therapy of MGD in private setting by a moist heat device PURSLOW C–Monmouth
14:50	2673	Automatic application of warmth and expression – a breakthrough in physical therapy of dry eye GREINER J–Boston
15:05 *	2674	Restoration of meibomian gland function in severe dry eye disease due to obstructive MGD with an automated physical therapy device FINIS D, HAYAJNEH J, KÖNIG C, BORRELLI M, SCHRADER S, GEERLING G–Dusseldorf
15:20 *	2675	Azithromycin and MGD: Is it possible to turn an off-label treatment into an on-label therapy? SULLIVAN DA, KAM WR, DING J, LIU Y–Boston
15:35 *	2676	Clinical experiences with short-term delivery of azithromycin in conjunctival inflammation and MGD DOAN S–Paris

Electrophysiology, physiological Optics, Vision Sciences

Moderators: Miguel CASTELO BRANCO, Graham HOLDER, Werner SPILEERS

- T001 Association between ocular optical components and refractive errors in bank's Employees of Sari, Iran
YEKTA AA, HASHEMI H, NAKHAE MA, KHABAZKHOOB M, OSTADIMOGHADDAM H, HERAVIAN J, AZIMI A, YEKTA R—Mashhad, Tehran
- T002 Objective and subjective examinations for evaluation the degree of drusen-related optic nerve neuropathy
POJDA-WILCZEK D, WYCISIO-GAWRON P—Katowice
- T003 Using statistical decomposition to improve the identification of the photopic negative response of the erg
SAROSSY M, HADOUX X, TANG J—Melbourne, Montpellier
- T004 Follow-up of patients under therapy with hydroxichloroquine via merg, sd-oct, af and automated perimetry
MOGAVERO V, RUBERTO G, RAIMONDI M, LANTERI S, PICCININI P, BIANCHI PE—Pavia
- T005 Clinical application of 3D monitor in ophthalmologic field: Measurement of metamorphopsia
KIM YT, KIM JW—Seoul
- T006 Reproducibility of retinal oximetry measurements in healthy and diseased retinas
TÜRKSEVER C, ORGÜL S, TODOROVA MG—Basel
- T007 Prevalence of refractive error in school childrens with color vision deficiencies
OSTADIMOGHADDAM H, YEKTA AA, HERAVIAN J, AHMADI HOSSEINI M, VATANDOUST S, ABOLBASHARI F, SHARIFI F—Mashhad
- T008 Changes in ocular factors according to motion-in-depth of 3D display and viewer age
YUM HR, SHIN SY, KANG HB, PARK SH—Seoul, Bucheon-si
- T009 Effects of long duration dive (8, 10 and 12 hours) with hyperbaric hyperoxia on Navy divers' eye and visual function
VALERO B, CASTAGNA O, BRUGIER A, VIGNAL R, DE FARIA A, BOURNIQUEL M, SEKFALI R, BLATTEAU JE, GIRAUD JM—Toulon
- T010 A novel technique for measuring dark adaptation using a dual stimulus method: Effects of aging and AMD on dark adaptation
RODRIGO E, TAHIR HJ, PARRY NRA, KELLY JMF, ASLAM T, CARDEN D, MARRAY IJ—Manchester
- T011 Color vision evaluation test
IONICA V—La Colle sur Loup
- T012 Color perception levels in patients with hyperopia
BOGATYREVA E, KOVALEVSKAYA M—Voronezh
- T013 Comparing short-duration electro-oculogram with and without mydriasis in controls
TÜRKSEVER C, ORGÜL S, TODOROVA MG—Basel

Glaucoma

Moderators: Adèle EHONGO, Jean-François ROULAND, Philippe KESTELYN, Gordana SUNARIC MEGEVAND

- T014 Topical treatment- are we adhering to guidelines?
★ ANSARI E, FAGJENBAUM M—Maidstone
- T015 Treatment satisfaction: Can we trust our glaucoma patients?
★ TISSIER P, LEMIJ H, BAUDOQUIN C—Clermont Ferrand, Rotterdam, Paris
- T016 Patient satisfaction after preservative free latanoprost; the PASSY survey in Germany
★ ERB C—Berlin
- T017 Two simple animal models of intraocular pressure elevation for testing therapeutic drugs in glaucoma
GRILLO-ANTONELLI S, CIMBOLINI N, FERAILLE L, ELENA P—La Gaude
- T018 Impact of preservatives' elimination on tolerance and efficacy of latanoprost
MISIUK HOJLO M, MULAK M, POMORSKA M, REKAS M, WIERZBOWSKA J, PROST M, WASYLUK J, LUBINSKI W, PODBORACZYNSKA-JODKO K, ROMANIUK W, KINASZ R, ORTYL-MARKIEWICZ R, MOCKO L, ZALESKA-ZMIJEWSKA A, ROKICKI D—Wroclaw, Warsaw, Szczecin, Katowice, Legnica
- T019 Intravenous hypertonic saline - the effect of splitting the dose
TORVINEN P, HARJU M, KIVELÄ T—Helsinki
- T020 IOP-lowering effect and ocular toxicity of ONO-0476, a prodrug of a novel prostanoid EP2 receptor agonist, in normotensive cynomolgus monkeys
★ GOTO Y, MORIYUKI K, YAMAMOTO H, YAMANE S, SUGITANI M, HIROTA Y—Osaka
- T021 The estimate prevalence of glaucoma & trend of glaucoma care in south korea based on national claim database
SEO SJ, BAE HW, LEE YH, LEE SY, HONG S, SEONG GJ, KIM CY—Seoul
- T022 Cannabinoids: a novel treatment for glaucoma
SAMUDRE S, HOSSEINI A, LATTANZIO F—Chesapeake, Norfolk
- T023 The effect of preservative free tafluprost on intraocular pressure in patients with ocular hypertension or primary open angle glaucoma
HOMMER A, KROMUS M, SCHMIDL D, GARHOFER G, SCHMETTERER L—Vienna
- T024 Dynamic dark-light changes in anterior chamber and iris parameters in angle closure patients with novel automatic algorithm using anterior segment optical coherence tomography (AS-OCT)
LEE TL, ANG L, TIAN J, YIP L—Singapore
- T025 Test-retest reliability on measuring anterior chamber parameters with a novel automatic algorithm using anterior segment optical coherence tomography
ANG L, LEE T, NG J, YIP L—Singapore
- T026 Comparison of prelaminar thickness between primary open angle glaucoma and normal tension glaucoma patients
JUNG Y, PARK H, PARK C—Seoul

Glaucoma

**Moderators: Adèle EHONGO,
Jean-François ROULAND, Philippe KESTELYN,
Gordana SUNARIC MEGEVAND**

T027 Changes in ganglion cell complex thickness in patients treated with intravitreal anti-vascular endothelial growth factor therapy
CHO B, LEE JY, YOO RM—Seoul

T028 Hemifield patten electroretinogram and macular thickness asymmetry parameters in ocular hypertension patients
FINZI A, TASSI F, GIZZI C, CELLINI M—Bologna

T029 Swept source optical coherence tomography artifacts in glaucoma patients
LEE SY, SEO SJ, LEE YH, BAE HY, KIM CY—Seoul

T030 Position of the central retinal vessel trunk and location of visual field and parapapillary nerve fibers damage in early to moderate glaucoma
BESOMBES G, GRUNEWALD F, ROULAND J—Lille

T031 Evaluation of peripapillary choroidal thickness in patients with glaucoma
MUMCUOGLU T, OZGE G, OZGONUL C—Ankara

T032 Progression rate in glaucoma using spectral-domain optical coherence tomography
LEE Y—Seoul

T033 HRT versus OCT in diagnosing preperimetric glaucoma
BOUHACINA BENMANSOUR A, ROULAND J—Lille

T034 Structure-function relationship: Ganglion cell-inner plexiform layer thickness by SD-OCT and central visual field sensitivity
CHAPRON T, MARECHAL M, EL CHEHAB H, FENOLLAND JR, MARILL AF, ROSENBERG R, DELBARRE M, MOUINGA A, RENARD JP—Paris

T035 Color Doppler imaging and glaucoma: comparison of Doppler Waveform and velocities of retrobulbar vessels between a glaucomatous patient and a healthy subject
VERTICCHIO VERCELLIN A, CUTOLO C, DELLAIORE C, LAVA M, TINELLI C, CALLIADA F, MILANO G—Pavia

T036 Evaluation of CANON SD HS 100 OCT : Reproducibility of macular ganglion cell complex (GCC) thickness measurement in normal, hypertensive and glaucomatous eyes
ROSENBERG R, MARILL AF, FENOLLAND JR, EL CHEHAB H, DELBARRE M, MARECHAL M, MOUINGA A, RENARD JP—Paris

T037 Visual field defects in pre-perimetric glaucoma identified by customized oct - guided white-on-white automated perimetry
MAGOURITSAS G, GEORGIADIS O, PORTALIOU DM, MOSCHONAS K—Athens

T038 Analyze of visual field indices in ocular hypertension: PROG-F3 study
DELBARRE M, GIRAUD JM, APTEL F, EL CHEHAB H, RENARD JP—Paris, Grenoble

T039 Interest of central 10-2 visual field in glaucomatous and glaucoma suspects patients with normal central 24-2 visual field
MARECHAL M, CHAPRON T, EL CHEHAB H, FENOLLAND JR, MARILL AF, ROSENBERG R, DELBARRE M, MOUINGA A, RENARD JP—Paris

T040 Risk factors for an initial central scotoma compared with an initial peripheral scotoma
CHO B, KANG JW, PARK BJ—Seoul

T041 The association of nailfold capillaroscopy with systemic matrix metalloproteinase-9 concentration in normal-tension glaucoma
LEE N, PARK C—Seoul

T042 ★ Refractory open angle glaucoma treated by high intensity focused ultrasound (HIFU). Results at one year of a prospective series
ROULAND J, APTEL F—Lille, Grenoble

T043 Comparison of two methods for location of the ciliary body before glaucoma treatment using High Intensity Focused Ultrasound (HIFU)
APTEL F, ROULAND J, CHAVEROT D, DUPUY C, COPPIN J—Grenoble, Lille, Rillieux-la-Pape

T044 ★ Multicenter clinical trial of ultrasonic circular cyclo coagulation in glaucoma patients naive of filtering surgery. Preliminary results at 6 months
APTEL F, DENIS P, ROULAND J, RENARD JP, BRON AM—Grenoble, Lyon, Lille, Paris, Dijon

T045 Intraocular pressure dynamics during one year followup after phacotrabeculectomy versus trabeculectomy for primary open angle glaucoma
POPA CHERECHEANU A, COMAN C, PIRVULESCU R, DASCALU AM, GEAMANU A, STANA D, DUTA S, GRADINARU S, IANCU R—Bucharest

T046 Choroidal detachment in post trabeculectomy patients in an asian tertiary eye centre
XU YP, YIP WLL, YONG KYV, LIM BA, WONG HT, GAN N—Singapore

T047 Bleb needling outcomes for failed trabeculectomy blebs in Asian eyes: a 2 year follow up
TSAI A, BOEY PY, HTOON HM, WONG TT—Singapore

T048 Serial changes in the bleb wall after glaucoma drainage implant surgery: Characteristics during the hypertensive phase
JUNG KI—Seoul

T049 Management of secondary glaucoma in patients with uveitis
MUMCUOGLU T, OZGE G—Ankara

T050 *rf* Self-tonometry is useful to detect IOP elevations in DALK patients with apparently normal intraocular pressures
SMEDOWSKI A, TARNAWSKA D, WYLEGALA E—Katowice

T051 *rf* Filtering blebs functionality after trabeculectomy: a clinical and in vivo confocal microscopy study
VIEIRA L, SANTOS A, LISBOA M, AMARAL A, CUNHA JP, MADURO V, REINA M—Lisbon

T052 ★ *rf* Different aspects of IOP measurements with GAT versus DCT in glaucoma patients
MEIER-GIBBONS F—Rapperswil


Immunology / Microbiology

Moderators: Uwe PLEYER, Moncef KHAIRALLAH

- T053 Long-term efficacy of interferon in severe uveitis associated with Behçet disease
DIWO E, GUEUDRY J, WESCHLER B, SAADOUN D, LE HOANG P, BODAGHI B—Paris, Rouen
- T054 Efficacy and safety of anti TNF in non-infectious uveitis: a multi-center retrospective study
BIDAUT GARNIER M, VALLET H, SEVE P, HERON E, PERLAT A, TIEULIE N, PERARD L, LEHOANG P, SAADOUN D, BODAGHI B—Besançon, Paris, Lyon, Rennes, Nice
- T055 *rf* FGFB and TGFB contribute to tissue remodeling, fibrosis and inflammation in the orbital tissue of severe Grav
PAWLOWSKI P, RESZEC J, ECKSTEIN A, JOHNSON K, GRZYBOWSKI A, CHYCZEWSKI L, MYSLIWIEC J—Bialystok, Essen, Poznan
- T056 MHC Class II expression in the retina during experimental autoimmune uveitis
LIPSKI D, DEWISPELAERE R, FOUCAUT V, CASPERS L, BRUYNS C, WILLERMAIN F—Brussels
- T057 Staphylococcal Panton-Valentine leucotoxin targets retina through the ganglion cell layer in a rabbit toxin-induced endophthalmitis model
HEITZ P, TAWK M, PRÉVOST G, GAUCHER D—Strasbourg
- T058 *rf* Infectious keratitis: 4 years in a tertiary hospital
ANJOS R, VICENTE A, BORGES B, VIEIRA L, PINTO M, MADURO V, ALVES N, CANDELARIA P—Lisboa
- T059 *rf* Study of TOXO KO vaccine efficiency on the ophtalmological damage bound to Toxoplasma gondii, on a mouse model of ocular toxoplasmosis
LEMEE G, MORISSE S, TARFAOUI N, DIMIER-POISSON I, SECHE E, PISELLA P—Tours
- T060 ★ Dexamethason implant versus posterior sub-tenon triamcinolone acetate for treatment of macular edema and/or vitritis in intraocular inflammatory diseases. Retrospective cases-series
ERRERA MH—Paris
- T061 Ocular manifestations among hiv children at the regional hospital of bafoussam - cameroon
DOMNGANG NOCHE C, KAGMENI G, KEMAYOU D, BELLA A—Bangangte, Yaounde
- T062 *rf* Eswab® transport media and 16S RNA PCR in the microbiological diagnosis of infectious keratitis
BAUDONNET R, GARNIER F, ROBERT PY—Limoges
- T063 Impact of herpes zoster on quality of life and age-related functional decline
LABETOULLE M—France
- T064 Antiviral effects of HSV1-specific meganucleases in a mouse model of relapsing herpes keratitis
LABETOULLE M, GABISON E, ROUSSEAU A, ARNOULD S, GALETTO R, PASDELOUP D—Kremlin Bicêtre, Paris, Gif/Yvette
- T065 Comparative immunological study of lamellar and penetrating keratoplasty in murine model
LEE HS, CHOI MINY, JOO CHOUN—Seoul

Molecular Biology / Genetics / Epidemiology

Moderators: Bart LEROY, Jochen GRAW

- T066 Funcionality characterization of RS2229094 (T>C) polymorphism and LTA expression in human retinas
DELGADO TIRADO S, PASTOR IDOATE S, RODRIGUEZ HERNANDEZ I, ROJAS J, GONZALEZ BUENDIA L, GONZALEZ SARMIENTO R, PASTOR JC—Valladolid, Salamanca
- T067 Comparative analysis of two ocular endothelial cells
MAMMADZADA P, GUDMUNDSSON J, KVANTA A, ANDRE H—Stockholm
- T068  Exogenous regulation of the HIF pathway in RPE cells
ANDRE H, EKSTROM M, TAKEI A, MA Y, KVANTA A—Stockholm
- T069 *rf* Visual dysfunction and pupillary responses are dissociated in the Opa3 mutant mouse with retinal degeneration
VOTRUBA M, DAVIES JR, DOUGLAS RH, DAVIES VJ—Cardiff, London
- T070 Severe retinal degeneration in females with c.2543del mutation in the RPGR gene
KOUSAL B, SKALICKA P, VALESOVA L, COLCLOUGH T, HART-HOLDEN N, O'GRADY A, HARDCASTLE AJ, LISKOVA P—Praha, Manchester, London, Prague
- T071 The functional role of RPGR protein complex in retinitis pigmentosa
SHU X, PATNAIK S, CRAFT J, MCCULLOCH D—Glasgow
- T072 *rf* Biomarkers of Age-Related Macular Degeneration (AMD): Four new obesity-related genetic loci are associated with advanced AMD
PATERNO JJ, HELISALMI S, TOKARZ P, BLASIAK J, HILTUNEN M, UUSITUPA M, KAARNIRANTA K—Kuopio, Lodz
- T073 Epidemiology of age-related-macular-degeneration in north of France
DURIEUX P, DELEMOTTE A, LABREUCHE J, ROULAND J, LABALETTE P—Lille, Anzin
- T074 *rf* BAX and BCL-2 genes in patients with Retinal Detachment with and without Proliferative Vitreoretinopathy. The Retina 4 project
GONZALEZ-BUENDIA L, PASTOR-IDOATE S, RODRIGUEZ-HERNANDEZ I, ROJAS J, GONZALEZ-SARMIENTO R, PASTOR JC—Valladolid, Salamanca
- T075 Lysyl Oxidase-Like 1 gene haplotypes and their association with pseudoexfoliation glaucoma in the Spanish population
ALVAREZ L, GARCIA M, GONZALEZ-IGLESIAS H, ESCRIBANO J, RODRIGUEZ-CALVO PP, FERNANDEZ-VEGA L, COCA-PRADOS M—Oviedo, Albacete
- T076 Analysis of the polymorphic variants of genes involved in miRNA pathway and its impact on matrix metalloproteinases (MMPs) in pathogenesis of primary open angle galucoma
MAJSTEREK I, WALCZAK A, MARKIEWICZ L, PRZYBYLOWSKA-SYGUT K, SZYMANEK K, GACEK M, SZAFLIK J, SZAFLIK JP—Lodz, Warsaw
- T077 A prospective study of ocular manifestations in transthyretin-related familial amyloid polyneuropathy
MENEY J, BARREAU E, MINCHEVA Z, CAUQUIL C, LABETOULLE M, ADAMS D, ROUSSEAU A—Le Kremlin-Bicêtre

**Molecular Biology / Genetics /
Epidemiology**

Moderators: Bart LEROY, Jochen GRAW

- T078 *rf* Analysis of Keratoconus genetic factors within Keratoconus Loci and mtDNA
NOWAK DM, KAROLAK JA, KUBICKA M, KULINSKA K, POLAKOWSKI P, SZAFLIK JP, GAJECKA M—Poznan, Warsaw
- T079 Impact of age of myopia onset and parental myopia severity on the eventual myopia status in an individual
LIM SJ—Edinburgh
- T080 ADVISE (ADenoVirus Initiative Study in Epidemiology)
DUQUESROIX B, TUIL E, MESSMER EM—Valbonne, Paris, Munich
- T081 Novel and known FRMD7 mutations and copy number variation in Belgian patients with X-linked idiopathic infantile nystagmus
ALMOALLEM B, BAUWENS M, WALRAEDT S, DELBEKE P, VERDIN H, VAN CAUWENBERGH C, DE LEENEER K, HOOGHE S, KESTELYN P, AL-OBEIDAN S, DE ZAEYTIJD J, LEROY BP, DE BAERE E—Ghent

**Neuro-ophthalmology / Strabism. /
Paediatric Ophthalm. / History of
Ophthalm.**

Moderators: Aki KAWASAKI, Carl ARNDT

- T082 Change of ocular components after cycloplegia in children using the IOLMaster
CHANG HR, JANG HJ—Seoul
- T083 Fluorescein angiography in the management of ROP occurred at a late postmenstrual age: our experience on seven premature infants
GUAGLIANO R, BARILLA' D, BERTONE C, SPALLONE L, MAFFIA A, BIANCHI PE—Pavia
- T084 Interest of an ophthalmological consultation dedicated to the children presenting autism spectrum disorders
JANY B, MONTANARI S, BASSON W, JONQUA F, MILLE C, MILAZZO S—Amiens
- T085 Susac syndrome revealed by retinal arterial occlusions in a 12 year old girl
BEAUJEUUX P, CLOCHE V, TRECHOT F, ANGIOI K—Nancy
- T086 Subfoveal choroidal thickness in myopic and non myopic children
FONTAINE M, SAUER A, GAUCHER D, SPEEG-SCHATZ C—Strasbourg
- T087 Comparative study of RNFL, GCA (macular ganglionar cells) OCT alteration and MRI lesions in a population of multiple sclerosis patients (MS) with a recent history (less than 4 years)
BOURNIQUEL M, VALERO B, DE FARIA A, GIRAUD JM—Toulon
- T088 Multifocal and toric implantation in a paediatric population: a retrospective study
HEITZ A, RITZ M, SAUER A, SPEEG-SCHATZ C—Strasbourg
- T089 Strabismus and nystagmus in the congenital cataracts
LEE S, PARK J—Busan
- T090 Results of the surgical treatment of concomitant strabismus with preliminary modeling of operation by using three-dimensional biomechanical eye's model
BUSHUYEVA NN, ROMANENKO DV—Odessa
- T091 Clinical features of oculomotor disorders and nystagmus among children presenting congenital glaucoma
AZIZ A, MATONTI F, SAUVAN L, FAKHOURY O, PIERI E, DENIS D—Marseille
- T092 *rf* A new pediatric vision screener employing polarization-modulated, retinal-birefringence-scanning-based strabismus detection and bull's eye focus detection
IRSCH K, GAMATIKOV B, WU YK, GUYTON D—Baltimore
- T093 *rf* Neosynephrine and tropicamide eyedrops for pupil dilation in premature infants is almost twice as efficient as tropicamide eyedrops alone
LUX AL, GUILLOIS B, DEGOUMOIS A, MOURIAUX F, DENION E—Caen
- T094 *rf* 3D shape perception in strabismus subjects
SAWAMURA H, GILBERT C, TODD JT, VANDENBERGHE R, ORBAN GA—Tokyo, Oxford, Columbus, Leuven, Parma

- T095 Microglial activation in a rat model of NAION
REMOND A, FEL A, SIMONUTTI M, IVKOVIC I, FROGER N, SAHEL J, LE HOANG P, BODAGHI B, PICAUD S, TOUITOU V—Paris
- T096 Metastasis of breast cancer presenting as one and half syndrome
HYUNKYUNG KIM, TAEYOON LA—Suwon
- T097 The use of statistical modeling to predict temporal artery biopsy outcome from presenting symptoms and laboratory results
LEE M, DE SMIT E, WONG TEN YUEN A, SAROSSY M—Melbourne
- T098 The role of cerebrospinal fluid in optic disc pit maculopathy: a case report studied by enhanced depth imaging optical coherence tomography (EDI-OCT)
MARTINEZ VELEZ M, ASCASO FJ, HUERVA V, CRISTOBAL J, ZABADANI K, ALMENARA C, HERRERA L, PEREZ NAVARRO I, CARMELLO C—Zaragoza
- T099 Choroidal thickness and volume in healthy children measured by enhanced depth imaging optical coherence tomography
HERRERA L, PEREZ NAVARRO I, CARMELLO C, ZABADANI K, ALMENARA C, PÉREZ D, MARTINEZ M, SANCHEZ A, PINILLA I, ESTEBAN O—Zaragoza
- T100 The choroid profiles at the posterior pole measured by enhanced depth imaging optical coherence tomography in healthy Korean children
LEE J, KIM J—Daegu
- T101 Comparative difference of the choroidal thickness according to the refractive errors measured by enhanced depth imaging optical coherence tomography
LEE J, YU S—Daegu
- T102 The application of Colour Contrast Sensitivity test to the early prediction of chiasm damage in cases of pituitary adenoma
KRIAUCIUNIENE L, SLATKEVICIENE G, LIUTKEVICIENE R, ZALIUNIENE D, BERNOTAS G, GLEBAUSKIENE B, TAMASAUSKAS A—Kaunas
- T103 *rf* Brain structural and functional reorganization due to long term retinal peripheral degeneration in retinitis pigmentosa
FERREIRA S, PEREIRA AC, QUENDERA B, MATEUS C, SILVA E, CASTELO-BRANCO M—Coimbra
- T104 *rf* Visual intelligence in action: A question of balance? Neuroplasticity: recent findings on the visual system for the practitioner
VANDERMEULEN J—Geleen/ Sittard
- T105 Sudden bilateral vision loss and binasal campimetric involvement in an unusual case of lateral geniculate myelinolysis
JIMENEZ DEL RIO B, PALACIN M, PÉREZ D, ASCASO FJ—Zaragoza, Calatayud
- T106 Prediction of Parkinson's disease severity based on RNFL thickness evaluated by OCT
JIMENEZ DEL RIO B, ASCASO FJ, CRISTOBAL J, PÉREZ D, IBAÑEZ J, LÓPEZ DEL VAL J—Zaragoza
- T107 Ganglion cell complex analysis in Parkinson's disease by optical coherence tomography
VIEIRA L, ANJOS R, SOUSA A, SILVA N, VICENTE A, BORGES B, COSTA L, FERREIRA J, CUNHA JP—Lisboa
- T108 *rf* Usefulness of ophthalmology psychophysical test for diagnosis and monitoring support in mild Alzheimer's disease
GARCIA MARTIN ES, DE HOZ R, ROJAS B, RAMIREZ AI, SALAZAR JJ, GIL P, YUBERO R, TRIVINO A, RAMIREZ JM—Madrid
- T109 Optic neuropathy caused by type A botulinic toxin
MORREALE BUBELLA R, VADALA M, MORREALE BUBELLA D—Palermo
- T110 *★* A case report survey (CRS) on the natural history of visual acuity in patients with Leber's hereditary optic neuropathy (LHON)
METZ G, COPPARD N, PETRAKI D, MEIER T, KLOPSTOCK T, SAHEL J—Liestal, Munich, Paris
- T111 *rf* *★* Clinical experience with Raxone® (Idebenone) in the treatment of patients with Leber's hereditary optic neuropathy (LHON)
METZ G, GALLENMÜLLER C, VON LIVONIUS B, LOB F, COPPARD N, MEIER T, KLOPSTOCK T—Liestal, Munich
- T112 *rf* Microcystic macular edema in optic nerve atrophy: case series
VOIDE N, BORRUAT F—Lausanne
- T113 Mutational and clinical spectrum in Korean with Leber's hereditary optic neuropathy
YUM HR, KIM MS, SHIN SY, PARK SH—Seoul
- T114 Leber hereditary optic neuropathy and a new MT-ND1 pathologic mutation
ESTEBAN O, MARTINEZ-ROMERO I, HERRERO-MARTIN MD, LLOBET L, EMPERADOR S, MARTIN-NAVARRO A, NARBERHAUS B, ASCASO FJ, LOPEZ-GALLARDO E, MONTOYA J, RUIZ-PESINI E—Zaragoza
- T115 Prevalence of optic neuropathy in alcoholic patients and predictive value of optic nerve alterations for its diagnosis
MICHAU S, RIGOLE H, PERNEY P, VILLAIN M, DAIEN V—Montpellier, Nimes

SECOND AFTERNOON SESSION | 16:30 - 18:00

SIS RV/EOVS Myopia and pathological myopia - etiology and therapeutic approaches Hermes

Mike FRANCKE

16:30	2711	Biological mechanism of myopia development SCHAEFFEL F-Tübingen
16:47	2712	Myopia and high myopia - genetics and environmental factors MORGAN I-Canberra
17:09 *	2713	Interventions to slow the progression of myopia OHLENDORF A-Tuebingen
17:26	2714	Progressive myopia and their associated pathologies (definitions and therapies) MAIER M-Munich
17:43 *	2715	Scleral crosslinking as a therapeutic approach to treat progressive myopia ISELI HP-Zurich

SIS G Alternatives to the face-to-face glaucoma specialist consultation Rhodes 1

Achal KOTECHA

16:30	2721	Experiences with developing virtual clinics in a specialist centre KOTECHA A-London
16:52	2722	Virtual glaucoma clinic in Wales MORGAN JE-Cardiff
17:14	2723	Virtual glaucoma services in Finland TUULONEN A-Tampere
17:36	2724	Enhanced access to glaucoma diagnosis and management via patient centered collaborative teleglaucoma (TG) approaches in Northern Alberta and in Ethiopia DAMJI KF-Alberta

SIS COS New advances in amniotic membrane transplantation Rhodes 2

Jean-Jacques GICQUEL, Harminder S DUA

16:30	2731	An update on ocular surface reconstruction with the amniotic membrane GICQUEL J-Poitiers
16:52	2732	Variation and limitations of the amniotic membrane DUA H-Nottingham
17:14	2733	Customised amniotic membrane: a surgeon's dream come true HOPKINSON A-Nottingham
17:36	2734	Amniotic membrane applications in children BREMONT-GIGNAC D-Amiens

Course 9 Radiotherapy in ophthalmology
PO

Leonidas ZOGRAFOS, Laurence DESJARDINS

Rhodes 3

Advanced

The advanced course of radiotherapy in ophthalmology covers all the technical and medical details of irradiation treatment in ocular oncology. Following an historical overview of the evolution of ocular radiotherapy all the modern technics of ocular radiotherapy are described. The Brachytherapy and Teletherapy with Proton beam of uveal melanomas the irradiation treatment of choroidal hemangiomas, the irradiation treatment of metastatic tumors and lymphomas as well as radiotherapy of pediatric tumors are clearly illustrated.

16:30	2741	Introduction – Descriptions of the techniques ZOGRAFOS L–Lausanne
16:45	2742	Brachytherapy of uveal melanomas KIVELÄ T–Helsinki
17:00	2743	Proton beam radiotherapy of uveal melanomas DESJARDINS L–Paris
17:15	2744	Irradiation treatment of choroidal hemangiomas ZOGRAFOS L–Lausanne
17:30	2745	Irradiation treatment of metastatic tumors and lymphomas SCHALENBOURG A–Lausanne
17:45	2746	Radiotherapy in pediatric oncology MUNIER F–Lausanne

SIS
IM **Inflammation and retinal angiogenesis**

Heping XU, Ahmed ABU EL ASRAR

Rhodes 4

16:30	2751	Innate immunity and retinal angiogenesis XU H–Belfast
16:48	2752	Oxidative stress and retinal vascular damage in diabetic retinopathy LYONS T–Belfast
17:06	2753	Inflammation and angiogenesis in age-related macular degeneration SENNLAUB F–Paris
17:24	2754	Regenerating the retinal vasculature using endothelial progenitor cells STITT A–Belfast
17:42 ★	2755	What do retinal telangiectasia tell us about the control of vasculature in the retina? FRUTTIGER M–London

SIS
MBGE **Grand rounds in ophthalmic genetics**

Bart LEROY, Christian HAMEL

Gallieni 1 & 2

16:30	2761	Cases HAMEL C–Montpellier
16:52	2762	Cases LEROY BP–Ghent
17:14	2763	Cases LISKOVA P–Prague
17:36	2764	Cases AUDO I–Paris

SECOND AFTERNOON SESSION | 16:30 - 18:00

SIS
ACB

Wound healing in health and disease

Hannu UUSITALO, Roger BEUERMAN

Gallieni 5



16:30	2771	The corneal epithelial basement membrane: Master regulator of the stromal myofibroblast response to injury WILSON S, TORRICELLI A—Cleveland
16:52	2772	Cytoskeletal regulators are implicated in fibrosis in mechanical injury and infection in the mouse cornea BEUERMAN R—Singapore
17:14 *	2773	The role of inflammation and extracellular matrix in the wound healing after glaucoma surgery UUSITALO H—Tampere
17:36	2774	Matrix wound healing in the optic nerve O'BRIEN C—Dublin

INDUSTRY-SPONSORED SYMPOSIUM 3



What's new in ocular surface disorders?

Moderator: Leopold SCHMETTERER

18:00		Introduction
18:10	2831	The burden of dry eye PURSLOW C–Monmouth
18:35	2832	Trehalose and hyaluronic acid association; added benefits PINTO-BONILLA I–Castellon
19:00	2833	Visualization of tear film thickness after eyedrop instillation SCHMETTERER L–Vienna
19:25		Conclusions



**FRIDAY
OCTOBER 3
2014**

SIS RV	VEGF, VEGF antagonists and opponents in the retina		Hermes
	Wolfram EICHLER		
08:30	3211	VEGF family members (alternatively, molecular identities of anti-VEGF agents) SENNLAUB F—Paris	
08:45	3212	The role of ER stress in regulation of retinal angiogenesis and VEGF signaling ZHANG S—Buffalo	
09:00	3213	Systemic safety of VEGF antagonists and their influence on vascular homeostasis MACHALINSKA A—Szczecin	
09:15	3214	TGF-beta in ocular angiogenesis WANG X, ABRAHAM S, JEFFS N, SWIRE M, LUHMANN U, LANGE C, BAINBRIDGE J, MOSS S, GREENWOOD J— Singapore, London	
09:30	3215	Glial cells as producers of VEGF and opponents in the retina EICHLER WOLFR—Leipzig	
09:45	3216	Anti-VEGF in the retina STAHL A—Freiburg	

SIS G	Surgical training in glaucoma, and other sub-specialities: wet-lab, virtual reality, and novel technology		Rhodes 1
	Andrew MCNAUGHT, Gordana SUNARIC MEGEVAND		
08:30	3221	Wet lab training of trabeculectomy and tube surgery SHAH P—Birmingham	
08:48	3222	Simulated Ocular Surgery (VR) HAYNES R—Bristol	
09:06 ★	3223	Simulated ocular surgery: cataract, glaucoma, strabismus and VR surgery FERRIS J—Gloucestershire	
09:24	3224	Plastic eye surgery simulator for trabeculectomy MCNAUGHT A—Cheltenham	
09:42	3225	European Board of Ophthalmology new subspecialty diploma; example: glaucoma surgery SUNARIC MEGEVAND G—Geneva	

SIS COS **Ophthalmology in war zones** **Rhodes 2**
Hermann GÜMBEL, Robert SCOTT

08:30		Introduction by Thomas Fuchsluger
08:35	3231	The science from ocular war injuries SCOTT ROBER—Birmingham
08:51	3232	French military ophthalmologists experience in Afghanistan War - 2006 - 2013 GIRAUD JM, EL CHEHAB H, VALERO B, VIGNAL R, RENARD JP—Toulon, Paris
09:07	3233	Ophthalmic combat injuries in the German Sector of Northern Afghanistan 2003 - 2013 GÜMBEL H—Ulm
09:23	3234	War ocular trauma and burns in Kaboul NATO Hospital RIGAL SASTOURNE JC—Paris
09:39		Conclusions

SIS PO **Animal models in eye research** **Rhodes 3**
Martine J JAGER, Nathalie CASSOUX

08:30	3241	Experimental retinal vein occlusion, a model of non-neovascular microvascular remodeling PAQUES M—Paris
08:48	3242	Animal models of glaucoma BRON AM—Dijon
09:06	3243	Learning about herpes infections by using animal models ATHERTON S—Augusta, Georgia
09:24	3244	Using animal models for the study of uveitis DICK A—Bristol
09:42	3245	Animal models in ocular oncology CASSOUX N, JAGER M—Paris, Leiden

FP **ACB 2/2 : Corneal and retinal cell biology** **Rhodes 4**
Goran PETROVSKI, Saeed AKHTAR

08:30	3251	Corneal stromal cells: A potential cell source for ocular surface regeneration SIDNEY LE, BRANCH MJ, MCINTOSH OD, DUA H, HOPKINSON A—Nottingham
08:42	3252	Effect of hydration on the ultra-structural distribution of collagen fibrils and proteoglycans in human corneal stroma AKHTAR S, KHAN A, PETROVSKI G, ALBERT R, KIRAT O, ALMUBRAD T—Riyadh, Szeged, Debrecen
08:54	3253	Functional and molecular characterization of ex vivo cultured neuronal- and glial- like cells from idiopathic epiretinal membranes PETROVSKI G, LUMI X, YAN X, GRAW J, FACSKO A, HAWLINA M, ANDJELIC S—Szeged, Ljubljana, Munich
09:06	3254 <i>rf</i>	Predegenerated Schwann cells promote neuroprotection and regeneration of retinal ganglion cells in ex vivo rat retinal explants SMEDOWSKI A, PIETRUCHA-DUTCZAK M, KAARNIRANTA K, LEWIN-KOWALIK J—Katowice, Kuopio
09:12	3255 <i>rf</i>	Pinosylvin protects retinal pigment epithelial cells from oxidative stress by activating Nrf2-mediated antioxidant defence system KOSKELA A, REINISALO M, HYTTINEN J, KAARNIRANTA K, KARJALAINEN R—Kuopio
09:18	3256 <i>rf</i>	Autophagy stimulus promotes HuR protein phosphorylation and SQSTM1/p62 protein up-regulation in ARPE-19 cells AMADIO M, MARCHESI N, GOVONI S, PASCALE A, KAARNIRANTA K—Pavia, Kuopio
09:24	3257 <i>rf</i>	Cytotoxicity of mesoporous silicon microparticles with different surface modifications on ARPE-19 cells KORHONEN E, RIIKONEN J, XU W, LEHTO VP, KAUPPINEN A—Kuopio

SIS MBGE **The retinal pigment epithelium in retinal dystrophies** Gallieni 1 & 2

Bart LEROY, Isabelle MEUNIER

08:30	3261	Cellular & molecular origins of the electro-oculogram CONSTABLE P—London
08:52	3262	Phenotypes of bestrophinopathies LEROY BP—Ghent
09:14	3263	RPE Disease beyond BEST1 MEUNIER I, HAMEL C—Montpellier
09:36	3264	Gene therapy for bestrophinopathies GUZIEWICZ K, BELTRAN W, CIDECIYAN A, KOMÁROMY A, IWABE S, DUTROW E, ZANGERL B, HAUSWIRTH W, JACOBSON S, AGUIRRE G—Philadelphia, East Lansing, Kensington, Gainesville

SIS NSPH **Innovation in ocular allergy: pediatric features** Gallieni 5

Dominique BREMOND-GIGNAC, Jean-Luc FAUQUERT



08:30	3271	IgE, anti-IgE, and allergic keratoconjunctivitis - part 1 DOAN S—Paris
08:52	3272	IgE, anti-IgE, and allergic keratoconjunctivitis - part 2 CHIAMBARETTA F—Clermont Ferrand
09:14	3273	Food allergy and ocular surface FAUQUERT JL—Clermont-Ferrand
09:36	3274	Molecular allergens and tear investigation CHABANE H—Paris



David SULLIVAN

Schepens Eye Research Institute and Harvard Medical School (Boston, MA)

New therapeutic approaches and challenges for the treatment of dry eye disease ✦

Introduction by Nadja KNOP



Innumerable individuals suffer from tear film dysfunctions, which are collectively diagnosed as dry eye disease (DED). In the United States alone DED afflicts tens of millions of people, especially women, and is one of the most frequent causes of patient visits to eye care practitioners. DED is characterized by a vicious cycle of tear film hyperosmolarity and instability and ocular surface stress, leading to increased friction, inflammation and damage to the eye. DED is caused primarily by meibomian gland dysfunction, and is associated with significant pain, decreased vitality and poorer general health. Because of diminished worker productivity, the burden of DED for the United States is estimated to be over \$55.4 billion. There is no safe and effective global treatment for DED, and its therapy remains a profound unmet need throughout the world. A virtual kaleidoscope of new therapeutic approaches have been proposed to treat the mucin, aqueous and/or lipid tear film deficiencies, as well as the ocular surface damage, associated with DED. My presentation will highlight these approaches, and also address the significant clinical endpoint challenges that serve as barriers to the successful development of potential treatments for DED.

Award of the EVER Certificate of Honour

SECOND MORNING SESSION | 11:00 - 12:30

FRIDAY - October 3

SIS RV	Drug retinal toxicity		Hermes
	Andrzej GRZYBOWSKI, Francisco ASCASO		
11:00	3411	Pigmentary retinopathy ASCASO FJ-Zaragoza	
11:18	3412	Crystalline retinopathy NADIM N-Beirut	
11:36	3413	Retinal vasculopathies GRZYBOWSKI A-Poznan	
11:54	3414	Fingolimod-associated cystoid macular oedema LIU L, CUTHBERTSON F-Bristol, Bath	
12:12	3415	Retinal drug toxicity in the absence of visible fundus changes LAWRENSEN J-London	

FP	G 2/2 : Vision & Clinical research		Rhodes 1
	Sayeh POURJAVAN, Aachal KOTECHA		
11:00	3421	Glaucoma pathology: an eye on the brain DEKEYSTER E, AERTS J, VALIENTE-SORIANO FJ, DE GROEF L, SALINAS-NAVARRO M, VIDAL-SANZ M, ARCKENS L, MOONS L-Leuven, Murcia	
11:12	3422	Performance of advanced technologies for community-based glaucoma case-finding LAWRENSEN J, DABASIA P, EDGAR D, GARWAY-HEATH D-London	
11:24	3423	Visual acuity loss in open-angle glaucoma patients: causes and risk factor AYCHOUA N, JANSONIUS NM-Groningen	
11:36 	3424	Lateral inhibition in the human visual system in healthy subjects and in patients with glaucoma JUNOY MONTOLIO FG, MEENS W, JANSSENS MSA, STAM L, JANSONIUS NM-Groningen	
11:48 	3425	Angle closure glaucoma in Asians: comparison of biometric and anterior segment parameters between Japanese and Chinese subjects HO H, OZAKI M, MIZOGUCHI T, NONGPIUR M, HOW A, HE M, WONG T, PERERA S, AUNG T-Singapore, Hyuga, Sasebo, Guangzhou	
12:00 ★	3426	IOP measurement from corneal vibration parameters analysis: first clinical trial partial results BITOUN P, BENZACKEN L, BOUAFIA K, HAOUCHINE B, CHAPPELLE P, CHAMBARD JP, JOURROT P, PEAN V-Bondy, Aulnay, Gif s/y, Saint Louis, Etavigny	

SIS
COS

New approaches for unmet needs in ophthalmology

Rhodes 2

Thomas FUCHSLUGER, Einar STEFANSSON, Antonia JOUSSEN

11:00	3431	Intraocular pressure modulation by neuropeptides - the effect of vasopressin BOGNER B, RUNGE C, STROHMAIER C, TROST A, KASER-EICHBERGER A, KREFFT K, GRABNER G, KIEL JW, SCHROEDL F, REITSAMER HA—Salzburg, San Antonio, TX
11:15	3432	Novel cell therapeutical approaches to treat the corneal endothelium FUCHSLUGER T—Düsseldorf
11:30	3433	Reconstitution of a corneal endothelium by intracameral injection of cultured endothelial cells BRUNETTE I, BOSTAN C, THERIAULT M, FORGET K, PROULX S—Montréal
11:45	3434	Function follows morphology? New aspects of macula OCT analysis GUTHOFF R—Dusseldorf
12:00	3435	Diabetic macular edema - back to laser therapy? JOUSSEN A—Berlin
12:15 ★	3436	Noninvasive drug delivery to the retina STEFANSSON E—Reykjavik

FP

IM 2/2 : Challenges in uveitis

Rhodes 3

Moncef KHAIRALLAH, Andrew DICK

11:00 ★	3441	Healthcare resource use and costs in persistent non-anterior non-infectious uveitis THORNE J, TUNDIA N, SKUP M, MACAULAY D, REVOL C, CHAO J, BAO Y, DICK A—Baltimore, North Chicago, New York, Bristol
11:12	3442	The effect of intravitreal adalimumab on the treatment of active noninfectious ocular inflammation: A pilot study HAMAM R, MANSOUR A—Beirut
11:24	3443	Diagnostic and prognostic value of cerebrospinal fluid analysis in Vogt-Koyanagi-Harada syndrome MOUALLEM A, TOUITOU V, BODAGHI B, CHAMPION E, DARUGAR A, FARDEAU C, CASSOUX N, LE HOANG P—Paris
11:36 ★	3444	Characterization of uveitis in association with multiple sclerosis MACKENSEN F, MESSENGER W, HILDEBRANDT L, SUHLER E, ROSENBAUM JT—Heidelberg, Portland
11:48	3445	The Dublin Uveitis Evaluation Tool (DUET) – an algorithm for earlier diagnosis of spondyloarthropathies by ophthalmologists in acute anterior uveitis. O'ROURKE M, HAROON M, RAMASAMY P, FITZGERALD O, MURPHY C—Dublin
12:00 ★	3446	Changes in vitreous haze over time with intravitreal sirolimus in noninfectious posterior-segment uveitis (NI-PSU): results of SAKURA Study 1 BODAGHI B, ALI Y, YANG Y, CHERNOCK M, THURAU S, PAVESIO C—Paris, Emeryville, Munich, London

SECOND MORNING SESSION | 11:00 - 12:30

SIS LC /NSPH Pediatric cataract surgery Rhodes 4

Stefan LÖFGREN

11:00 *	3451	Long-term follow-up of the bag-in-the-lens in children TASSIGNON MJ–Edegem
11:18	3452	Cataract surgery in infants: should I implant an IOL? VANDERVEEN D–Boston
11:36	3453	Cataract surgery in children with syndromes or mental retardation BREMONT-GIGNAC D–Amiens
11:54	3454	Pars plana vitrectomy and IOL implantation in uveitic children with cataract NYSTRÖM A, PÅLSSON S, SJÖDELL L, JAKOBSSON G, BYHR E, ANDERSSON GRÖNLUND M, ZETTERBERG M–Möndal
12:12	3455	Update from the Swedish national pediatric cataract quality registry TORNQVIST K–Lund

SIS EOVS Doctor, I see things that aren't there Gallieni 1 & 2

Graham HOLDER

11:00	3461	The initial consultation SPILEERS W–Leuven
11:22	3462	Genetically determined disorders LEROY B–Ghent
11:44	3463	Neurological considerations KAWASAKI A–Lausanne
12:06	3464	The role of electrophysiological investigation HOLDER GE–London

FP PBP 1/1 : Choroidal neovascularisation, optic nerve and diabetic retinopathy Gallieni 5

Neville OSBORNE, Leopold SCHMETTERER

11:00 *	3471	Prognostic factors in myopic choroidal neovascularisation SILVA R, WONG TY, ASMUS F–Coimbra, Singapore, Berlin
11:12 *	3472	Visual outcomes following intravitreal aflibercept in patients with myopic choroidal neovascularisation KOROBELNIK J, IKUNO Y, ASMUS F–Bordeaux, Osaka, Berlin
11:24	3473	Correlation between peripapillary choroidal thickness and retinal vessel oxygen saturation in young healthy individuals VAN KEER K, ABEGÃO PINTO L, WILLEKENS K, STALMANS I, VANDEWALLE E–Leuven, Lisbon
11:36 *	3474	Findings in low luminance kinetic and static perimetry KRSTEL H, GAGYI-PALFFY Z, BEUTELSPACHER S, SCHLICHTENBREDE F, JONAS J–Mannheim, Wetzlar
11:48	3475	Silencing HuR: a new potential pharmacological strategy to target VEGF AMADIO M, PASCALE A, GOVONI S, DRAGO F, BUCOLO C–Pavia, Catania
12:00	3476	Ghrelin's effects in diabetic retinopathy: Inhibition of choroid retinal cells migration cultured under a hyperglycemic environment. ROCHA DE SOUSA A, SILVA-GOMES R, PEREIRA-SILVA P, AZEVEDO-PINTO S, MOLEIRO A, CONCEIÇÃO G, LEITE-MOREIRA AF–Porto

INDUSTRY-SPONSORED SYMPOSIUM 4



Aflibercept: Setting its sight on DME

Moderators: Reinier SCHLINGEMANN, Ian PEARCE, Jean François KOROBNIK

12:35	3531	Science behind the disease SCHLINGEMANN R—Amsterdam
12:45	3532	Managing the DME patient PEARCE I—Liverpool
12:55	3533	VIVID and VISTA: Clinical trial results and implications KOROBNIK J—Bordeaux
13:15		Q&A

FIRST AFTERNOON SESSION | 13:30 - 15:00

SIS RV	Recent developments in laser Doppler flowmetry		Hermes
	Christophe CHIQUET, Constantin POURNARAS		
13:30	3611	Pulsatile versus non-pulsatile choroidal blood flow in Primary Open-Angle Glaucoma (POAG) RIVA C, ABOU SAMRA W, POURNARAS C—Lausanne, Mansoura, Geneva	
13:48	3612	LDF and assessment of autoregulation SCHMETTERER L—Vienna	
14:06	3613	Effect of acute hypoxia or hyperoxia on the optic nerve head and choroidal blood flow in healthy humans CHIQUET C, ZHOU T, GALLICE M, APTEL F, TRUFFER F, GEISER M—Grenoble, Sion	
14:24	3614	Choroidal blood flow and choroidal thickness POURNARAS C, DONATI G, FROUNTZOU E, GEISER M, RIVA CE—Geneva, Sion, Lausanne	
14:42	3615	Laser Doppler flowmetrie on small animal GEISER M, TRUFFER F, MENTEK M, BERNABEI M, APTEL F, CHIQUET C—Sion, Grenoble, Modena	

Course 10 How to get your research published? Rhodes 1

General Uwe PLEYER

Junior researchers often face the challenge of get their interesting work published. The goal of this session will be to provide some keys to write a high quality paper that will help to transform innovative ideas into a research article. The panelists will discuss major aspects of the editorial process including basic decisions: where to submit the work, how to organize and prepare a manuscript, how to deal the review process in particular the revision process for eventual resubmission.

The panelists will raise the discussion on issues like: How to choose a journal? How to organize your paper?

What are the characteristics of a good manuscript? Delayed response: When is it appropriate to ask for the status of your manuscript?

How to interpret the letter from the editor? How to write a good reply to the reviewers? What to do when your paper is rejected?

When can it be appropriate to request a reevaluation of a rejected paper?

In addition, the personal view from an authors and editors perspective will be given in a vivid discussion with the participants.

13:30	3621	How to get your research published? PLEYER U, STEFANSSON E, KIVELÄ T, DUA H—Berlin, Reykjavik, Helsinki, Nottingham
13:52	3622	How to get your research published? STEFANSSON E—Reykjavik
14:14	3623	How to get your research published? KIVELÄ T—Helsinki
14:36	3624	How to get your research published? DUA H—Nottingham

SIS COS Corneal dystrophy & laser keratoplasty: updates Rhodes 2

Berthold SEITZ, Philippe KESTELYN, Keith BARATZ

13:30		Introduction by Thomas Fuchsluger
13:35	3631	Excimer vs Femtosecond laser for nonmechanical keratoplasty – Where are the true benefits? SEITZ B, EL-HUSSEINY M, JANUNTS E, LANGENBUCHER A, SZENTMARY N—Homburg
13:52	3632	New insights into genetics of Fuchs dystrophy BARATZ K—Rochester
14:09	3633	Corneal dystrophies related to cholesterol metabolism (fish eye and Schnyder dystrophy) KESTELYN P—Gent
14:26	3634	Current revision of the international classification of corneal dystrophies (IC3D) LISCH W—Augenklinik
14:43	3635	Confocal microscopy and optical coherence tomography imaging of corneal dystrophies WYLEGALA E—Katowice

FP	PO 1/1		Rhodes 3
		Steffen HEEGAARD, Alexandre MOULIN	
13:30	3641	Characteristic features of choroidal tumors in Deep Range Imaging OCT (DRI-OCT) ROMANOWSKA DIXON B, JAKUBOWSKA B, MARKIEWICZ A—Krakow	
13:42	3642	Diagnostic contribution of ocular imaging techniques in a multimodal diagnostic approach of small pigmented choroidal tumors ZOGRAFOS L, PETROVIC A, SCHALENBOURG A—Lausanne	
13:54	3643	Eviscerated eyes unexpectedly containing uveal melanoma VAN GINDERDEUREN R, MOMBAERTS I—Leuven	
14:06	3644	Aquaporin-4 and potassium channel kir4.1 in amd and serous retinal detachment secondary to choroidal melanoma MADIGAN M, DIEP M, JUNGHANS B, VALTER K—Sydney, Canberra	
14:18	3645	Preclinical scheduling for metastatic ocular melanoma treatment by using a xenograft model approach LEMAITRE S, NEMATI F, THULEAU A, LABIOD D, RODRIGUES M, DE PLATER L, PIPERNO S, SASTRE X, MARIANI P, ROMAN ROMAN S, GENTIAN D, DECAUTIN D, CASSOUX N—Paris	
14:30	3646	MAP kinase and pi3k/mTOR pathways involvement in tumor progression of conjunctival melanocytic proliferations MOULIN A, BUCHER M, SCHALENBOURG A, NICOLAS M—Lausanne	
14:42	3647	Orbital solitary fibrous tumor – Case series and new perspectives IRION L, BONSHK R, KUMAR A, QURESHI F, COOK A, ATAULLAH S, BARBIER J, LEATHERBARROW B—Manchester	
14:54	3648 <i>rf</i>	Secondary Intraocular lymphoma of the iris following a successefully treated diffuse large B-cell lymphoma of the orbit MEYER P, GRAEFF E—Basel	

SIS IM	The precarious notion of disease phenotype in inflammatory eye conditions	Rhodes 4
	Piergiorgio NERI, Carl P HERBORT	
13:30	3651	Early diagnosis and treatment changes disease phenotype in birdshot retinochoroiditis HERBORT C—Lausanne
13:48	3652	The outcomes of Mycophenolate Mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada Disease ABU EL ASRAR A—Riyadh
14:06	3653	When the clinician has to rely on disease phenotype alone for diagnosis: the example of Behçet's uveitis TUGAL-TUTKUN I—Istanbul
14:24	3654	When disease mechanism is more important than disease phenotype: the example of multifocal choroiditis of the choriocapillaris type NERI P, ARAPI I, PIRANI V, GRETI G—Agugliano, Ancona
14:42	3655	Disease phenotypes in emerging infectious ocular conditions: how strongly disease defining are they? KHAIRALLAH M, KAHLOUN R, ZAOUALI S—Monastir

FIRST AFTERNOON SESSION | 13:30 - 15:00

FP RV 2/6 : Retinal surgery Gallieni 1 & 2

Yannick LE MER, Catherine CREUZOT


13:30	3661	One year results of the follow-up of patients with asymptomatic idiopathic epiretinal membrane FERRERO A, BONNABEL A, GASCARD L, BRON AM, CREUZOT-GARCHER C—Dijon
13:42	3662	Inner retinal defects exist preoperatively in patients with epiretinal membrane THEOCHARIS IP—Athens
13:54	3663	Automatic identification of eyes at risk of developing idiopathic macular hole C. SILVA AS, FIGUEIRA J, LOBO C, SIMÃO S, MEIRELES A, GOMES N, BERNARDES R—Coimbra, Porto, Braga
14:06	3664	Predicting visual outcome after macular hole surgery using fundus - controlled microperimetry SURGUCH V, ASATRYAN S—Moscow
14:18	3665 <i>rf</i>	Differences in optical coherence tomography findings in early intervention vs late intervention surgically treated submacular hemorrhages CANASTRO M, FARIA M, MARQUES-NEVES C, MONTEIRO-GRILLO M, NETO E, PERPETUA C, PROENCA H—Lisbon
14:24	3666	Retinal detachment in congenital glaucoma ZHAO L, WEI B—Beijing

FP NSPH 2/2 Gallieni 5

François-Xavier BORRUAT, Miguel CASTELO-BRANCO

13:30	3671	Progressive visual loss in Retinitis Pigmentosa leads to cortical and subcortical reorganization of the human brain PEREIRA AC, FERREIRA S, QUENDERA B, MATEUS C, SILVA E, CASTELO-BRANCO M—Coimbra
13:42	3672	Incidences of visual disorders on academic difficulties KOVARSKI C, PORTALIER S, FAUCHER C, CARLU C, MIOTTI H, ORSSAUD O—Lyon, Québec, Paris, Boulogne
13:54	3673	Compressive chiasmal lesions: optical coherence tomography, ganglion cell and inner plexiform layers and visual field tests VICENTE A, ANJOS R, COSTA L, VIEIRA L, SANTOS A, FERREIRA J, AMADO D, CUNHA JP—Lisboa
14:06	3674	Macular and retinal degeneration in Alzheimer's disease CUNHA JP, SANTOS A, FERREIRA J, AMADO D, LOURO C, CASTANHEIRA-DINIS A, VICENTE A—Lisbon
14:18	3675 <i>rf</i>	Usefulness of ophthalmology psychophysical test for diagnosis and monitoring support in mild Alzheimer's disease GARCIA MARTIN ES, DE HOZ R, ROJAS B, RAMIREZ AI, SALAZAR JJ, GIL P, YUBERO R, TRIVINO A, RAMIREZ JM—Madrid
14:24	3676 <i>rf</i>	Brain structural and functional reorganization due to long term retinal peripheral degeneration in retinitis pigmentosa FERREIRA S, PEREIRA AC, QUENDERA B, MATEUS C, SILVA E, CASTELO-BRANCO M—Coimbra
14:30	3677 <i>rf</i>	Visual intelligence in action: A question of balance? Neuroplasticity: recent findings on the visual system for the practitioner VANDERMEULEN J—Geleen/ Sittard
14:36	3678 <i>rf</i>	Microcystic macular edema in optic nerve atrophy: case series VOIDE N, BORRUAT F—Lausanne

**Physiology / Biochemistry /
Pharmacology****Moderators: Gerhard GARHÖFER,
Amandio ROCHA DE SOUSA**

- F001 Functional presence of Na⁺-K⁺-2Cl⁻ cotransporter in rabbit lacrimal gland ductal epithelial cells
TÓTH-MOLNÁR E, KATONA M, VIZVARI E, FACSKO A, VENGLOVECZ V, RAKONCZAY Z, HEGYI P—Szeged
- F002 Pharmacological matrix metalloproteinase (MMP) inhibition blocks axonal regeneration in the damaged retinotectal system of the adult zebrafish
LEMMENS K, BOLLAERTS I, BHUMIKA S, VAN HOUCKE J, VAN HOVE I, MOONS L—Leuven
- F003 Inhaled nitric oxide dilates retinal arterioles in minipigs
PETROPOULOS I, MARTIN AL, MANGIORIS G, MENDRINOS E, RIMENSBERGER PC, POURNARAS C—Geneva
- F004 Interaction between leukocytes and erythrocytes in the human retina: Effects of pentoxifylline on hyperoxia-induced vasoconstriction during increased neutrophil counts
FUCHSJAGER-MAYRL G, TOLD R, WOLZT M, SCHMETTERER L, SCHMIDT-ERFURTH U, GARHOFER G—Vienna
- F005 Genetic deletion of β 1- and β 2-adrenergic receptors rescues the retina from hypoxia-induced pathologic angiogenesis
DAL MONTE M, CAMMALLERI M, FORNACIARI I, CASINI G, BAGNOLI P—Pisa
- F006 Aquaporin 4 is required to induce retinal angiogenesis in a mouse model of oxygen-induced retinopathy
DAL MONTE M, NICCHIA GP, CAMMALLERI M, FRIGERI IA, FORNACIARI I, PISANI F, BAGNOLI P, SVELTO M—Pisa, Bari
- F007 Development of new anti-VEGF drug by SRPK1 inhibitor screening
MOROOKA S, OKUNO Y, HOSOYA T, HAGIWARA M, YOSHIMURA N—Kyoto, Tokyo
- F008 Rapamycin down-regulates REDD1 to blunt cell death: a potential way to maintain retinal ganglion cell function as in glaucoma
DEL OLMO AGUADO S, NÚÑEZ ÁLVAREZ C, OSBORNE NN—Oviedo
- F009 Ocular hypotensive properties of Cornus mas extract and loganic acid
SZUMNY D, KUCHARSKA AZ, PIORECKI N, SZUMNY A, SOZANSKI T, DZIEWISZEK W, CHLEBDA E, SZELAG A—Wrocław, Boleszraszyce
- F010 The role of Cl⁻ channels in ion transport across the apical and basolateral sides of the mouse retinal pigment epithelium
SKARPHEDINSDOTTIR S, EYSTEINSSON T, ARNASON S—Reykjavik
- F011 New non-invasive technique for dosing eye drops concentration in tears
GAUTHIER AS, FRIOT M, PRONGUÉ A, ROYER B, DELBOSC B—Besançon
- F012  Lymphocytic microparticles modulate macrophages function in experimental choroidal neovascularization
TAHIRI H, OMRI S, CHUN Y, DUHAMEL F, CHEMTOB S, HARDY P—Montréal
- F013 Rabbit cornea epithelization after the antlerogenic stem cells of Cervus elaphus homogenate
SZUMNY D, CEGIELSKI M, GROSMAN-DZIEWISZEK P, SZELAG A, BOCHNIA M, DZIEWISZEK W—Wrocław

- F014 Acquired trichomegaly and hypertrichosis after treatment with epidermal growth factor receptor inhibitors
LAUWERS N, AERTS L, SMETS RME—Edegem
- F015 Ocular toxicity of voriconazole: a case report and review of literature
MOUNIER A, DOUMA I, EL CHEHAB H, VIE A, AGARD E, RUSSO A, DOT C—Lyon

Retina / Vitreous

**Moderators: Christophe CHIQUET,
Constantin POURNARAS, Pascal MASSIN,
Anita LEYS, Jost JONAS**

- F016 Characterisation of RPGRIP1 and its interacting partners in Zebrafish
KOTAPATI RAGHUPATHY R, MCCULLOCH D, CRAFT J, SHU X—Glasgow
- F017 The embryonic stem cell derived retinal pigment epithelial cell trial for Stargardt macular dystrophy: preliminary phase 1 results in Asian
KWON HJ, SONG W, CHOI J, CHUNG SY, KIM HJ, LEE JH—Gyunggido, Seoul
- F018 SD OCT and fundus auto fluorescence findings in Stargardt disease
EL MATRI L, CHEBIL A, KORT F, CHARFI H, MAMOURI R, HSAIRI A—Tunis
- F019 Tamoxifen retinopathy
HALFELD FURTADO DE MENDONCA R, LUZ LEITÃO GUERRA R, DE OLIVEIRA MAIA JR O, YUKIHIKO TAKAHASHI W—Juiz de Fora, Salvador, São Paulo
- F020 Ocular manifestations in a patient with osteopetrosis
KABANAROU S, MOSCHONAS K, PAPAPANOS P, KOUROUPAKI A, TSAKIRIS K, XIROU T—Athens, Corinth
- F021 Bilateral macular coloboma of sorsby: contribution of the oct
BELAHDA A, MATONTI F, RENDU I, DENIS D—Marseille
- F022 Clinical presentation of a Roma family with autosomal recessive Usher Syndrome
KOEV K, CHERNINKOVA S, KAMENAROVA K, GEORGIEV R, KANEVA R—Sofia
- F023 POFAL Study: «Protection Oculaire Face aux Agressions Lasers», Phase I
EL CHEHAB H, BEMELMANS A, NOUVEL-JAILLARD C, NIEPON ML, RENARD JP—Paris, Fontenay-Aux-Roses
- F024 Comparison of efficacy between focal laser photocoagulation and photodynamic therapy in CSCR
STRUPAITE R, KUOLIENE K, STRELKAUSKAITE E, ASOKLIS R—Vilnius
- F025 Intravitreal Bevacizumab in treatment of chronic central serous chorioretinopathy: the efficacy according to indocyanine green angiography findings
KU HC, RHIM WI, LEE MK, LEE EK—Seoul
- F026 Improved analysis of the outer foveal microstructure - OCT imaging of healthy and abnormal retina
SJÖSTRAND J, NILSSON M, ROSÉN R, POPOVIC Z—Gothenburg, Stockholm
- F027 Retinal nerve fibre layer thickness measurements in myopia by optical coherence tomography
MORREALE BUBELLA R, MORREALE BUBELLA D—Palermo
- F028 Macular Bruch's membrane defects in Hi
JONAS J, YOU Q, PENG XY, XU L, WEI WB, WANG Y, CHEN CX—Mannheim, Beijing
- F029 The relation between peripapillary and macular thickness with refractive errors
OSTADIMOGHADDAM H, AHMADI HOSSEINI M, YEKTA AA, SEDAGHAT M, AZIMI A, MOHAMMADIAN M, NAKHJANPOUR N, FAZILATI F—Mashhad

- F030 *rf* Macular response to a carotenoid supplement in healthy eyes
MARQUINA I, BRAUTASET R, NILSSON M—Stockholm
- F031 Age-related changes of ocular parameters in an emmetropic Spanish healthy population
ZABADANI K, ASCASO FJ, HERRERA L, ESTEBAN O, MARTINEZ M, CARMELLO C, PEREZ NAVARRO I, ALMENARA C, CASAS P, CRUZ N, CABEZON L, CRISTOBAL J—Zaragoza
- F032 Unilateral peripapillary intrachoroidal cavitation and optic disc rotation
DAI Y, JONAS J, LING Z, SUN X—Shanghai, Heidelberg
- F033 Performance characteristics of multicolor versus blue light and infrared imaging in the identification of reticular pseudodrusen
AL MUHTASEB H, BADAL J, BIARNÉS M, MONÉS J—Barcelona
- F034 Retinal vessel course and retinal nerve fiber bundle trajectories in the human eye
JANSONIUS NM, QIU K, SCHIEFER J, NEVALAINEN J, PAETZOLD J, SCHIEFER U—Groningen, Munich, Oulu, Tuebingen
- F035 The comparison of OCT findings and retinal artery diameter in good and poor prognosis RAO patients
PARK J, JO S, LEE S—Busan
- F036 Cilioretinal artery occlusion and protein S deficiency in pregnancy
CARMELLO C, MATEO OROBIA AJ, HERRERA L, ZABADANI K, PINILLA I, PEREZ NAVARRO I, ALMENARA C, ESTEBAN O, ASCASO J, CASAS P—Zaragoza
- F037 Comparison of subfoveal choroidal thickness changes following two different doses of intravitreal bevacizumab therapy for branch retinal vein occlusion
LEE S—Gyeong-Ju
- F038 Correlation between hiperreflective foci in patients with macular edema secondary to retinal vein occlusion, and visual outcomes after an intravitreal dexamethasone implant injection
ALMENARA MICHELENA C, ASCASO FJ, LAVILLA L, CRISTOBAL J, ZABADANI K, CARMELLO C, MARTINEZ M, HERRERA L, ESTEBAN O—Zaragoza
- F039 Follow-up of IOP and central macular thickness after repeated dexamethasone implants in retinal vein occlusion, about 29 cases
VIE A, DOT C—Lyon
- F040 REMIDO 2 Study: Retrospective Multicentric study of the dexamethasone drug delivery system, OZURDEX, in the treatment of macular edema following retinal vein occlusion; 2 years follow-up
POMMIER S—L'isle sur la Sorgue
- F041 Can Ozurdex® make the difference in a retinal vein occlusion population with longstanding macular edema and multiple prior treatments?
VAN CALSTER J—Leuven
- F042 Why should we systematically screen sleep apnea syndrome in RVO patients?
RUSSO A, DOT C—Lyon
- F043 Inhibition of NO and COX products modifies the hypoxia-induced dilatation of retinal vessels in vivo
KAYA M, PEDERSEN L, BEK T—Aarhus
- F044 A new model for studying diameter regulation of porcine retinal arterioles and capillaries in vitro
JENSEN PS, BEK T—Aarhus

- F045 Diabetic retinopathy: A descriptive study of a method of investigation: BOA's project
BAZIN L—Brest
- F046 Retinal vessel oxygen saturation in diabetic patients with and without cardiovascular disease and its association with renal function
HEITMAR R, BLANN A—Birmingham
- F047 Severity of type 2 diabetes in Seine St Denis among patients with diabetic macular edema treated by antiVEGF
STEPHAN S, FAJNKUCHEN F, GIOCANTI-AUREGAN A—Avicenne
- F048 Comparison of the time required for panretinal photocoagulation and associated pain between Navilas® and conventional laser therapy in diabetic retinopathy
KIM MS, KIM JS—Seoul
- F049 Prognostic factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy: comparative study in the same person
LEE S, YEOM M, PARK J—Busan
- F050 Effects of combination of antioxidants and omega 3 fatty acids in diabetic retinopathy
SANTANDER-TRENTINI F, VIVAR-LLOPIS B, CHAQUES-ALEPUZ V, ALONSO L, ZANON-MORENO V, GALLEGO-PINAZO R, DOLZ-MARCO R, SHOAIE-NIA K, PINAZO-DURAN MD—Valencia
- F051 Use of bromfenac eye drops in the treatment of diabetic macular edema: a pilot study
BLASETTI F, CASU G, D'AMICO RICCI G, BOSCIA F, PINNA A—Sassari
- F052 ★ The efficacy of dexamethasone implant (Ozurdex 700 µg) in refractory diabetic macular oedema
KARTTUNEN T, KAARNIRANTA K, KINNUNEN K—Kuopio
- F053 Complete retinal fluid resorption with low visual acuity in patients with diabetic macular edema (DME) over the course of ranibizumab treatment: OCT analysis
PENAUD B, GIOCANTI-AUREGAN A, LEVY O, CHAINE G, FAJNKUCHEN F—Bobbigny
- F054 The efficacy and safety of intravitreal bevacizumab in the treatment of diabetic macular oedema
MALYSKO K, KUOLIENE K, CIMBALAS A, ASOKLIS R—Vilnius
- F055 Results from the treatment of refractory diabetic macular oedema with Bevacizumab in a clinical setting
PAPANDREOU I, TING M, MENSAH E—London
- F056 Ocular distribution and pharmacokinetics of 125I-OPT302 and 125I-Aflibercept (EYLEA) following intravitreal administration to pigmented rabbits
STRUBLE C, TESTER A, GEROMETTA M, KREUGER M, PRUSAKIEWICZ J, BALDWIN M—Madison, Wisconsin, Victoria
- F057 Antiangiogenic effect of ALS-L1023 on experimental choroidal neovascularization in mice
KANG S, RHO YJ—Seoul
- F058 Tissue plasminogen activator as an anti-angiogenic agent in experimental laser-induced choroidal neovascularization
OZONE D, NOZAKI M, OHBAYASHI M, HASEGAWA N, KATO A, YASUKAWA T, OGURA Y—Nagoya
- F059 Effect of a single intravitreal injection of anti-VEGF agents on retinal arteriolar caliber in mini pig eyes
MANGIORIS G, PETROPOULOS I, MENDRINOS E, POURNARAS C—Geneva
- F060 Evaluation of two methods for measurements of macular pigment optical density (MPOD)
BIRKELDH U, WAHLBERG RAMSAY M, NILSSON M, BRAUTASET R—Stockholm
- F061 Major American dietary patterns are related to age-related macular degeneration
CHIU CJ, CHANG ML, ZHANG FF, LI T, GENSLER G, SCHLEICHER M, TAYLOR A—Boston, Rockville
- F062 ★ Method for comparative evaluation of therapeutic efficacy in dry AMD patients using 3D-CTAG
MILYUTKINA S, FINK W, KOVALEVSKAYA M—Voronezh, Pasadena
- F063 Relation between subfoveal choroidal thickness and visual acuity in patients with wet and dry age-related macular degeneration
ZABADANI K, HERRERA L, ASCASO FJ, CARAMELLO C, ALMENARA C, PEREZ NAVARRO I, MARTINEZ M, ESTEBAN O, PADGETT E, CABEZON L, CRUZ N, CRISTOBAL J—Zaragoza
- F064 AMD Drusenoid deposits "Lipid Type" characteristics and evolution. Multimodal imaging evaluation
GONZALEZ C—Toulouse
- F065 Predictive value of outer retina Enface OCT imaging in geographic atrophy progression
GIOCANTI-AUREGAN A, TADAYONI R, DOURMAD P, MAGAZZINI S, COHEN SY—Bobbigny, Paris
- F066 ★ Assessment of risk factors of age macular degeneration in general population with STARS 2.0 questionnaire
CREUZOT-GARCHER C, CHIAMBARETTA F, COHEN SY, KOROBELNIK J, SOUIED E, WEBER M, DELCOURT C—Dijon, Clermont Ferrand, Créteil, Bordeaux, Nantes
- F067 ★ Detecting recurrence of macular edema in patients with wet AMD after anti-VEGF treatment using 3D-CTAG test
MILYUTKINA S, FINK W, KOVALEVSKAYA M—Voronezh, Pasadena
- F068 Management of choroidal neovascularisation in late onset retinal degeneration
WIRYASAPUTRA S, YONG SO—Singapore
- F069 Intravitreal anti-VEGF in submacular hemorrhage due to age related macular degeneration
DESSERRE J, LABALETTE P—Lille
- F070 Five-year results of ICG-Guided Photodynamic Therapy combined with intravitreal Ranibizumab for juxtapapillary polypoidal choroidal vasculopathy with macular involvement
PETROPOULOS IK, MATTER MA, DESMANGLES PM—Geneva
- F071 Intravitreal ranibizumab for neovascular age-related macular degeneration with a Treat and Extend protocol: anatomical and functional results
MEILLON C, KOEHRER P, ISAICO R, BONNABEL A, BRON AM, CREUZOT-GARCHER C—Dijon
- F072 Treatment of neovascular AMD by Aflibercept (Eylea) with proactive protocol
GONZALEZ C—Toulouse
- F073 Neovascular amd: multimodal criteria of neovascular activity
GONZALEZ C—Toulouse
- F074 The impact of intravitreal aflibercept on pigment epithelial detachment morphology in eyes with persistent subretinal fluid despite a minimum of 14 previous treatments with ranibizumab in patients with neovascular age-related macular degeneration
PASU S, LUK S, MITRY D, KURUMTHOTTICAL M, YOUNIS S—London

Retina / Vitreous

**Moderators: Christophe CHIQUET,
Constantin POURNARAS, Pascal MASSIN,
Anita LEYS, Jost JONAS**

F075 **★** The functional effects and expression of HGF and FGF in the choroid
STEWART EA, AMOAKU WM—Nottingham

F076 **★** Cost of complications for patients with non-infectious non-anterior uveitis
TUNDIA N, SKUP M, OYE B, OKALIBE X, CHAO J, BAO Y, DICK A—North Chicago, Chicago, Bristol

F077 Influence of lornoxicam and triamcinolone on the dynamics of eye remodeling in concanavalin model of inflammation
ERDIAKOV A, GAVRILOVA S—Moscow

F078 **★** Risk of ocular complications in persistent non-infectious non-anterior uveitis
DICK A, TUNDIA N, SKUP M, SORG R, ZHAO C, BAO Y, CHAO J—Bristol, North Chicago, Boston

F079 Ophthalmologists play a key role in the management of syphilis presenting with ocular involvement
BONNIN N, LAURICHESSE H, BEYTOUT J, LESENS O, ANDRE M, AUMAITRE O, CHIAMBARETTA F—Clermont-Ferrand

F080 Bilateral ocular involvement in a patient with tertiary syphilis
ZOZOLOU M, MINAKAKIS P, KANELLAS D, XIROU T, KABANAROU S, VAIKOUSIS E—Piraeus, Athens

F081 A rare case of Crohn's disease with papilledema of the optic nerve
KOEV K—Sofia

F082 Multifocal choroïditi: is it a granulomatosis close to sarcoidosis?
BENLAHBIB M, HAJJI Z, BENCHERIFA F, BOULANOUAR A, BERRAHO A—Rabat

F083 Cystoid macular edema and ocular toxocariasis in adult patients
DESPREAUX R, FARDEAU C, CHAMPION E, BRASNU E, BODAGHI B, LEHOANG P—Paris

F084 Reactivation of oxoplasmic retinochoroiditis after macula hole surgery
HALFELD FURTADO DE MENDONCA R, DE OLIVEIRA MAIA JR O—Juiz de Fora, Salvador

F085 Serous macular detachment of the neuro-epithelium in patient with tuberculous choroidal granuloma.
HALFELD FURTADO DE MENDONCA R, DE OLIVEIRA MAIA JR. O—Juiz de Fora, Salvador

F086 Ocular manifestations in Korean patients with transbronchial lung biopsy-proven sarcoidosis
SHIN J, YUNG Y—Seoul

F087 Bilateral multifocal chorioretinitis and optic neuritis due to epstein-barr virus; a case report.
CHATZIRALLI I, PARIKAKIS E, PEPONIS V, DRAKOS E, MITROPOULOS P—Athens

F088 A review of acute posterior multifocal placoid epitheliopathy
PEREZ NAVARRO I, ALMENARA MICHELENA C, CARAMELLO C, HERRERA L, PEREZ GARCIA D, MARTINEZ M, ESTEBAN O—Zaragoza

F089 Eye AIDS pathology evaluation by using ultrasound examination
KRIAUCIUNIENE L, BARZDZIUKAS V, LIUTKEVICIENE R, GUMBELEVICIUS A—Kaunas

F090 Transient branch retinal artery occlusion as the first microvascular sign of systemic lupus erythematosus
PAWLOWSKI P, ZINCZUK M, PAWLOWSKA M, RESZEC J—Bialystok, Gdynia

F091 Immunosuppressive treatment in sympathetic ophthalmia long-term visual outcome
HRARAT L, FARDEAU C, LEHOANG P—Stains, Paris

F092 Rare ocular involvement due to leukocidin "panton valentine" (pvl) positive staphylococcus aureus after bacterial endocarditis
ZOZOLOU M, MINAKAKIS P, PASCHALIDIS T, XIROU T, KABANAROU S, VAIKOUSIS E—Piraeus, Athens

F093 Mycophenolate mofetil and cyclophosphamide treatment suppress inflammation intensity in experimental model of autoimmune uveitis
KLIMOVA A, SEIDLER STANGOVA P, HEISSIGEROVA J, SVOZILKOVA P, KUCERA T—Prague

F094 Intravitreal dexamethasone implant in the treatment of postoperative cystoid macular edema (Irvine Gass syndrome): one year retrospective study
LANDRÉ C, GASTAUD P, BAILLIF S—Nice

F095 Intravitreal ranibizumab for the treatment of irvine-gass syndrome
CHATZIRALLI I, PARIKAKIS E, PEPONIS V, TSIOTRA V, MITROPOULOS P—Athens

F096 Efficacy of dexamethasone intravitreal implants in macular oedema excluding venous occlusions : results about 80 patients
DEGOUMOIS A, AKESBI J, LAURENS C, RODALLEC T, ADAM R, BLUMEN-OHANA E, LAPLACE O, VIREVIALLE C, LE DÛ B, GUYADER V, NORDMANN JP—Caen, Paris

F097 Prognostic factors for epiretinal membrane surgery
PAPANDREOU I, FALLON T—London

F098 **rf** Comparison of ocriplasmin efficacy and treatment guidance as determined by European regulatory agencies
KOROBELNIK J—Bordeaux

F099 Severe inferior retinal folding after retinectomy: an uncommon form of posterior proliferative vitreoretinopathy
BARCATALI MG, DENION E—Caen

F100 Clinical review of rhegmatogenous retinal detachment in Korea — Does seasonal variation exist in rhegmatogenous retinal detachment?
JIN H, LIM HS, LEE KH—Suwon

F101 Significant visual improvement after spontaneous resolution of longstanding macular detachment due to optic disc pit
PARIKAKIS E, CHATZIRALLI I, STRATOS E, PEPONIS V, KARAGIANNIS D, TSIOTRA V, MITROPOULOS P—Athens

F102 Vitreoretinal complications in hematology patients after hematopoietic stem cell transplantation
PARK YH, YOO YS, SHIN JA, LEE J—Seoul, Goyang

F103 Glucose levels in the vitreous in patients with retinal detachment
ARNDT C, HUBAULT B, DUCASSE A, RAMONT L—Reims

- F104 Optic nerve oximetry mapping using a novel metabolic hyperspectral retinal camera
DESJARDINS M, SYLVESTRE JP, TRUSSART R, ARBOUR JD, LESAGE F—Montréal
- F105 *rf* Differences in optical coherence tomography findings in early intervention vs late intervention surgically treated submacular hemorrhages
CANASTRO M, FARIA M, MARQUES-NEVES C, MONTEIRO-GRILLO M, NETO E, PERPETUA C, PROENCA H—Lisbon
- F106 *rf* ★ Multicenter OZurdex long term assessment for diabetic macular edema: MOZART 2 study
MATONTI F, HAJJAR C, PARRAT E, MERITE PY, POMMIER S, MEYER F, PROST-MAGNIN O, GUIGOU S—Marseille, Guadeloupe, Aix-en-Provence, L'Isle-sur-la-Sorgue, Dijon, Avignon
- F108 *rf* ★ Posterior hyaloid findings as visualized by SD OCT
KRASTEL H, HOFMANN F, BAIER D, KAHLERT CHR, KUZNIAR A, HARDER B, JONAS J—Mannheim, Wetzlar, Chemnitz
- F109 *rf* Variations and repeatability of macular pigment and its spatial profiles in south Asian and white subjects
HUNTJENS B, CTORI I—London
- F110 *rf* Hyperosmolar stress induces TonEBP activation in human retinal pigmented epithelial cells
LIBERT S, WILLERMAIN F, SALIK D, DELPORTE C—Anderlecht, Brussels
- F111 *rf* Semi-automated quantification of the parafoveal capillary network in diabetic subjects
KAPSALA Z, PALLIKARIS A, MOSCHANDREAS J, TSILIMBARIS MK—Heraklion
- F112 *rf* Prognostic factors and complications of vitrectomy in patients with advanced diabetic retinopathy
AJAMIL RODANES S, MANZANAS LEAL L, LÓPEZ GÁLVEZ MI—Valladolid
- F113 *rf* Study of endothelial progenitor cells in young diabetic patients with type 1 diabetes mellitus
TSILIMBARIS M, SIMANTIRAKI D, KAPSALA Z, TSIKA C, PONTIKOGLOU C, MAMOULAKIS D, PAPADAKI H—Heraklion
- F114 ★ Five-year incidence of branch retinal vein occlusion and its systemic and retinal risk associations: The Funagata study
KAWASAKI R, SUGANO A, KAWASAKI Y, OIZUMI T, DAIMON M, KATO T, KAYAMA T, YAMASHITA H—Yamagata, Hiroaki

Business meetings of the scientific sections

- ACB - Anatomy / Cell Biology Gallieni 1 & 2
- COS - Cornea / Ocular Surface Rhodes 2
- EOVS - Electrophysiology / physiological Optics / Vision Sciences Rhodes 1
- G - Glaucoma Rhodes 1
- IM - Immunology / Microbiology Rhodes 4
- LC - Lens / Cataract..... Rhodes 2
- MBGE - Molecular Biology / Genetics / Epidemiology Gallieni 5
- NSPH - Neuro-ophthalmology / Strabismology / Paediatric ophthalmology / History Rhodes 4
- PO - Pathology / Oncology Rhodes 3
- PBP - Physiology / Biochemistry / Pharmacology Hermes
- RV - Retina / Vitreous Hermes

Agenda

1. Report of the chair of section
2. Report of the programme secretary
3. Next year’s meeting:
 - nomination of the 2015 section programme secretary (different from the section chair)
 - proposals of 2015 Special Interest Symposia (SIS)
 - proposals of 2015 Courses
 - proposals for 2016 Keynote speakers
4. Comment on the EVER activities
5. Other business

In addition to the agenda, the sections **NSPH** and **PO** will nominate at least 2 candidates for section chair 2015-2020.

**JM
RV****Retinal oximetry**

Einar STEFANSSON, Constantin POURNARAS

Hermes

16:30	3711	Retinal Oxygen distribution in normal and pathological cases; animal models and humans POURNARAS C—Genève
16:40	3712	Assessment of retinal blood oxygen saturation in patients with primary open angle glaucoma SHAHIDI AM, HUDSON C, PATEL SR, TAYYARI F, FLANAGAN JG—Toronto
16:50	3713	Physiology of retinal oxygen extraction SCHMIDL D—Vienna
17:00	3714	Retinal oximetry in glaucoma MCNAUGHT A—Cheltenham
17:10	3715	Retinal oximetry in diabetic retinopathy BEK T—Aarhus C
17:20	3716	Retinal oximetry in AMD HEITMAR R—Birmingham
17:30 ★	3717	The effect of image quality on retinal oximetry HARDARSON S—Reykjavik
17:40 ★	3718	Retinal oxgen metabolism under visual stimulation of neuronal activity in health and disease HAMMER M, RAMM L, PETERS S, JENTSCH S, SAUER L, AUGSTEN R—Jena

**SIS
G****Glaucoma, what should we look at: vitamins, lipids, light?**

Alain BRON, Gordana SUNARIC MEGEVAND

Rhodes 1

16:30	3721	Vitamins and glaucoma CORDEIRO M—London
16:52	3722	Fatty acids and glaucoma ACAR N, BRON AM, CREUZOT-GARCHER C, BRETILLON L—Dijon
17:14	3723	Cholesterol and glaucoma BRETILLON L—Dijon
17:36	3724	Possible pros- and cons- of the effects of visual light on the progression of glaucoma OSBORNE NN—Oxford

SECOND AFTERNOON SESSION | 16:30 - 18:00

SIS COS Strategies in cornea & ocular surface to improve vision Rhodes 2

Diego PONZIN, Claus CURSIEFEN, Harminder S DUA

16:30	3731	Current and future use of contact lenses GRUENERT A–Duesseldorf
16:48	3732	Can we predict corneal graft rejection based on proangiogenic cytokines level at the time of transplantation? DEKARIS I–Zagreb
17:06	3733	Topical antiangiogenic therapy with Aganirsen eye drops reduces need for transplantation in herpetic keratitis CURSIEFEN C–Erlangen
17:24	3734	Ensuring advanced therapy treatments for ocular surface patients PONZIN D–Venice
17:42	3735	Emerging clinical concepts in ocular surface reconstruction DUA H–Nottingham

SIS PO/G Neovascular glaucoma after conservative irradiation of uveal melanoma: how to prevent and treat it Rhodes 3

Laurence DESJARDINS, Leonidas ZOGRAFOS

16:30	3741	Physiopathology of neovascular glaucoma and preventive Anti VEGF injections ZOGRAFOS L–Lausanne
16:48	3742	Prevention of neovascular glaucoma by endoresection of the uveal melanoma scar after proton beam therapy CASSOUX N–Paris
17:06	3743	Prevention of neovascular glaucoma by transcleral resection of the uveal melanoma BECHRAKIS N–Innsbruck
17:24	3744	Treatment of neovascular glaucoma by Anti VEGF injections and laser MASCHI C–Nice
17:42	3745	Surgical treatment of glaucoma following irradiation of uveal melanoma SHARKAWI E–Lausanne

WS

ARVO @ EVER: Snapshot of what's new in ocular anatomy and pathology

Rhodes 4

Sarah COUPLAND, Steffen HEEGAARD



16:30	3751	Stem cells in ocular diseases - implications to physiological and pathological angiogenesis PETROVSKI G—Szeged
16:48	3752	Genetics of keratoconus WILLOUGHBY C—Liverpool
17:06	3753	Endogenous production of anti-inflammatory molecules maintaining ocular immune privilege WALLACE G—Birmingham
17:24	3754	New insights into uveal melanoma KALIRAI H—Liverpool
17:42	3755	Update on adenoid cystic carcinomas VON HOLSTEIN S—Copenhagen

SIS
MBGE**Retinal gene therapy: an update**

Gallieni 1 & 2

Bart LEROY, Isabelle AUDO

16:30	3761	Viral vectors BARNARD A—Oxford
16:52	3762	Gene therapy for RPE65-related Leber congenital amaurosis LEROY BP—Ghent
17:14	3763	Gene therapy for choroideremia BARNARD A—Oxford
17:36	3764	Gene therapy for Stargardt disease AUDO I, MOHAND-SAID S, ZEITZ C, BARALE PO, J-A SAHEL—Paris

SIS
NSPH**The hidden history of ophthalmology from the 16 to the 20 century**

Gallieni 5

Andrzej GRZYBOWSKI, Francisco ASCASO

16:30	3771	Hermenegildo Arruga (1886-1972): an example that the improvement in retinal surgery goes on ASCASO FJ—Zaragoza
16:48	3772	A journey to Berlin, Utrecht, Paris and London in the footsteps of a cosmopolitan ophthalmologist of the second half of the 19th century KESTELYN P—Gent
17:06	3773	The invention of the contact lenses (1888) HEITZ R—Strasbourg
17:24	3774	Nicolas Claude Fabri de Peiresc (1580-1637) and the lost humanism GODARD G—Malakoff
17:42	3775	Photocoagulation: early pioneers, pitfalls and progress GRZYBOWSKI A—Poznan

20:00 - 23:00

CONGRESS DINNER

The EVER 2014 congress dinner at hotel NEGRESCO.
Availability is limited and registration is required.

Members / non-members: 90 EUR

Members in training: 60 EUR

Hotel NEGRESCO: 37, promenade des Anglais, Nice





**SATURDAY
OCTOBER 4
2014**

SIS RV **Myopic macular disease** **Hermes**
 Hadi ZAMBARAKJI, Tina XIROU

08:30	4211	Natural history and epidemiology of myopic macular disease KOURENTIS CHR—Athens
08:45	4212	Diagnostic evaluation for myopic macular disease KABANAROU S, XIROU T—Athens
09:00	4213	Photodynamic therapy outcomes in myopic CNV XIROU T—Glyfada
09:15	4214	Surgical management and treatment outcomes of myopic foveoschisis POURNARAS JA—Lausanne
09:30	4215	Surgical management and treatment outcomes of myopic macular hole retinal detachment ZAMBARAKJI H—London
09:45	4216	Anti VEGF treatment in myopic CNV SOUBRANE G—Paris

SIS G **Glaucoma progression despite good pressure control** **Rhodes 1**
 Sayeh POURJAVAN, Aachal KOTECHA

08:30	4221	What is good pressure control STEVENS A—Gent
08:52	4222	IOP fluctuation and its measurements POURJAVAN S—Zaventem
09:14	4223	Sleep apnoe and perfusion pressure KIEKENS S, DE GROOT V—Edegem
09:36	4224	Influence of cerebrospinal fluid pressure and its composition around the optic nerve on the development of glaucoma. Overview DE GROOT V, WOSTIYN P, VAN DAM D, AUDENAERT K, DE DEYN PP—Antwerp, Ghent

SIS COS **S.Fyodorov Eye Microsurgery Complex symposium: new trends in corneal transplantation** **Rhodes 2**
 Boris MALYUGIN, Zinaida MOROZ

08:30		Introduction by Thomas Fuchsluger
08:35	4231	S.Fyodorov Eye Microsurgery Complex: Past, present and future MALYUGIN B, CHUKRAYOV A—Moscow
08:52	4232	Russian KPro – UV crosslinked cornea complex implanation: Techniques and clinical results MOROZ Z, KOVSHUN E, GOLOVIN A—Moscow
09:09	4233	Local immun correction with MMSC-like limbal cells in high-risk keratoplasty patients TONAEVA H, BORZENOK SA, ONISHENKO NA
09:26	4234	Simultaneous penetrating keratoplasty and artificial iris-lens diaphragm implantation POZDEYEVA N, PASHTAYEV NP—Cheboksary
09:43	4235	Femtosecond laser-assisted anterior lamellar keratoplasty for keratoconus PASHTAEV A, MALYUGIN B—Moscow

WS
PO

OOG - Ocular Oncology Group 1

Tero KIVELÄ, Emine KILIC

Rhodes 3



08:30	4241	Eye neoplasms: a bibliometric analysis from 1966 to 2012 MOURIAUX F, BOUDRY C—Caen
08:42	4242	BAP1 germline mutations in Finnish uveal melanoma patients TURUNEN J, MARKKINEN S, WILSKA R, MUONA M, RAIVIO V, TÄLL M, LINDH S, LEHESJOKI AE, KIVELÄ T—Helsinki
08:54	4243	Multiple malignancies in uveal melanoma patients - the LOOC experience HEUSSEN FM, DAMATO B, KALIRAI H, COUPLAND SE, HEIMANN H—Liverpool, San Francisco
09:06	4244	NRAS, BRAF and KIT expression/mutational status, miRNA related profile and clinico-pathologic parameters in pigmented lesions of the conjunctiva PARROZZANI R, FRIZZIERO L, PERRINI P, ALESSANDRINI L, BLANDAMURA S, MIDENA E—Roma, Padova
09:18	4245	Can we trust the biopsy for prognostication in patients with choroidal malignant melanomas? KIILGAARD J, BAGGER M, TOLSTRUP ANDERSEN M, HEEGAARD S, KLARSKOV ANDERSEN M—Copenhagen
09:30	4246	SF3B1 and EIF1AX mutations in uveal melanoma: a protective factor, or not? KILIC E, KOOPMANS AE, YAVUZYIGITGLU S, VAARWATER J, VAN IJCKEN WFJ, PARIDAENS D, DE KLEIN JEMM—Rotterdam
09:42	4247 <i>rf</i>	Identification and characterization of melanin in choroidal melanoma by electron paramagnetic resonance spectroscopy (EPR) ROMANOWSKA DIXON B, KLONOWSKA A, PLONKA P, SARNA T—Krakow
09:48	4248 <i>rf</i>	Optico-reconstructive surgery after blockexcision of iridociliary tumors SAAKYAN S, ANDREEVA T, CHENTSOVA E—Moscow

SIS
LC

Optical effects of cataracts

Ralph MICHAEL, Rafael I. BARRAQUER

Rhodes 4

08:30	4251	How protein aggregations and lens fiber disorder result in nuclear and cortical cataracts MICHAEL R, BARRAQUER R—Barcelona
08:48	4252	Refractive error changes in cortical, nuclear, and posterior subcapsular cataracts ELLIOTT D—Bradford
09:06	4253	Intraocular stray light compared with subjective lens grading scores in normal and cataractous eyes BARRAQUER R, ALLENDE-MUÑOZ MJ, PINILLA-CORTÉ L, MONTENEGRO G, MICHAEL R—Barcelona
09:24 ★	4254	Optics of light scattering in the human eye lens VAN DEN BERG T—Amsterdam
09:42	4255	Is it possible to see through a cataractous lens? ARTAL P—Murcia

FP **RV 3/6 : Vein occlusion** **Gallieni 1 & 2**
 Jost B JONAS, Stephanie BAILLIF

08:30 *	4261	Intravitreal aflibercept for macular oedema due to branch retinal vein occlusion CLARK WL, BROWN D, TEMPER B—Columbia, Houston, Berlin
08:42 *	4262	Vision-related function in the COPERNICUS and GALILEO trials PEARCE I, LORENZ K, WITTRUP-JENSEN K—Liverpool, Mainz, Berlin
08:54 *	4263	Visual acuity outcomes by baseline perfusion status in the COPERNICUS and GALILEO trials PIELEN A, FELTGEN N, TEMPER B—Hannover, Goettingen, Berlin
09:06 *	4264	A post-market surveillance study on the processing and follow-up of patients with BRVO and CRVO prescribed Ozurdex LARSEN L, MERKOUKIS N, LEABACK R—Glostrup, Uppsala, Marlow

FP **quartett diagnostica Research Award Session** **Gallieni 5**
 Thomas FUCHSLUGER, Jean-Jacques GICQUEL



Grants supported by quartett for best papers in COS
 - Translation Medicare
 - Basic Research
 - Clinical Research
 The grants will be handed over during this session.



JAY NEITZ

Department of Ophthalmology, University of Washington Medical School (Seattle)

Lessons learned from gene therapy for color blindness in primates

Introduction by Werner SPILEERS


Color blindness is the most common genetic disorder. The possibility of curing color blindness using gene therapy was explored by adding a third type of cone pigment to dichromatic retinas of squirrel monkeys. This opened a new avenue to explore the requirements for establishing the neural circuits for a new dimension of color sensation. The addition of a third opsin in adults was sufficient to produce trichromatic color vision. Thus, trichromacy can arise from a single addition of a third cone class in a primate and it does not require an early developmental process. This has implications for understanding how our brain processes conscious visual information and it illuminates the opportunities and limits of gene therapy for treating human vision disorders.

Award of the EVER Certificate of Honour

SECOND MORNING SESSION | 11:00 - 12:30

SIS RV	Vitreoretinal interface disorders		Hermes
	Jean - Antoine C POURNARAS, Yannick LE MER		
11:00	4411	Pathophysiology of vitreoretinal interface disorders POURNARAS C—Genève	
11:18	4412	Assessment and novel classification of vitreoretinal interface disorders GUALINO V—Montauban	
11:36 *	4413	Enzymatic vitreolysis LE MER Y—Paris	
11:54	4414	What's new for the surgical management of vitreoretinal interface disorders? POURNARAS JA—Lausanne	
12:12	4415	Case study POURNARAS JA—Lausanne	

FP	COS 3/5 : Corneal infections and wound healing		Rhodes 1
	Philippe KESTELYN, Marc MURAINÉ		
11:00	4421	Orphan drug for acanthamoeba keratitis (ODAK) project: validation of an acanthamoeba polyphaga keratitis model GUEUDRY J, RAZAKANDRAINIBE R, HUMBERT C, AIFA A, FRANCOIS A, LE GOFF L, FAVENNEC L, MURAINÉ M—Rouen	
11:12	4422	Topical treatment with a new matrix therapy agent (RGTA, CACICOL-20) improves epithelial wound healing after penetrating keratoplasty JULIENNE R, HAOUAS M, TRONE MC, HE Z, CROUZET E, THURET G, GAIN P—Saint-Etienne	
11:24	4423	The use of amniotic membrane homogenate is improved by a retinoid pre-treatment in healing corneal alkali burns, in a mouse model DANIEL E, BONNIN N, BELVILLE C, COMPTOUR A, BLANCHON L, SAPIN V, CHIAMBARETTA F—Clermont-Ferrand	
11:36	4424	Rho-associated kinase inhibition prevents pathological neovascularization after corneal trauma SIJNAVE D, VAN BERGEN T, VANDEWALLE E, STALMANS I—Leuven	
11:48	4425 <i>rf</i>	Cytological features of inflammatory cells infiltration indicates the etiology of infectious keratitis SMEDOWSKI A, TARNAWSKA D, WYLEGALA E—Katowice	
11:54 *	4426 <i>rf</i>	Anti-glaucoma drugs and their additives, testing the influence of excipients on the corneal healing process in the EX-Vivo Eye Irritation Test (EVEIT) system DUTESCU M, PINHEIRO R, PANFIL C, SCHRAGE N—Aachen	
12:00	4427 <i>rf</i>	3D reconstruction of corneal endothelial cell shape: new insight in structure-function relationships HE Z, BERNARD A, DEFOE D, PISELLI S, ACQUART S, FOREST F, DUMOLLARD JM, PEOC'H M, GAIN P, THURET G—Saint-Etienne, Johnson City	
12:06	4428 <i>rf</i>	Terrien's marginal degeneration: Nordic collaborative study KURKINEN M, DROLSUM L, FAGERHOLM P, HJORTDAL J, HOLOPAINEN J—Helsinki, Oslo, Linköping, Aarhus	

SIS COS	Keratoprosthesis I		Rhodes 2
	Christopher LIU, Jodhbir Singh MEHTA, Thomas FUCHSLUGER		
11:00	4431	Keratoprosthesis. Personal experience BARRAQUER J—Barcelona	
11:10	4432	UK results for the OOKP LIU CSC, AVADHANAM VS, HEROLD J, BUSUTTIL A, THORP TAS—Brighton	
11:26	4433	Indian MOOKP results IYER G—Chennai	
11:42	4434	Singapore results for OOKP and superfunctional OOKP implants MEHTA J, TAN X, TAN D—Singapore	
11:58	4435	The Boston type 1 keratoprosthesis and endophthalmitis: a systematic review COLE ST, AVADHANAM VS, LIU CSC—Brighton	
12:14	4436	Challenges to globalizing keratoprosthesis surgery CHODOSH J—Boston	

WS
PO**OOG - Ocular Oncology Group 2**

Laurence DESJARDINS, Edoardo MIDENA

Rhodes 3



11:00	4441	Incidence of iris melanomas in Denmark from 1942-2013 JøRGENSEN A, WADT K, HEEGAARD S, PRAUSE J, KIILGAARD J—Copenhagen
11:12	4442	Intraretinal hyperreflective spots in eyes with radiation induced maculopathy MIDENA E, PARROZZANI R, MIDENA G, FRIZZIERO L, VUJOSEVIC S, PILOTTO E—Padova, Roma
11:24	4443	Tumour regression pattern according to tumour shape after brachytherapy for 330 uveal melanomas MAMUNUR R, KIVELÄ T—Helsinki
11:36	4444	Reasons for secondary enucleation after eye preserving treatment of uveal melanoma SAAKYAN S, AMIRYAN A, MIRONOVA I—Moscow
11:48	4445	Retrospective study of combined treatments for conjunctival melanoma DESJARDINS L, YIN Y, CASSOUX N, LUMBROSO LE ROUIC L, DENDALE R, SASTRE X, ASSELAÏN B, PLANCHER C, LEVY C—Paris
12:00	4446 <i>rf</i>	Gene expression in conjunctival melanoma cell lines treated with the histone deacetylase (HDAC) inhibitor valproic acid (VPA) MUNOZ-ERAZO L, MADIGAN M, CONWAY RM—Sydney
12:06	4447 <i>rf</i>	HSP90 inhibitors and conjunctival melanoma MADIGAN M, QUAH X, MCALPINE S, CONWAY RM—Sydney
12:12	4448 <i>rf</i>	Periorbital necrotizing fasciitis in a 69 year old patient. Medical management and use of hyperbaric oxygen as further adjunctive therapy PORTALIOU DM, KOUROUPAKI A, KABANAROU S, KARVELA I, FERETIS E, XIROU T—Athens
12:18	4449 <i>rf</i>	Aneurysmal bone cyst: an exceptional entity in the orbit LEMAITRE S, ZMUDA M, JACOMET PV, BERGES O, GALATOIRE O—Paris

FP

COS 4/5 : Ocular surface inflammation

Dominique BREMOND-GIGNAC, Jennifer CRAIG

Rhodes 4

11:00	4451	Role of Azithromycin in the treatment of children meibomian gland disease LAZREG S, BENALI ABDELLAH M—Dar el Beida, Blida
11:12	★ 4452	Prospective evaluation of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) CRAIG JP, TURNBULL PR, CHEN A—Auckland
11:24	4453	Novel method for the isolation and measurement of microRNA and microRNA related targeted genes in conjunctival epithelial cells in primary Sjogren's syndrome patients PILSON Q, NÍ GABHANN J, MURPHY C—Dublin
11:36	★ 4454	Effects of punctal occlusion on clinical signs, symptoms, and tear cytokines in patients with dry eye BEUERMAN R, TONG LMG, SIMONYI S, HOLLANDER DA, STERN ME—Singapore, Irvine, California
11:48	4455 <i>rf</i>	Anti-evaporative mechanism of wax esters: implications for the function of tear fluid PAANANEN RO, RANTAMÄKI AH, HOLOPAINEN J—Helsinki
11:54	4456 <i>rf</i>	Systematic allergy investigation of patients with red eyes MUNK SJ, GARVEY LH, HEEGAARD S, HANSEN KS, SKOV L, ZACHARIAE C, MENNÉ T, JULIAN HO, HALKJÆR LB, JOHANSEN JD—Copenhagen
12:00	4457 <i>rf</i>	Changes of inflammatory cytokines and tear osmolarity in systemic sclerosis after treatment with liposomes sprayed GAGLIANO C, AMATO R, FALLICO M, TORO M, AVITABILE T, FOTI R—Catania
12:06	4458 <i>rf</i>	Morphogenesis of eyelid meibomian gland GUEDIRA TARIHGT G, TARIHGT N, SEVESTRE H, COPIN H, BREMOND-GIGNAC D—Amiens

Course 11 Examination of eye movements and common peripheral NSPH and central oculomotility disorders

François-Xavier BORRUAT, Pierre-François KAESER

Gallieni 1 & 2

Beginners

When facing a patient with diplopia or abnormal eye movements, it is mandatory to perform a thorough, precise and systematic examination of eye movements. This course aims at providing participants with a structured approach to oculomotility disorders and will consist of four sections:

1. Review of the anatomical and physiological bases of oculomotility;
2. Demonstration of normal versus abnormal eye movements, with the help of videos;
3. Discussion of common peripheral and central eye movement disorders (paralysis of cranial nerves III, IV and VI; internuclear ophthalmoplegia; skew deviation);
4. Presentation of interactive cases using Audience Response System. The audience will participate, allowing the attendees to use the acquired knowledge in clinical situations.

At the end of this course participants should have acquired a systematic and practical approach to the patient with diplopia or central oculomotility disorders.

11:00	4461	Eye movement examination BORRUAT F–Lausanne
11:22	4462	Third, fourth and sixth cranial nerves palsy KAESER PF–Lausanne
11:44	4463	Common supranuclear eye movement disorders BORRUAT F–Lausanne
12:06	4464	Interactive case presentations KAESER PF, BORRUAT F–Lausanne

FP RV 4/6 : Diabetes

Pascale MASSIN, Stephanie BAILLIF

Gallieni 5

11:00	★ 4471	Impact of Baseline (BL) Visual Acuity (VA) in the VIVID-DME and VISTA-DME trials MASSIN P, KOROBELNIK J, METZIG C–Paris, Bordeaux, Berlin
11:12	★ 4472 <i>rf</i>	Multicenter OZurdex long term assessment for diabetic macular edema: MOZART 2 study MATONTI F, HAJJAR C, PARRAT E, MERITE PY, POMMIER S, MEYER F, PROST-MAGNIN O, GUIGOU S–Marseille, Guadeloupe, Aix-en-Provence, L'Isle-sur-la-Sorgue, Dijon, Avignon
11:18	4473	Incidence of macular edema following single versus 4 session pattern scanning laser panretinal photocoagulation in diabetic retinopathy PALLOT C, KOEHRER P, ISAICO R, KODJIKIAN L, MASSIN P, JONVAL L, BERTAUX AC, D'ATHIS P, BRON AM, CREUZOT-GARCHER C–Dijon, Lyon, Paris
11:30	4474	Serous retinal detachment associated with diabetic macular edema over the course of Ranibizumab treatment QU L, FAJNKUCHEN F, CHAINE G, GIOCANTI-AUREGAN A–Paris, Bobigny
11:42	4475	Spectral domain ocular coherence tomography finding post vitrectomy and membrane delamination for proliferative diabetic retinopathy DOOLEY I, LAVIERS H, PAPAVALSILEIOU E, MCKECHNIE C, ZAMBARAKJI H–London
11:54	4476	Improved outcome after primary vitrectomy in diabetic patients treated with simvastatin LOUKOVAARA S, SAHANNE S, TUUMINEN R–Helsinki
12:06	4477 <i>rf</i>	Pronostic factors and complications of vitrectomy in patients with advanced diabetic retinopathy AJAMIL RODANES S, MANZANAS LEAL L, LÓPEZ GÁLVEZ MI–Valladolid

INDUSTRY-SPONSORED SYMPOSIUM 5



Changing Perspectives in DME: Recognising & Understanding Chronic DME

Moderator: Gisèle SOUBRANE

12:35		Introduction by Gisèle SOUBRANE
12:40	4531	The role of inflammation in chronic DME SOUBRANE G—Paris
12:50	4532	The long-term benefit of new sustained delivery micro-implant in patients with chronic DME CUNHA-VAZ J—Coimbra
13:00	4533	Understanding and managing steroid induced elevation of IOP GONI F—Barcelona
13:10	4534	European early experience AUGUSTIN A—Karlsruhe
13:20		Q&A, Conclusion by Gisèle SOUBRANE

JM **OOG: Business meeting**

PO Sarah COUPLAND, Nathalie CASSOUX



1. Minutes of previous Business Meeting
2. Financial report and Website update
3. OOG Bylaws update
4. Nominations for membership to OOG
5. Update on current collaborative studies/new proposals
6. Details of next OOG Spring Meeting in Moscow
7. Proposals for future Spring meetings
8. Results of OOG Committee Election
9. Any Other Business (AOB)
10. Closure and Farewell

FIRST AFTERNOON SESSION | 13:35 - 15:05

WS FAN: Fluorescein Angiography Club 1

Hermes

RV Mary VAN SCHOONEVELD

Cases with retinal imaging are presented and discussed with a panel. Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all EVER delegates.



Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room.

www.fan-int.org

Course 12 What's new in visual development and binocular vision

Rhodes 1

NSPH Dominique BREMOND-GIGNAC, Stefan LÖFGREN

Advanced

Development is incomplete at birth, particularly in premature infants. Maturation of the visual system, including neurological and ocular components, is influenced by many factors including prenatal conditions, postnatal binocular alignment and postnatal visual stimulation. In early life, particularly during sensitive periods of development, abnormal visual input, for example caused by visual deprivation mechanism, amblyopia, or ocular misalignment, leads to abnormalities in visual development, including abnormal eyeball growth and neurological changes. This SIS aims to discuss new mechanisms and anomalies of visual development.

13:35	4621	Visual deprivation: mechanism and practical applications BREMOND-GIGNAC D—Amiens
14:05	4622	Lens and visual development LÖFGREN S—Stockholm
14:35	4623	Postural control and binocular anomalies KAPOULA Z, MORIZE A, DANIEL F, ORSSAUD C, JONQUA F, BREMOND GIGNAC D—Paris

SIS Keratoprosthesis II: Artificial Corneas

Rhodes 2

COS May GRIFFITH, Thomas FUCHSLUGER, Christopher LIU



13:35	4631	Electrospun nanofibrous scaffolds and corneal tissue engineering SALEHI S, BAHNERS T, GUTMANN J, FUCHSLUGER T—Düsseldorf, Krefeld
13:50	4632	Functional properties of nerves regenerating within bioengineered corneas GALLAR J—San Juan de Alicante
14:05	4633	Hydrogel based keratoprosthesis STORSBERG J—Potsdam
14:20	4634	Next generation corneal implants as alternative to high risk donor transplantation GRIFFITH M, ISLAM M, IAKYMENKO S, PASYECHNIKOVA N, BUZNYK O—Linköping, Stockholm, Odessa
14:35	4635	Biocompatibility and functionality of a tissue-engineered stroma transplanted in the living animal BRUNETTE I, BOULZE PANKERT M, GOYER B, ZAGUIA F, BAREILLE M, PERRON MC, LIU X, DOUGLAS CAMERON J, PROULX S—Montréal
14:50	4636	KPro Biomaterials AVADHANAM VS, INGLAVE G, SANDEMAN S, LIU CSC—Brighton

WS
PO**OOG - Ocular Oncology Group 3**

Francis MUNIER, Maria Antonia SAORNIL ALVAREZ

Rhodes 3



13:35	4641 <i>rf</i>	Vascularized vitreous seeding regression following systemic and intravitreal chemotherapy for advanced "late" retinoblastoma HADJISTILIANO T, DE FRANCESCO S, BORRI M, MICHELI L, GALIMBERTI D, CAINI M, GALLUZZI P, MENICACCI F—Siena
13:41	4642	Anterior ischemic optic neuropathy following selective intra-arterial chemotherapy for unilateral retinoblastoma DE FRANCESCO S, MENICACCI F, BORRI M, HADJISTILIANO T—Siena
13:53	4643	Cavitary retinoblastoma: clinical features and treatment outcome HADJISTILIANO T, DE FRANCESCO S, BORRI M, GALLUZZI P, DELUCA MC, BRACCO S—Siena, Reggio Emilia
14:05	4644	Proteomic analysis of aqueous humor in retinoblastoma patients: a focus on intra-arterial chemotherapy effects MICHELI L, LANDI G, MORIGGI M, VANNONI D, VASSO M, MENICACCI F, GELFI C, LEONCINI R, HADJISTILIANO T—Siena, Milan
14:17	4645	Intraocular Metastasis as presentation of unknown systemic neoplasia SAORNIL ALVAREZ M, RAMOA R, GARCIA-ALVAREZ C, MUNOZ M, LOPEZ-LARA F—Valladolid
14:29	4646	Unusual lesion of the orbit in a larynx cancer patient GRISHINA E—Moscow
14:41	4647	Genetic analysis of an orbital metastasis from a primary hepatic neuroendocrine carcinoma HEEGAARD S, VON HOLSTEIN S, PRAUSE J, STENMAN G—Copenhagen, Gothenburg
14:53	4648 <i>rf</i>	Suspicious choroidal mass – an interdisciplinary challenge GRAEFF E, GRIESHABER M, MEYER P—Basel

SIS
LC**Accommodation**

Rafael I. BARRAQUER, Ralph MICHAEL

Rhodes 4

13:35	4651	Mechanical performance of the lens capsule in accommodation BURD H—Oxford
13:53	4652	Brillouin spectroscopy and lens refilling STACHS O—Rostock
14:11	4653	Mechatronic system to restore accommodation GUTHOFF RF—Rostock
14:29	4654	The AkkoLens Lumina accommodative intraocular lens ROMBACH M—Breda
14:47	4655	Summary and discussion BARRAQUER R, MICHAEL R—Barcelona

FIRST AFTERNOON SESSION | 13:35 - 15:05

WS

FRO - Belgian Fund for Research in Ophthalmology 1

Gallieni 1 & 2

Laure CASPERS



13:35	4661	FRO 2014: Exploring the role of cis-acting pre-mRNA splicing dynamics in the pathogenesis and treatment of Stargardt disease BAUWENS M, DE BAERE E, LEROY BP—Ghent
13:47	4662	FRO 2014: Shine a light on glaucoma: an optogenetic approach towards retinal ganglion cell protection DEKEYSTER E, GEERAERTS E, MOONS L—Leuven
13:59	4663	FRO 2014: The pathophysiologic role of SNORD115 and SNORD116 in late-onset Fuchs' endothelial corneal dystrophy DE ROO A, FOETS B, VAN DEN OORD J—Leuven
14:11	4664	FRO 2014: ROCK as a potential target in the treatment of different retinopathies HOLLANDERS K, SPILEERS W—Leuven
14:23	4665	FRO 2014: MMP-2 as a potential benefactor in zebrafish optic nerve regeneration LEMMENS K, BOLLAERTS I, MOONS L—Leuven
14:35	4666	FRO 2014: Automated detection, classification and notification of pathological corneas using the Oculus Pentacam RUIZ HIDALGO I—Edegem
14:47	4667	FRO 2014: Potential implications of epigenetic changes in human retinal pigmented epithelium during diabetic retinopathy SALIK D—Bruxelles

FP

RV 5/6 : Vitreo macular interface

Gallieni 5

Jean François KOROBNELNIK, Constantin POURNARAS

13:35	4671	Analysis of the vitreomacular interface in a French population-based study (The MONTRACHET study: Maculopathy, Optic Nerve, nuTRition, neurovAsCular and HEarT diseases) BOUCHE-PILLON J, KOEHRER P, BINQUET C, TZOURIO C, BRON AM, CREUZOT-GARCHER C—Dijon, Bordeaux
13:47 ★	4672 <i>rf</i>	Posterior hyaloid findings as visualized by SD OCT KRSTEL H, HOFMANN F, BAIER D, KAHLERT CHR, KUZNIAR A, HARDER B, JONAS J—Mannheim, Wetzlar, Chemnitz
13:53	4673 <i>rf</i>	Comparison of ocriplasmin efficacy and treatment guidance as determined by European regulatory agencies KOROBNELNIK J—Bordeaux
13:59	4674	Cystoid macular edema after epiretinal membrane surgery: Incidence, risk factors and evolution with treatments LEROY B, CONART JB, SELTON J, HUBERT I, ANGIOI K, BERROD JP—Nancy
14:11	4675	Cytologic analysis in vitreo-retinal surgery ARNDT C, DUCASSE A, DIEBOLD MC, BOULAGNON C—Reims
14:23	4676	Treatment of vitreomacular traction with ocriplasmin in a non-reimbursed setting WILLEKENS K, PINTO LA, VANDEWALLE E, STALMANS I, STALMANS P—Leuven, Lisbon

Anatomy / Cell Biology

Moderators: Goran PETROVSKI,
Kai KAARNIRANTA

- S001 Embryology of extraocular muscles : A new vision
TRECHOT F, MICARD E, CENDRE R, TONNELET R, ANGIOI K,
BRAUN M—Nancy
- S002 Mapping angiogenesis on choroidal membranes of a murine
laser-induced CNV model
TUNIK S, ARONSSON M, KVANTA A, ANDRE H—Stockholm
- S003 Changes in choroidal thickness and corneal parameters in
diabetic eyes
NORVYDAITE D, LAURINAVICIUTE G, STECH S, SKVARCIANY I,
GALGAUSKAS S, ASOKLIS R—Vilnius
- S004 Choroidal thickness in young myopic adults assessed by
enhanced depth imaging optical coherence tomography
KADZIAUSKIENE A, AUGYTE A, GALGAUSKAS S, STECH S,
STRELKAUSKAITE E, ASOKLIS R—Vilnius
- S005 Comparison of ocular tissue weights (volumes) and tissue
collection techniques in commonly used preclinical animal
species.
STRUBLE C, HOWARD S, RELPH J—Madison, Wisconsin
- S006 Microglia activation in mice retina contralateral to experi-
mental glaucoma: increased cell number and retraction of
processes beyond GCL
RAMIREZ AI, GALLEGO B, ROJAS B, DE HOZ R, SALAZAR JJ,
VALIENTE-SORIANO FJ, AVILES-TRIGUEROS M, VILLEGAS PEREZ MP,
VIDAL-SANZ M, TRIVINO A, RAMIREZ JM—Madrid, Murcia
- S007 Temporal response of the phagocytic microglia in the axoto-
mized rat retina: optic nerve crush vs. transection
NADAL-NICOLAS FM, JIMENEZ-LOPEZ M, SALINAS-NAVARRO M,
NIETO-LOPEZ L, CANOVAS-MARTINEZ I, SOBRADO-CALVO P, VIDAL-
SANZ M, AGUDO-BARRIUSO M—Murcia
- S008 *rf* Autophagy stimulus promotes HuR protein phosphorylation
and SQSTM1/p62 protein up-regulation in ARPE-19 cells
AMADIO M, MARCHESI N, GOVONI S, PASCALE A, KAARNIRANTA
K—Pavia, Kuopio
- S009 *rf* Cytotoxicity of mesoporous silicon microparticles with
different surface modifications on ARPE-19 cells
KORHONEN E, RIIKONEN J, XU W, LEHTO VP, KAUPPINEN A—Kuopio
- S010 A novel proteotoxic stress-associated mechanism for
macular corneal dystrophy
KAARNIRANTA K, SZALAI E, SMEDOWSKI A, WYLEGALA E,
FELSZEZGHY S—Kuopio, Debrecen, Katowice
- S011 *rf* Predegenerated Schwann cells promote neuroprotection and
regeneration of retinal ganglion cells in ex vivo rat retinal
explants
SMEDOWSKI A, PIETRUCHA-DUTCZAK M, KAARNIRANTA K,
LEWIN-KOWALIK J—Katowice, Kuopio
- S012 *rf* Pinosylvin protects retinal pigment epithelial cells from
oxidative stress by activating Nrf2-mediated antioxidant
defence system
KOSKELA A, REINISALO M, HYTTINEN J, KAARNIRANTA K,
KARJALAINEN R—Kuopio

Cornea / Ocular Surface

Moderators: Thomas FUCHSLUGER,
Jean-Jacques GICQUEL,
Dominique BREMOND-GIGNAC

- S013 *rf* Influence of pressure on in vitro human corneal endothelial
cells derived from human induced pluripotent stem cell
(hiPSC)
JUMELLE C, SUFFEE N, FOREST F, HE Z, BERNARD A,
NANGOUM-FOSSO T, NAIGEON N, PERRACHE C, PEOC'H M,
GAIN P, THURET G—Saint-Etienne
- S014 *rf* Development of an ECM hydrogel for corneal tissue
engineering
AHEARNE M—Dublin
- S015 *rf* Ocular chronic graft versus host disease after allogeneic
hematopoietic stem cell transplantation – preliminary data
JEPPESEN H, LINDEGAARD J, SENGELOEV H, JULIAN HO, PRAUSE J,
HEEGAARD S—Copenhagen, Glostrup
- S016 *rf* Positive cultures in corneas stored with cold storage
technique to be used for corneal grafting
JULIAN HO, LINDEGAARD J, HØJGAARD-OLSEN K, HEEGAARD S—
Copenhagen
- S017 In vivo corneal confocal microscopy allows direct observation
of microbiological features in infectious keratitis
WYLEGALA E, SMEDOWSKI A, TARNAWSKA D, NOWINSKA A,
DOBROWOLSKI D—Katowice
- S018 Role of SD-OCT in the diagnosis and management of a
late-onset corneal LASIK flap tear secondary to screwdriver
trauma
ESTEBAN O, RODRIGUEZ NA, ASCASO FJ, SOLANAS S—Zaragoza,
Pamplona, Tudela
- S019 Comparison of corneal power and astigmatism in normal
eyes using 4 different devices
HAN KE, LEE HK, HWANG HS, SHIN MC—Gangwon-Do Chuncheon
- S020 presbyopia and hyperopia treatment by Presbylasik using
a central multifocal excimer laser profile with a
micromonovision
SAIB N, ABRIEU N, BERGUIGA M, RAMBAUD C, FENOLLAND JR,
BONNEL S, FROUSSART-MAILLE F, RIGAL-SASTOURNE JC—Paris
- S021 Distribution of orbiscan indices in a young population of Iran
YEKTA AA, HASHEMI H, KHABAZKHOOB M, YAZDANI N,
OSTADIMOGHADDAM H, DERAKHSHAN A, MOUSAVI M,
HERAVIAN J, NOROUZIRAD R, YEKTA R—Mashhad, Tehran, Dezful
- S022 Structure of Collagen fibril and proteoglycans at different
depth of corneal stroma of CXL treated rats
AKHTAR S, SMEDOWSKI A, KHAN A, KAARNIRANTA K,
ALMUBRAD T—Riyadh, Silesia, Kuopio
- S023 Expression of HGF/c-Met in control and keratoconus corneas
YOU J, ROUFAS A, WEN L, HODGE C, SUTTON G, MADIGAN M—
Sydney, Kensington
- S024 Observational comparative study of different predictive
scores of infraclinic keratoconus in refractive laser surgery in
case of recused patients
CHENY T, ABRIEU M, RAMBAUD C, BERGUIGA M, SENDON D,
THOUVENIN R, FROUSSART-MAILLE F, RIGAL-SASTOURNE JC—
Clamart

Cornea / Ocular Surface

**Moderators: Thomas FUCHSLUGER,
Jean-Jacques GICQUEL,
Dominique BREMOND-GIGNAC**

- S025 Fluorophotometry study of riboflavin in iontophoresis procedure and conventional cross linking
DANIEL E, CASSAGNE M, BONNIN N, BOREL A, VIENNET A, COULANGEON LM, MONNEYRON N, MALECAZE F, CHIAMBARETTA F—Clermont-Ferrand, Toulouse, Vichy, Nice
- S026 Scleral collagen crosslinking (SXL) by riboflavin and blue light inhibits eye growth of young rabbits
KORBER N, GOHLER C, KOCH C, KARL A, PENK A, HUSTER D, REICHENBACH A, FRANCKE M, WIEDEMANN P, ISELI HP—Leipzig, Zuerich
- S027 Translation of the therapeutic approach of scleral collagen crosslinking (SXL) from animal to human
RATTUNDE U, KORBER N, GOHLER C, KOCH C, KARL A, SCHULDT C, REICHENBACH A, FRANCKE M, WIEDEMANN P, ISELI HP—Leipzig, Zuerich
- S028 Characterization of extracellular matrix remodelling enzymes in the sclera after collagen cross linking (SXL)
GOHLER C, KARL A, KORBER N, KOCH C, REICHENBACH A, WIEDEMANN P, FRANCKE M—Leipzig
- S029 Reproducibility of keratometric measurements obtained with OCULUS® Pentacam® HR in the evaluation of keratoconus progression
SILVA N, VIEIRA L, ANJOS R, ALVES N, MADURO V, FEIJAO J, CANDELARIA P—Lisboa
- S030 Peripheral neuropathy in chronic renal failure: an in vivo confocal microscopy study
VIEIRA L, ANJOS R, SOUSA H, SOUSA A, BORGES A, BRANCO P, ALVES N, MADURO V, CANDELARIA P—Lisboa
- S031 Mathematical model of corneal reendothelialization after inadvertent descemetorhexis
TRONE M, JULIENNE R, RANNOU K, BERNARD A, HE Z, GAVET Y, THURET G, GAIN P—Saint-Etienne
- S032 Investigation of anterior chamber flare and corneal Langerhans cells in rheumatoid arthritis and in dry eye
MARSOVSZKY L, BAUSZ M, NÉMETH J, RESCH M—Budapest
- S033 Influence of pterygium excision surgery on corneal biomechanical properties
CARMELLO C, MATEO OROBIA AJ, PÉREZ D, IBAÑEZ J, HERRERA L, ZABADANI K, MARTINEZ M, DEL BUEY MA, PINILLA I, ASCASO J—Zaragoza
- S034 Late diagnosis of donor-to-host herpes infection in a descemetic deep anterior lamellar keratoplasty (dDALK) procedure for keratoconus: case report.
MENICACCI F, SARNICOLA E, MENICACCI C, SARNICOLA V—Siena, Grosseto
- S035 Adenovirus keratoconjunctivitis in relation with refractive surgery. Effects and treatment of sequelae
PEREZ NAVARRO I, DEL BUEY MA, HERERRA L, CARMELLO C, ALMENARA C, IDOATE A, MARTINEZ M, ESTEBAN O, PEREZ GARCIA D, PINILLA I—Zaragoza
- S036 Laser in situ keratomileusis: epidemiology and risk factors of flap folds
SENDON D, RAMBAUD C, ABRIEU M, BERGUIGA M, FROUSSART-MAILLE F, RIGAL-SASTOURNE JC—Paris, Clamart
- S037 Treatment of corneal ulcers in ocular surface inflammation
LAZREG S—Dar el Beida
- S038 Treatment of alkali-injured corneas by nanofibers seeded with mesenchymal stem cells or loaded with cyclosporine a
HOLAN V, CEJKOVA J, CEJKA C, TROSAN P, ZAJICOVA A—Prague
- S039 Bioengineering of endothelial grafts using femtosecond Laser cut corneal lamellae or collagen lenticules, endothelialized with immortalized or hiPSC-derived endothelial cells
FOREST F, HE Z, MOULARD A, SUFFEE N, FOREST F, DUMOLLARD JM, PEOC'H M, GAIN P, THURET G—Saint-Etienne
- S040 3D reconstruction and segmentation methods for endothelial cell count of stored corneas
BERNARD A, HOR G, TIFFET T, RANNOU K, GAVET Y, PINOLI JC, ACQUART S, GAIN P, THURET G—Saint-Etienne
- S041 Comparison of ultrathin manual and automated stripping of the endothelium in Fuchs endothelial dystrophy
DUNCOMBE A, MATHIEU B, ROSSI P, TOUBEAU D, GUEUDRY J, MURAINÉ M—Rouen, Dijon
- S042 Surgeon graft less viable endothelial cells than the eye bank cell count suggests
NEFZAOUI C, TRONE MC, HE Z, BERNARD A, PISELLI S, ACQUART S, THURET G, GAIN P—Saint-Etienne
- S043 Sclero-corneal lenses' supply for the treatment of keratoconjunctivitis sicca in patients with refractory ocular GvHD
RICHEM M, MAGRO L, RANDON T, ERNOULD F, YAKOUB-AGHA I, LABALETTE P—Lille
- S044 Diquafosol sodium ophthalmic solution for the treatment of dry eye in soft contact lens wearers
YAMADA M, SHIGEYASU C, FUKUI M—Tokyo
- S045 Ocular protection index is related to ocular surface disease index in dry eye disease patients
BADIAN R, UTHEIM TP, RÆDER S, UTHEIM Ø, CHEN X, STOJANOVIC A, EIDET JR—Oslo
- S046 The effects of lower lid laxity on the response to dry eye treatment
LEE N, YIM H—Seoul, Incheon
- S047 Evaluation of self-report questionnaires as predictive tests for obtaining pathological schirmer i, tear film break-up time and ocular protection index scores in dry eye disease patients
BADIAN R, UTHEIM TP, RÆDER S, UTHEIM Ø, CHEN X, EIDET JR—Oslo
- S048 Clinical performance of preservative-free, hypotonic solution of 0.15% sodium hyaluronate for mild to moderate dry eye
PURSLOW C—Cardiff
- S049 Immediate impact of hyaluronic and methylcellulose artificial tears on tear film stability
WYLEGALA E, SMEDOWSKI A, TARNAWSKA D, CIESLIK T, WEGLARZ B, NOWINSKA A, DOBROWOLSKI D—Katowice, Kielce
- S050 Comparison of the lubricant eye drops Optive®, Vismed® and Cationorm® on the corneal healing process in an ex-vivo model of the anterior ocular segment, the Ex Vivo Eye Irritation Test (EVEIT) System.
DUTESCU R, PINHEIRO R, PANFIL C, SCHRAGE N—Aachen
- S051 Structure and microanalysis of tear film ferning of camel tears, human tears and refresh plus
AKHTAR S, MASMALI A, KHAN A, ALMUBRAD T—Riyadh

- S052 Effects of a tear supplement containing hyaluronic acid (HA) on tear film thickness in healthy subjects
WIRTH M, SCHMIDL D, KAYA S, NAPORA K, WERKMEISTER R, GARHOFER G, SCHMETTERER L—Vienna, Salzburg
- S053 Substitutes of fetal bovine sera for the culture of human corneal limbal stem cells
IÑIGO PORTUGUÉS A, MEANA A, VÁZQUEZ N, CHACÓN M, RIESTRA ANAC, ORIVE G, ANITUA E, MERAYO-LLOVES J—Oviedo, Vitoria
- S054 Decreased basal tear in aged mice is linked to morphological and functional changes in corneal sensory nerve fibers
IÑIGO PORTUGUÉS A, ALCALDE I, GONZÁLEZ-GONZÁLEZ O, GALLAR J, BELMONTE C, MERAYO-LLOVES J—Oviedo, San Juan de Alicante
- S055 Engineering the corneal stroma: The effect of a three-dimensional environment and growth factor supplementation on keratocyte phenotype
SIDNEY LE, DUNPHY SE, ROSE FRAJ, HOPKINSON A—Nottingham
- S056 Plasmapheresis and autologous serum eye-drops in the treatment of acute ocular complications from toxic epidermal necrolysis (Lyell syndrome)
PINNA A, NUVOLI E, BLASETTI F, POSADINU MA—Sassari
- S057 In vivo confocal microscopy of mucous membrane pemphigoid, a new tool for the diagnosis. Reporting 6 cases
JULIENNE R, TRONE MC, HAOUAS M, PERROT JL, LABELLE B, GRIVET D, CINOTTI E, CAMBAZARD F, THURET G—Saint-Etienne
- S058 Role of PACAP for impairment of cornea epithelial wound healing
SEKI T, NAKAMACHI T, FARKAS J, WATANABE J, IZUMI S, SHIODA S—Tokyo, Toyama,
- S059 Looking at the eyelids of 4884 patients in Germany, Poland and Spain: the MEIBUM* survey
★
KAERCHER T, ZAGORSKI Z, BENITEZ DEL CASTILLO JM—Heidelberg, Naleczow, Madrid
- S060 Epidemiology of corneal ulceration and ocular surface disease among patients with Graves' orbitopathy
KLYSIK A—Lodz
- S061 Anti-evaporative mechanism of wax esters: implications for the function of tear fluid
rf
PAANANEN RO, RANTAMÄKI AH, HOLOPAINEN J—Helsinki
- S062 Systematic allergy investigation of patients with red eyes
rf
MUNK SJ, GARVEY LH, HEEGAARD S, HANSEN KS, SKOV L, ZACHARIAE C, MENNÉ T, JULIAN HO, HALKJÆR LB, JOHANSEN JD—Copenhagen
- S063 Changes of inflammatory cytokines and tear osmolarity in systemic sclerosis after treatment with liposomes sprayed
rf
GAGLIANO C, AMATO R, FALLICO M, TORO M, AVITABILE T, FOTI R—Catania
- S064 Morphogenesis of eyelid meibomian gland
rf
GUEDIRA TARIHT G, TARIHT N, SEVESTRE H, COPIN H, BREMOND-GIGNAC D—Amiens
- S065 Cytological features of inflammatory cells infiltration indicates the etiology of infectious keratitis
rf
SMEDOWSKI A, TARNAWSKA D, WYLEGALA E—Katowice
- S066 Anti-glaucoma drugs and their additives, testing the influence of excipients on the corneal healing process in the EX-Vivo Eye Irritation Test (EVEIT) system
rf
□◎
DUTESCU M, PINHEIRO R, PANFIL C, SCHRAGE N—Aachen
- S067 3D reconstruction of corneal endothelial cell shape: new insight in structure-function relationships
rf
HE Z, BERNARD A, DEFOE D, PISELLI S, ACQUART S, FOREST F, DUMOLLARD JM, PEOC'H M, GAIN P, THURET G—Saint-Etienne, Johnson City
- S068 Terrien's marginal degeneration: Nordic collaborative study
rf
KURKINEN M, DROLSUM L, FAGERHOLM P, HJORTDAL J, HOLOPAINEN J—Helsinki, Oslo, Linköping, Aarhus
- S069 Spatial statistical analysis of the human corneal endothelial mosaic
RANNOU K, GUERRERO P, GAVET Y, PINOLI JC, THURET G, GAIN P—Saint-Etienne
- S070 Innovative, non-contact wide field imaging of corneal endothelium
ABERRA GUEBROU S, HE Z, GUILHEM M, PINOLI JC, GAIN P, THURET G—Saint-Etienne
- S071 Red light has the capacity to blunt corneal endothelial cell damage in situ.
NÚÑEZ ÁLVAREZ C, OLMO-AGUADO S, MERAYO-LLOVES J, OSBORNE NN—Oviedo
- S072 In vivo and ex vivo confocal microscopy of eyelid melanoma: case report
HAOUAS M, GUILLEMOT C, GRIVET D, CINOTTI E, PERROT JL, LABELLE B, CAMBAZARD F, FOREST F, DUMOLLARD JM, PEOC'H M, GAIN P, THURET G—Saint-Etienne
- S073 Secondary, vocational crystalline keratopathy – case report
WYLEGALA E, SMEDOWSKI A, JANISZEWSKA D, TARNAWSKA D, NOWINSKA A, DOBROWOLSKI D—Katowice
- S074 The effects of paclitaxel on angiogenesis and lymphangiogenesis in the mouse cornea.
JASIELSKA M, KOCIOK N, BRÄUTIGAM M, JOUSSEN M, PLEYER U, MAIER AK—Lublin, Berlin
- S075 Circumferential lymphangiectasia haemorrhagica conjunctivae: a rare case of spontaneous resolution
ASCASO FJ, HUERVA V, TRAVESET A, SANCHEZ MC—Zaragoza, Lleida
- S076 Anterior stromal puncture with Nd: YAG laser for recurrent corneal erosion
KO BY, KIM SY—Daejeon

Lens / Cataract

Moderators: Stefan LÖFGREN, Peter BARRY

S077 Distribution, molecular structure and functional analysis of carnitine transporter (SLC22A5) in canine lens epithelial cells
OCHIAI H—Sagamihara Kanagawa

S078 Anterior lens epithelial cells attachment to the basal lamina
ANDJELIC S, DRASLAR K, HVALA A, LOPIC N, STRANCAR J, HAWLINA M—Ljubljana

S079 Caspase-3 in ultraviolet radiation cataract
TALEBI ZADEH N, YU Z, KRONSCHLÄGER M, SÖDERBERG P—Uppsala

S080 Ocular heat flow associated with threshold in vivo exposure to 1090 nm infrared radiation for cataract induction
YU Z, SCHULMEISTER K, TALEBIZADEH N, KRONSCHLÄGER M, SÖDERBERG P—Uppsala, Seibersdorf

S081 Comparative study of the incidence of macula edema in healthy and diabetic patients after uncomplicated cataract surgery
MIRACHTSIS T, GEORGIADOU I, SIOULIS C, MARKOU C, LAKE S, MOSCHOU V, GEORGIADIS N—Thessaloniki

S082 Statin use and increased risk of cataract surgery
ERIE J, CHAMBERLAIN A, HODGE D—Rochester

S083 Preliminary study of the association between corneal histocytological changes and surgically induced astigmatism after phacoemulsification
ZHAO G, LIN J, XU Q—Qingdao

S084 Changes of corneal endothelium in diabetes patients after cataract phacoemulsification surgery by confocal microscopy
LIN J, ZHAO G—Qingdao

S085 Comparison of two different surgical treatments of presbyopia for hyperopic patients over 55 years old: Presbylasik (Supracor) and Prelex (presbyopic lens exchange)
MOYAL L, ABRIEU M, FROUSSART-MAILLE F, RIGAL-SASTOURNE JC—Paris

S086 Lens capsular bag dislocated into the anterior chamber following calcific phacolysis in an immunocompromised patient.
ALMENARA MICHELENA C, RODRIGUEZ A, ASCASO FJ, SOLANAS S, MAYA R, ANDONEGUI J—Zaragoza, Pamplona, Tudela

S087 Bromfenac 0.09% BID after Nd:YAG laser posterior capsulotomy: evaluation of visual acuity and macular retinal thickness.
LOMBARDO S, TINELLI C, ANTONIAZZI ER—Pavia

S088 A case series of late postoperative capsular block syndrome treated by Nd:YAG laser posterior capsulotomy
MARTINEZ VELEZ M, HUERVA V, SANCHEZ MC, ASCASO FJ, SOLDEVILA J—Zaragoza, Lleida

S089 Impact of lens thickness on hyper mature cataract surgical complications: preliminary results of a prospective study
ADDOU-REGNARD M, FAJNKUCHEN F, CHAINE G, GIOCANTI-AUREGAN A—Bobigny

S090 Simplified topical anaesthetic protocol for ambulatory cataract surgery: safety and satisfaction
FERTE A, BATA B, TRECHOT F, FUCHS-BUDER T, ANGIOI K—Nancy

S091 *rf* Change in intraocular pressure in the early period after cataract phacoemulsification
YUGAY MARIA, RYABTSEVA ALLA—Moscow

S092 Simulation of stray light with a phakic intraocular lens with a central hole
EPPIG T, LANGENBUCHER A—Homburg/Saar

S093 Pseudophakic photopsia – Optical simulations with a model eye to evaluate IOL design and material
LANGENBUCHER A, EPPIG T—Homburg/Saar

S094 Clinical outcomes after implantation of multifocal toric intraocular lenses.
THOUVENIN R, ABRIEU M, BERGUIGA M, RAMBAUD C, CHENY T, SENDON D, FROUSSART-MAILLE F, RIGAL-SASTOURNE JC—Clamart, Paris

S095 Long term results of toric intraocular lens implantation for correction of astigmatism in cataract patients with corneal ectasia
PARIKAKIS E, CHATZIRALLI I, STRATOS E, PEPONIS V, KARAGIANNIS D, DAVID G, MITROPOULOS P—Athens

S096 Indexing of cataract surgery video by content based video retrieval
MARTIANO DH, CHARRIERE K, LAMARD M, COCHENER B—Brest

S097 *rf* Comparison of optical and psychophysical methods to measure intraocular straylight
PENNOS A, GINIS HS, ARTAL P—Murcia

S098 Comparative study of anterior segment measurement with rotating dual Scheimpflug analyzer and optical low coherence reflectometry
ASCASO FJ, HUERVA V, SOLDEVILA J, LAVILLA L—Zaragoza, Lleida

Pathology / Oncology

**Moderators: Jens Folke KIILGAARD,
Steffen HEEGAARD**

- S099 Central nervous system abnormalities in retinoblastoma patients
DE FRANCESCO S, DE LUCA M, GALLUZZI P, HADJISTILIANOU T–Siena
- S100 *rf* Vascularized vitreous seeding regression following systemic and intravitreal chemotherapy for advanced “late” retinoblastoma
HADJISTILIANOU T, DE FRANCESCO S, BORRI M, MICHELI L, GALIMBERTI D, CAINI M, GALLUZZI P, MENICACCI F–Siena
- S101 Survival in uveal melanoma spanish patients: 1992-2012
SAORNIL ALVAREZ M, ALONSO P, GARCIA-ALVAREZ C, MUNOZ M, ALMARAZ A, LOPEZ-LARA F–Valladolid
- S102 Preliminary results of proton radiotherapy for choroidal melanoma in Department of Ophthalmology Jagiellonian University in Kraków
MARKIEWICZ A, ROMANOWSKA-DIXON B, BOGDALI A, KOWAL J, DEBICKA-KUMELA M, JAKUBOWSKA B–Kraków
- S103 The coexistence of uveal melanoma and non-pigment ciliary body epithelium adenoma in one eye
MARKIEWICZ A, BOGDALI A, ROMANOWSKA-DIXON B, POCIEJ W, KOWAL J, DEBICKA-KUMELA M, JAKUBOWSKA B–Kraków
- S104 *rf* Optico-reconstructive surgery after blockexcision of iridociliary tumors
SAAKYAN S, ANDREEVA T, CHENTSOVA E–Moscow
- S105 Clinical features, instrumental diagnostics and surgical treatment of orbital rhabdomyosarcoma in children
SAAKYAN S, AMIRYAN A, IVANOVA O, TATSKOV R–Moscow
- S106 *rf* Identification and characterization of melanin in choroidal melanoma by electron paramagnetic resonance spectroscopy (EPR)
ROMANOWSKA DIXON B, KLONOWSKA A, PLONKA P, SARNA T–Krakow
- S107 Intravitreal Ranibizumab for the treatment of choroidal neovascularization associated with choroidal nevus
HERRERA L, ZABADANI K, ALMENARA C, CARMELLO C, PEREZ NAVARRO I, ASCASO J, CAMINAL J, MARTINEZ M, ESTEBAN O, CRISTOBAL J–Zaragoza, Barcelona
- S108 An aggressive small choroidal melanoma
LAUWERS N, DE GROOT V, DE KEIZER RJW–Edegem
- S109 Melanomalytic glaucoma secondary to iris melanoma
AJAMIL RODANES S, GARCIA-ALVAREZ C, SAORNIL ALVAREZ M, LOPEZ-LARA F, FRUTOS-BARAJA JM, QUINONES M–Valladolid
- S110 *rf* Suspicious choroidal mass – an interdisciplinary challenge
GRAEFF E, GRIESHABER M, MEYER P–Basel
- S111 White center retinal hemorrhages revealing acute lymphoblastic leukemia
BENLAHBIB M, BENCHERIFA F, HAJJI Z, BOULANOUAR A, BERRAHO A–Rabat
- S112 Case of orbital mucosa-associated lymphoid tissue lymphoma accompanied with refractory serous retinal detachment
OSHITARI T, OTA S, KISHIMOTO T, YAMAMOTO S–Chiba
- S113 Suggestion of optimal response criteria in patients with ocular adnexal mucosa associated lymphoid tissue lymphoma
JUNG S, PAIK JISUN, YANG SW–Seoul
- S114 Caruncular naevi investigated by in vivo confocal microscopy: reporting the first 5 cases
JULIENNE R, GRIVET D, CINOTTI E, PERROT JL, LABELLE B, CAMBAZARD F, FOREST F, DUMOLLARD JM, PEOC’H M, GAIN P, THURET G–Saint-Etienne
- S115 *rf* HSP90 inhibitors and conjunctival melanoma
MADIGAN M, QUAH X, MCALPINE S, CONWAY RM–Sydney
- S116 *rf* Gene expression in conjunctival melanoma cell lines treated with the histone deacetylase (HDAC) inhibitor valproic acid (VPA)
MUNOZ-ERAZO L, MADIGAN M, CONWAY RM–Sydney
- S117 Merkel cell carcinoma: therapeutic discussion about two cases
BAILLIEULA, RICHEL M, DESSERRE J, MAURAGE CA, LABALETTE P–Lille
- S118 *rf* Aneurysmal bone cyst: an exceptional entity in the orbit
LEMAITRE S, ZMUDA M, JACOMET PV, BERGES O, GALATOIRE O–Paris
- S119 *rf* Periorbital necrotizing fasciitis in a 69 year old patient. Medical management and use of hyperbaric oxygen as further adjunctive therapy
PORTALIOU DM, KOUROUPAKI A, KABANAROU S, KARVELA I, FERETIS E, XIROU T–Athens
- S120 Case of relapsing polychondritis with different ocular inflammations
NANA F, TOSHIYUKI O, SHUICHI Y–Chiba
- S121 *rf* Secondary Intraocular lymphoma of the iris following a successefully treated diffuse large B-cell lymphoma of the orbit
MEYER P, GRAEFF E–Basel

SECOND AFTERNOON SESSION | 16:00 - 17:30

WS FAN : Fluorescein Angiography Club 2

Hermes

RV Mary VAN SCHOONEVELD

Cases with retinal imaging are presented and discussed with a panel. Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all EVER delegates.



Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room.

www.fan-int.org

SIS Aspects in the pathogenesis of glaucomatous optic neuropathy Rhodes 1

G Jost B JONAS

16:00	4721	Emerging evidence for the role of mitochondria in glaucoma GARWAY-HEATH D—London
16:22	4722	Vascular optic neuropathies versus glaucomatous optic neuropathy SCHMETTERER L—Vienna
16:44	4723	Does normal-pressure glaucoma and high-pressure glaucoma differ in the optic nerve head appearance? BRON AM—Dijon
17:06	4724	Brain pressure and glaucomatous and non-glaucomatous parameters JONAS J—Mannheim

WS EEBA symposium: Innovative approaches in the treatment of corneal & ocular surface diseases: potential new frontiers for eye, cell and tissue banking

Rhodes 2

COS Rudy NUIJTS, Vincent BORDERIE




16:00	4731	Penetrating keratoplasty – long-term follow-up data in low and high risk keratoplasties FUCHSLUGER T—Düsseldorf
16:13	4732	Small “Big Bubble” Technique to optimize DALK results BUSIN M—Forli
16:31	4733	Ultrathin DSAEK vs. Conventional DSAEK: Results from a Dutch multicentre randomised clinical trial NUIJTS R, DICKMAN MM, VAN DEN BIGGELAAR FJHM, BERENDSCHOT TTJM, VAN ROOIJ J, REMEIJER L, VAN DER LELIJ G, WIJDH RJH, VAN MARION FW—Maastricht, Rotterdam, Utrecht, Groningen, Beverwijk
16:49	4734	Human limbal epithelial cells cultured on dense fibrillated collagen I transparent matrices BORDERIE V, GHOUYAY D, MOSSER G—Paris
17:07	4735	Growth factor and interleukin concentration in amniotic membrane suspension (AMS) and amniotic tissue homogenates (AMTH) SZENTMARY N, STACHON T, BISCHOFF M, HUBER M, ZAWADA M, LANGENBUCHER A, SEITZ B—Homburg/Saar
17:25	4736	What’s new about contact lens complications? KUHN D—Riedlingen

FP

RV 6/6 : Cell biology and physiology in retinal disease

Rhodes 3

Ahmed ABU EL ASRAR, Catherine CREUZOT

16:00	4741	The proinflammatory cytokine high-mobility group box-1 mediates retinal neuropathy induced by diabetes ABU EL ASRAR A, SIDDIQUEI M, NAWAZ M, GEBOES K, MOHAMMAD G—Riyadh, Leuven
16:12 ★ 	4742	Apoptosis and proliferation in diabetic eyes STEWART EA, SAKER S, AMOAKU WM—Nottingham
16:30	4744	PGE2 and PGF2a stimulation of porcine retinal arterioles in vitro is associated with Ca ²⁺ activity in retinal perivascular cells KUDRYAVTSEVA O, BEK T—Aarhus
16:42	4745 <i>rf</i>	Semi-automated quantification of the parafoveal capillary network in diabetic subjects KAPSALA Z, PALLIKARIS A, MOSCHANDREAS J, TSILIMBARIS MK—Heraklion
16:48	4746 <i>rf</i>	Study of endothelial progenitor cells in young diabetic patients with type 1 diabetes mellitus TSILIMBARIS M, SIMANTIRAKI D, KAPSALA Z, TSIKA C, PONTIKOGLOU C, MAMOULAKIS D, PAPADAKI H—Heraklion
16:54	4747	Diabetic retinopathy and estimated cerebrospinal fluid pressure. The Beijing eye study 2011 JONAS J, WANG N, XU L, XU JIE, WANG Y, YOU Q—Mannheim, Beijing
17:06	4748 <i>rf</i>	Hyperosmolar stress induces TonEBP activation in human retinal pigmented epithelial cells LIBERT S, WILLERMAIN F, SALIK D, DELPORTE C—Anderlecht, Brussels

SIS
LC

Controversies on antibiotic use in ocular surgery

Rhodes 4

Andrzej GRZYBOWSKI, Rafael I. BARRAQUER

16:00	4751	Postoperative endophthalmitis BARRAQUER R—Barcelona
16:18	4752	The problem of bacterial resistance in medicine and in ophthalmology GRZYBOWSKI A—Poznan
16:36	4753	The evidence: the intraoperative antibiotic BARRY P—Dublin
16:54	4754	The evidence: pre-operative and post-operative antibiotics GRZYBOWSKI A—Poznan
17:12	4755	The evidence: the role of antibiotics in intravitreal injections LAM W—Toronto, Ontario

SECOND AFTERNOON SESSION | 16:00 - 17:30

WS FRO - Belgian Fund for Research in Ophthalmology 2 Gallieni 1 & 2

Laure CASPERS



16:00	4761	FRO 2014: Development of a new animal model for corneal endothelial research purposes SIJNAVE D, SPILEERS W—Leuven
16:12	4762	FRO 2014: using targeted next-generation sequencing to identify genes underlying keratoconus VALGAEREN H—Edegem
16:24	4763	FRO 2014: VEGF-Trap as a novel antifibrotic strategy to prevent filtration failure after glaucoma surgery VAN BERGEN T, STALMANS I—Leuven
16:36	4764	FRO 2014: Can Xiaflex® improve glaucoma surgery outcome? VAN DE VELDE S, STALMANS I—Leuven
16:48	4765	FRO 2014: Proteomic analysis of posterior capsular plaques and capsules in developmental cataracts VAN LOOVEREN J—Edegem
17:00	4766	FRO 2014: Exploring the role of a novel disease gene EML4 in autosomal recessive retinitis pigmentosa VAN SCHIL K, LEROY BP, DE BAERE E—Ghent
17:12	4767	FRO 2014: Inflammatory tear cytokine profile in acute HSV epithelial keratitis ZAKARIA N—Edegem

FP COS 5/5 : Corneal grafting Gallieni 5

Marc MURAINÉ, Mohamed GOWEIDA

16:00 ★	4771	Validation of a novel device to easy the preparation of endothelial graft for DMEK MURAINÉ M, HE Z, TOUBEAU D, GUEUDRY J, THURET G, LEFEVRE S, GAIN P—Rouen, Saint-Etienne
16:12	4772	Predictive value of color Doppler imaging of central retinal artery in outcome of corneal graft AMAOUCHE N, KOSKAS P, FADLALLAH A, COCHEREAU I, BERGES O, GABISON E—Paris
16:24	4773	Dynamics of Big Bubble (BB) formation in DALK: in vitro studies ELALFY M, FARAJ LANA, SAID DG, KATAMISH T, DUA H—Nottingham, Cairo
16:36	4774	Big bubble deep anterior lamellar keratoplasty from the perspective of the novel predescemetic corneal layer GOWEIDA M—Alexandria
16:48	4775 <i>rf</i>	Bioengineering of endothelial grafts using femtosecond Laser cut corneal lamellae or collagen lenticules, endothelialized with immortalized or hPSC-derived endothelial cells FOREST F, HE Z, MOULARD A, SUFFEE N, FOREST F, DUMOLLARD JM, PEOC'H M, GAIN P, THURET G—Saint-Etienne
16:54	4776 <i>rf</i>	3D reconstruction and segmentation methods for endothelial cell count of stored corneas BERNARD A, HOR G, TIFFET T, RANNOU K, GAVET Y, PINOLI JC, ACQUART S, GAIN P, THURET G—Saint-Etienne
17:00	4777 <i>rf</i>	Comparison of ultrathin manual and automated stripping of the endothelium in Fuchs endothelial dystrophy DUNCOMBE A, MATHIEU B, ROSSI P, TOUBEAU D, GUEUDRY J, MURAINÉ M—Rouen, Dijon
17:06	4778 <i>rf</i>	Surgeon graft less viable endothelial cells than the eye bank cell count suggests NEFZAOUI C, TRONE MC, HE Z, BERNARD A, PISELLI S, ACQUART S, THURET G, GAIN P—Saint-Etienne



Agenda

1. President's address, Constantin Pournaras
2. Minutes of the General Assembly 2013
3. Report of the Secretary General, Catherine Creuzot
4. Report of the Programme Secretary, Marcela Votruba
5. Report of the Treasurer, Jean-Jacques Gicquel
 - approval of the accounts 2013
 - discharge to the directors
 - approval budget for 2014
6. Results of the elections
7. Presentation of the board 2015
8. President Elect, Vice President Elect
9. Presentation and report of the Scientific Sections meetings
10. Future congresses
11. Prize giving
12. Miscellanea
13. Acknowledgments
14. Handover of chain of office





EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH

Science for Sight

**EVER
2015**

NICE



OCTOBER 7-10
www.ever.be





EVER

www.ever-f.eu

Awardees of the
EVERf Research Fellowships 2014

Dr. Ganne PRATYUSHA, India
Host institute: Vision Lab Cardiff Centre for Vision Sciences
Cardiff University, UK

Dr. Mohamed Shafik Mohamed ELALFY, Egypt
Host institute: Queens Medical Centre,
Nottingham, UK

*European Association for Vision and
Eye Research Foundation*



European University Professors of Ophthalmology

EUPO 2015

Course on UVEITIS and GLAUCOMA

June 5-6, 2015
Vienna, Austria

In conjunction with SOE 2015
www.eupo.eu



Acta Ophthalmologica

Edited by: Einar Stefánsson

Why should you be reading?

- Top class research - our impact factor now stands at 2.345*, with a ranking of 15/59 in the ISI Ophthalmology category
- Coverage that's relevant to you – encompassing all aspects of the anatomy, function and diseases of the eye.
- Official publication of EVER and all five Nordic Ophthalmological Societies.

Members of EVER receive FREE online access to *Acta Ophthalmologica* as part of their membership.

Visit www.actaophthalmologica.com for more information

WILEY

*2012 JCR, Thomson Reuters

14-87453

SOE
2015

CONGRESS

EUROPEAN SOCIETY OF
OPHTHALMOLOGY

6-9 JUNE 2015 • VIENNA, AUSTRIA

In conjunction with AAO



© WIEN TOURISMUS / PETER RIGAUD



© INGRAM IMAGE



© WIEN TOURISMUS / PETER RIGAUD

SEE YOU IN VIENNA!

www.soe2015.org



© WIEN TOURISMUS / CHRISTIAN STEMPER



© WIEN TOURISMUS / KARL THOMAS



AMERICAN ACADEMY
OF OPHTHALMOLOGY
The Eye M.D. Association

EB

Diploma Examination 2015

Friday 08 - Saturday 09 May 2015

Venue: Le Palais des
Congrès de Paris

**Excellence
in Education**



EBOD 2015

Applications open October 2014

Submission deadline 19 December 2014

Grant applications open October 2014

2015

Asia ARVO

Evolutions in Ophthalmology: From quality of vision to aging and regenerative science



Feb. 16 – 19, 2015
Pacifico Yokohama
Yokohama, Japan
Chair: Kazuo Tsubota, MD, FARVO (Keio University)

©2013 Takashi Murakami/Kaikai Kiki Co., Ltd.
All Rights Reserved.

DON'T MISS THIS OPPORTUNITY!
Submit your abstract now!!
Submissions open : Aug. 8 – Oct. 10, 2014

Host Organization

Department of Ophthalmology
Keio University School of Medicine
35 Shinanomachi, Shinjuku-ku
Tokyo 160-8582, Japan

Congress Secretariat

MediProduce, Inc.
8-5-40-513 Akasaka, Minato-ku
Tokyo 107-0052, Japan
Phone: +81-3-5775-2075 Fax: +81-3-5775-2076
E-mail: 2015asia-arvo@mediproduce.jp


arvo.org/asia-arvo

Keio University



Powerful Connections:
Vision Research and
Online Networking

ARVO
2015
MAY 3 – 7 | DENVER



Key Dates

Early meeting registration

Opens
15 September 2014

Abstract submission

15 October –
5 December 2014

Hotel reservations

Now open

 **ARVO**
The Association for Research
in Vision and Ophthalmology
arvo.org/am

E-SWIN

E-EYE

World innovation for Meibomian Gland Dysfunction treatment

E-EYE is the first and only device in the world to have obtained the medical CE certification for the treatment of Meibomian Gland Dysfunction (dry-eye syndrome).

E-EYE is a device that generates a polychromatic pulsed light by producing perfectly calibrated and homogeneously sequenced pulsed light. The sculpted pulses are delivered under the shape of train pulses.

The energy, spectrum and time period are precisely set to stimulate the Meibomian glands in order for them to return their normal function.

E-EYE has been subjected to a scientific study by Doctor Jennifer Craig*.

*Dr. Jennifer Craig
New Zealand National Eye Center
University of Auckland

E-EYE

Your patients will never again suffer from dry eye

Special offer launch in Europe

**15%
off**

to get an E-EYE
+ 50 user kits for free

Offer is valid before October 31, 2014



For further information, please contact us :


Valérie : +33 1 30 46 37 68
Sandrine : +33 1 30 46 37 69

Email us :
commercial@e-swin-pro.com


KEYNOTE SPEAKERS

KESTELYN P	> Wednesday, 15:30
SCHORDERET D	> Wednesday, 17:40
FOSTER R	> Wednesday, 18:15
ROORDA A	> Thursday, 10:15
BODAGHI B	> Thursday, 13:35
SULLIVAN D	> Friday, 10:10
NEITZ J	> Saturday, 10:15

Four digit numbers refer to oral presentations



One letter and three digit numbers refer to posters



ABERRA GUEBROU S: S070
 ABU EL ASRAR A: 3652, 4741
 ACAR N: 2223, 3722
 ADDOU-REGNARD M: S089
 AHEARNE M: S014, 1726
 AJAMIL RODANES S: F112, S109, 4477
 AKHTAR S: S022, S051, 3252
 ALMENARA MICHELENA C: F038, S086
 ALMOALLEM B: T081
 AL MUHTASEB H: F033
 ALVAREZ L: T075
 AMADIO M: S008, 3256, 3475
 AMAOUCHE N: 4772
 ANDJELIC S: S078
 ANDRE H: T068
 ANDROUDI S: 1642
 ANG L: T025
 ANJOS R: T058, 2433, 2648
 ANSARI E: T014
 APTEL F: T043, T044
 ARNDT C: F103, 4675
 ARTAL P: 4255
 ARVEILER B: 2661, 2663
 ASCASO FJ: S075, S098, 3411, 3771
 ASLAM T: 2533
 ATHERTON S: 3243
 AUDIO I: 2764, 3764
 AUGUSTIN A: 4534
 AVADHANAM VS: 4636
 AYCHOUA N: 3423
 AZIZA: T091
 BADIAN R: S045, S047
 BAILLIEUL A: S117
 BARATZ K: 3632
 BARCATALI MG: F099
 BARNARD A: 3761, 3763

BARRAQUER J: 4431
 BARRAQUER R: 4253, 4655, 4751
 BARRY P: 4753
 BASDEKIDOU C: 2212
 BAUDONNET R: T062, 2647
 BAUWENS M: 4661
 BAZIN L: F045
 BEAUJEU P: T085
 BECHRAKIS N: 3743
 BEHL C: 2421
 BEK T: 1611, 3715
 BELAHDA A: F021
 BENLAHBIB M: F082, S111
 BERNARD A: S040, 4776
 BESOMBES G: T030
 BEUERMAN R: 2772, 4454
 BIDAUT GARNIER M: T054
 BIKBOVA G: 2651
 BIRKELDH U: F060
 BITOUN P: 3426
 BLASETTI F: F051
 BODAGHI B: 1745, 3446
 BOGATYREVA E: T012
 BOGNER B: 3431
 BONNIN N: F079
 BORDERIE V: 4734
 BORRUAT F: 4461, 4463
 BOSCHI A: 1653
 BOUCHE-PILLON J: 4671
 BOUHACINA BENMANSOUR A: T033
 BOURNIQUEL M: T087
 BOYA P: 2422
 BREMOND-GIGNAC D: 2232, 2734, 3453, 4621
 BRETILLON L: 3723
 BRON AM: 1731, 3242, 4723
 BRUNETTE I: 3433, 4635

BURD H: 4651
 BUSHUYEVA NN: T090
 BUSIN M: 4732
 CAHUZAC A: 2215
 CANASTRO M: F105, 3665
 CARAMELLO C: F036, S033
 CASSOUX N: 3245, 3742
 CHABANE H: 3274
 CHANG HR: T082
 CHAPRON T: T034
 CHATZIRALLI I: F087, F095
 CHENY T: S024
 CHIAMBARETTA F: 3272
 CHIQUET C: 2214, 3613
 CHIU CJ: F061
 CHO B: T027, T040
 CHODOSH J: 4436
 CLARK WL: 4261
 COLE ST: 4435
 CONSTABLE P: 3261
 CORDEIRO M: 2622, 3721
 CORREIA A: 2443
 COSCAS G: 2411
 CRAIG JP: 4452
 CREUZOT-GARCHER C: F066, 2615
 C. SILVA AS: 3663
 CTORI I: 1665
 CUNHA JP: 3674
 CUNHA-VAZ J: 4532
 CURSIEFFEN C: 3733
 DA CRUZ L: 2254
 DAI Y: F032
 DAIEN V: 2654
 DAL MONTE M: F005, F006
 DAMATO B: 1622
 DAMJI KF: 2724

PRESENTING FIRST AUTHORS

- DANIEL E: S025, 4423
DEBELLEMANIERE G: 1771
DE FRANCESCO S: S099, 4642
DEGOUMOIS A: F096
DE GROOT V: 4224
DEKARIS I: 3732
DEKEYSTER E: 3421, 4662
DELBARRE M: T038
DELGADO TIRADO S: T066
DEL OLMO AGUADO S: F008
DE ROO A: 4663
DE SEZE J: 2262, 2264
DESJARDINS L: 2743, 4445
DESJARDINS M: F104
DESPREAUX R: F083
DESSERRE J: F069
DICK A: F078, 1641, 1646, 2253, 3244
DIRANI A: 2414
DIWO E: T053
DOAN S: 2676, 3271
DOBROWOLSKI D: 1634
DOMNGANG NOCHE C: T061
DONALD J: 2441
DONATI G: 2412
DOOLEY I: 4475
DUA H: 2732, 3624, 3735
DUNCOMBE A: S041, 4777
DUQUESROIX B: T080
DURIEUX P: T073
DUTESCU M: S066, 4426
DUTESCU R: S050
EICHLER WOLFR: 3215
ELALFY M: 4773
EL CHEHAB H: F023
ELDRED JA: 1773
ELLIOTT D: 4252
EL MATRI L: F018
EPPIG T: S092
ERB C: T016
ERDIAKOV A: F077
ERIE J: S082
ERRERA MH: T060
ESTEBAN O: S018, T114
FAUQUERT JL: 3273
FERREIRA S: T103, 3676
FERRERO A: 3661
FERRINGTON D: 2272
FERRIS J: 3223
FERTE A: S090
FINIS D: 2674
FINZI A: T028
FLECK O: 1664
FLORES M: 1667
FONTAINE M: T086
FOREST F: S039, 4775
FRUTTIGER M: 2244, 2755
FUCHSJAGER-MAYRL G: F004
FUCHSLUGER T: 3432, 4731
GAGLIANO C: S063, 4457
GAJECKA M: 1762
GALLAR J: 4632
GALLEGO B: 1673
GARCIA GARCIA L: 1764
GARCIA MARTIN ES: T108, 3675
GARHOFER G: 2222
GARWAY-HEATH D: 4721
GAUTHIER AS: F011
GAUTIER E: 1751
GEISER M: 3615
GICQUEL J: 2231, 2631, 2731
GIOCANTI-AUREGAN A: F065
GIRAUD JM: 3232
GLACET-BERNARD A: 1712
GODARD G: 3774
GOHLER C: S028
GONI F: 4533
GONZALEZ C: F064, F072, F073
GONZALEZ BUENDIA L: T074, 1768
GOTO Y: T020
GOWEIDA M: 4774
GRAEFF E: S110, 4648
GRAW J: 1761
GREINER J: 2673
GRIFFITH M: 4634
GRILLO-ANTONELLI S: T017
GRISHINA E: 4646
GRIVET D: 2432
GRUENERT A: 3731
GRUS F: 2423
GRZYBOWSKI A: 3413, 3775, 4752, 4754
GUAGLIANO R: T083
GUALINO V: 4412
GUEDIRA TARIGHT G: S064, 4458
GUEUDRY J: 4421
GUILLONNEAU X: 1754
GÜMBEL H: 3233
GUTHOFF R: 3434
GUTHOFF RF: 4653
GUZIEWICZ K: 3264
HADJISTILIANOU T: S100, 4641, 4643
HALFELD FURTADO DE MENDONCA R: F019, F084, F085
HAMAM R: 3442
HAMEL C: 2761
HAMMER M: 3718
HAN KE: S019
HAOUAS M: S072
HARDARSON S: 3717
HA THI B: 1724
HAYNES R: 3222
HE Z: S067, 4427
HEEGAARD S: 4647
HEITMAR R: F046, 3716
HEITZ A: T088
HEITZ P: T057
HEITZ R: 3773
HERBORT C: 1645, 1744, 3651
HERRERA L: S107, T099
HEUSSEN FM: 4243
HO H: 3425
HOLAN V: S038
HOLDER GE: 2664, 3464
HOLLANDERS K: 1661, 4664
HOLMES JM: 2454
HOMMER A: T023
HOPKINSON A: 1721, 2733
HOUTMAN AC: 2453
HRARAT L: F091
HUNTJENS B: F109, 1663
HYSI P: 2462
HYTTI M: 1675
HYUNKYUNG KIM: T096
IÑIGO PORTUGUÉS A: S053, S054
IONICA V: T011
IRION L: 3647
IRSCH K: T092, 2655
ISELI HP: 2715
IYER G: 4433

JACOBS D: 2473
 JANISZEWSKA D: 1631
 JANSONIUS NM: F034
 JANY B: T084
 JASIELSKA M: S074
 JENSEN PS: F044
 JEPPESEN H: S015, 1727
 JIMENEZ DEL RIO B: T105, T106
 JIN H: F100
 JONAS J: F028, 4724, 4747
 JØRGENSEN A: 4441
 JOUSSEN A: 3435
 JULIAN HO: S016, 1728
 JULIENNE R: S057, S114, 4422
 JUMELLE C: S013, 1725
 JUNG KI: T048
 JUNG S: S113
 JUNG Y: T026
 JUNOY MONTOLIO FG: 3424
 KAARNIRANTA K: S010, 2531
 KABANAROU S: F020, 4212
 KADZIAUSKIENE A: S004
 KAERCHER T: S059
 KAESER PF: 4462, 4464
 KALIRAI H: 3754
 KANG S: F057
 KAPOULA Z: 4623
 KAPSALA Z: F111, 4745
 KARDON R: 2263
 KARTTUNEN T: F052
 KAUPPINEN A: 2271
 KAWASAKI A: 1654, 3463
 KAWASAKI R: F114
 KAYA M: F043
 KESTELYN P: 3633, 3772
 KHAIRALLAH M: 1743, 3655
 KIEKENS S: 4223
 KIILGAARD J: 4245
 KILIC E: 4246
 KIM MS: F048
 KIM YT: T005
 KIVELÄ T: 1621, 1623, 2742, 3623
 KLIMOVA A: F093
 KLYSIK A: S060, 1774
 KNOP E: 2471
 KNOP N: 2671
 KO BY: S076
 KODJIKIAN L: 2614
 KOEV K: F022, F081
 KOLKO M: 1674
 KORBER N: S026
 KORHONEN E: S009, 3257
 KOROBELNIK J: F098, 2532, 3472, 3533, 4673
 KOSKELA A: S012, 3255
 KOTAPATI RAGHUPATHY R: F016
 KOTECHA A: 2721
 KOURENTIS CHR: 4211
 KOUSAL B: T070
 KOVARSKI C: 3672
 KRASTEL H: F108, 3474, 4672
 KRIAUCIUNIENE L: F089, T102
 KU HC: F025
 KUDRYAVTSEVA O: 4744
 KUHN D: 4736
 KURKINEN M: S068, 4428
 KURYSHEVA N: 2621
 KWON HJ: F017
 LABETOULLE M: T063, T064, 2233
 LAM W: 4755
 LANDRÉ C: F094
 LANGENBUCHER A: S093
 LARSEN L: 4264
 LAUWERS N: F014, S108
 LAWRENSON J: 3415, 3422
 LAZREG S: S037, 4451
 LEE HS: T065
 LEE J: T100, T101
 LEE M: T097
 LEE N: S046, T041
 LEE S: F037, F049, T089
 LEE SY: T029
 LEE T: T024
 LEE Y: T032
 LEINONEN M: 2444
 LEITGEB R: 1613
 LEMAITRE S: S118, 3645, 4449
 LEMEE G: T059, 2646
 LE MER Y: 4413
 LEMMENS K: F002, 4665
 LEROY B: 3462, 4674
 LEROY BP: 2662, 2762, 3262, 3762
 LIBERT S: F110, 4748
 LIM SJ: T079
 LIN J: S084
 LIPSKI D: T056
 LISCH W: 3634
 LISKOVA P: 1633, 2463, 2763
 LIU CSC: 4432
 LIU L: 3414
 LOEWENSTEIN A: 1715, 2612
 LÖFGREN S: 4622
 LOMBARDO S: S087
 LORENZ B: 2652
 LOUKOVAARA S: 4476
 LUX AL: T093, 2656
 LYONS T: 2752
 LYTVYNCHUK L: 1672
 MACHALINSKA A: 3213
 MACKENSEN F: 3444
 MADIGAN M: S115, 3644, 4447
 MAEDA A: 1753
 MAGOURITSAS G: T037, 1734
 MAIER M: 2714
 MAJSTEREK I: T076
 MALYSKO K: F054
 MALYUGIN B: 4231
 MAMMADZADA P: T067
 MAMUNUR R: 4443
 MANCZAK H: 2474
 MANGIORIS G: F059
 MARECHAL M: T039
 MARIOTTI C: 2252
 MARKIEWICZ A: S102, S103
 MARQUINA I: F030, 1666
 MARSOVSZKY L: S032, 2437
 MARTIANO DH: S096
 MARTINEZ VELEZ M: S088, T098
 MASCHI C: 3744
 MASSIN P: 2611, 4471
 MATONTI F: F106, 4472
 MCNAUGHT A: 3224, 3714
 MEHTA J: 4434
 MEIER-GIBBONS F: T052, 1737
 MEILLON C: F071
 MEKKI MB: 2475
 MELY R: 2472
 MENEY J: T077
 MENICACCI F: S034

PRESENTING FIRST AUTHORS

- METZ G: T110, T111, 2658
MEUNIER I: 3263
MEYER P: S121, 3648
MICHAEL R: 4251
MICHAU S: T115
MICHELI L: 4644
MIDENA E: 4442
MILYUTKINA S: F062, F067
MIRACHTSIS T: S081
MISIUK HOJLO M: T018
MOGAVERO V: T004
MOHNEY B: 2452
MORGAN I: 2712
MORGAN JE: 2722
MOROOKA S: F007
MOROZ Z: 4232
MORREALE BUBELLA R: F027, T109
MOUALLEM A: 3443
MOULIN A: 3646
MOUNIER A: F015
MOURIAUX F: 4241
MOYAL L: S085
MUMCUOGLU T: T031, T049
MUNIER F: 2746
MUNK SJ: S062, 4456
MUNOZ-ERAZO L: S116, 2641, 4446
MURAIINE M: 4771
NADAL-NICOLAS FM: S007
NADIM N: 3412
NANA F: S120
NEFZAOUI C: S042, 4778
NERI P: 1643, 2251, 3654
NORVYDAITE D: S003
NOWAK DM: T078, 1766
NOWINSKA A: 1632
NUIJTS R: 4733
NÚÑEZ ÁLVAREZ C: S071
NYSTRÖM A: 3454
O'BRIEN C: 2774
OCHIAI H: S077
OHLENDORF A: 2713
O'ROURKE M: 3445
OSBORNE NN: 2241, 3724
OSHITARI T: S112
OSMAN I: 2431
OSTADIMOGHADDAM H: F029, T007
OZONE D: F058
PAANANEN RO: S061, 4455
PALLOT C: 4473
PAPANDREOU I: F055, F097
PAQUES M: 3241
PARIKAKIS E: F101, S095
PARK J: F035
PARK YH: F102
PARROZZANI R: 4244
PARSA C: 2653
PASHTAEV A: 4235
PASU S: F074
PATERNO JJ: T072, 1765
PAWLOWSKI P: F090, T055, 2645
PEARCE I: 3532, 4262
PENAUD B: F053
PENNOS A: S097, 1777
PEREIRA AC: 3671
PEREZ NAVARRO I: F088, S035
PETROPOULOS I: F003, F070, 1713
PETROVSKI G: 3253, 3751
PICAUD S: 2623
PIELEN A: 4263
PILSON Q: 4453
PINNA A: S056
PINTO-BONILLA I: 2832
PISELLA P: 2632
PLEYER U: 1644, 1742, 3621
POJDA-WILCZEK D: T002, 2442
POMMIER S: F040
PONZIN D: 3734
POPA CHERECHEANU A: T045
PORTALIOU DM: S119, 4448
POURJAVAN S: 4222
POURNARAS C: 1711, 2613, 3614, 3711, 4411
POURNARAS JA: 4214, 4414, 4415
POZDEYEVA N: 4234
PUCHE N: 1714
PURSLOW C: S048, 2672, 2831
QU L: 4474
QUENDERA B: 2445
RAJAIYA J: 2644
RAMIREZ AI: S006
RANNOU K: S069
RATTUNDE U: S027
REICHENBACH A: 2242
REMOND A: T095
RICHET M: S043
RIGAL-SASTOURNE JC: 3234
RIVA C: 3611
ROCHA DE SOUSA A: 3476
RODRIGO E: T010
ROJAS B: 2245
ROMANOWSKA DIXON B: S106, 3641, 4247
ROMBACH M: 4654
ROSE K: 1763
ROSENBERG R: T036
ROULAND J: T042
RUIZ HIDALGO I: 4666
RUSSO A: F042
SAAKYAN S: S104, S105, 4248, 4444
SAIB N: S020
SALEHI S: 4631
SALIK D: 4667
SAMUDRE S: T022
SANTANDER-TRENTINI F: F050
SAORNIL ALVAREZ M: S101, 4645
SAROSSY M: T003
SAWAMURA H: T094, 2657
SCEMAMA TIMSIT C: 2213
SCHAEFFEL F: 2711
SCHALENBOURG A: 2745
SCHLINGEMANN R: 3531
SCHMETTERER L: 2224, 2624, 2833, 3612, 4722
SCHMIDL D: 3713
SCOTT ROBER: 3231
SEITZ B: 3631
SEKI T: S058
SEMOUN O: 2415
SENDON D: S036
SENNLAUB F: 1755, 2753, 3211
SEO SJ: T021
SHAH P: 3221
SHAHIDI AM: 3712
SHARKAWI E: 3745
SHIN J: F086
SHU X: T071
SIDNEY LE: S055, 3251
SIJNAVE D: 4424, 4761
SILVA N: S029, 2434
SILVA R: 3471
SINHA D: 2273

- SJÖSTRAND J: F026
 SKARPHEDINSDOTTIR S: F010
 SLIESORAITYTE I: 2446
 SMEDOWSKI A: S011, S065, T050, 1736, 3254, 4425
 SÖDERBERG P: 1775
 SOUBRANE G: 1614, 4216, 4531
 SPILEERS W: 3461
 STACHS O: 4652
 STAHL A: 3216
 STEFANSSON E: 3436, 3622
 STEPHAN S: F047
 STEVENS A: 4221
 STEWART EA: F075, 4742
 STITT A: 2754
 STORSBERG J: 4633
 STRUBLE C: F056, S005
 STRUPAITE R: F024
 SULLIVAN DA: 2675
 SUNARIC MEGEVAND G: 3225
 SURGUICH V: 3664
 SZATMARY G: 1652
 SZENTMARY N: 4735
 SZUMNY D: F009, F013
 TAHIRI H: F012
 TALEBI ZADEH N: S079
 TASSIGNON MJ: 3451
 TEN TUSSCHER M: 2451
 THEOCHARIS IP: 3662
 THIEME C: 2642
 THORNE J: 3441
 THOUVENIN R: S094
 THURET G: 1722
 TISSIER P: T015
 TONAEVA H: 4233
 TOPOUZIS F: 2221
 TORNQVIST K: 3455
 TORVINEN P: T019
 TÓTH M: 1671
 TÓTH-MOLNÁR E: F001
 TRECHOT F: S001
 TRONE M: S031, 2436
 TSAI A: T047
 TSIKA C: 1662
 TSILIMBARIS M: F113, 4746
 TUGAL-TUTKUN I: 3653
 TUNDIA N: F076
 TUNIK S: S002
 TÜRKSEVER C: T006, T013
 TURUNEN J: 4242
 TUULONEN A: 2723
 UUSITALO H: 2773
 UZZAN J: 2416
 VALERO B: T009
 VALGAEREN H: 4762
 VAN BERGEN T: 1733, 4763
 VAN CALSTER J: F041, 2643
 VAN DEN BERG T: 2633, 4254
 VANDERMEULEN J: T104, 3677
 VANDERVEEN D: 3452
 VAN DE VELDE S: 1732, 4764
 VAN GINDERDEUREN R: 3643
 VAN KEER K: 3473
 VAN LOOVEREN J: 4765
 VAN SCHIL K: 4766
 VERTICCHIO VERCELLIN A: T035
 VICENTE A: 3673
 VIDAL-SANZ M: 2424
 VIE A: F039
 VIEIRA L: S030, T051, T107, 1735, 2435
 VILLEGAS PEREZ MP: 2243
 VINCENT AL: 2461
 VOIDE N: T112, 3678
 VON HOLSTEIN S: 3755
 VOTRUBA M: T069, 1767
 VOTTONEN P: 1676
 WALLACE G: 3753
 WANG X: 3214
 WEGENER A: 1772
 WERKMEISTER R: 1612
 WILLEKENS K: 4676
 WILLERMAIN F: 1741
 WILLOUGHBY C: 3752
 WILSON S: 2771
 WILSON SL: 1723
 WIRTH M: S052
 WIRYASAPUTRA S: F068
 WOLFF B: 2211
 WONG W: 1752
 WYLEGALA E: S017, S049, S073, 1635, 3635
 XIROU T: 4213
 XU H: 2274, 2751
 XU YP: T046
 YAMADA M: S044
 YEKTA AA: S021, T001
 YEUNG A: 2234
 YOU J: S023
 YU Z: S080
 YUGAY MARIA: S091, 1776
 YUM HR: T008, T113
 YU-WAI-MAN P: 1651, 2261
 ZABADANI K: F031, F063
 ZAKARIA N: 4767
 ZAMBARAKJI H: 4215
 ZERBIB J: 2413
 ZHANG S: 3212
 ZHAO G: S083
 ZHAO L: 3666
 ZOGRAFOS L: 2741, 2744, 3642, 3741
 ZOZOLOU M: F080, F092



You need commitment, focus and passion to find new ways to fight the diseases of this world: innovation is at the heart of it.

Innovation for better health. Our commitment is to bring to patients around the world quality medicines for use in diagnosing, combating and preventing disease. Every day we work against time, researching new pathways, new molecules, new technologies – complementing our own capabilities with expertise of innovative partners from science and industry.

The success of this work is evidenced in new medicines for areas with significant unmet medical need such as oncology, cardiovascular and blood diseases, as well as gynecology and ophthalmology. Our aim is a better quality of life for all.



www.healthcare.bayer.com
www.pharma.bayer.com

Science For A Better Life

ABEGÃO PINTO L: 3473
 ABERRA GUEBROU S: **5070**
 ABOLBASHARI F: T007
 ABOU SAMRA W: 3611
 ABRAHAM S: 3214
 ABRIEU M: S024, S036, S085, S094
 ABRIEU N: S020
 ABU EL ASRAR A: **3652, 4741**
 ACAR N: **2223, 3722**, 1664
 ACQUART S: S040, S042, S067, 1724, 4427, 4776, 4778
 ADAM R: F096
 ADAMS D: T077
 ADDOU-REGNARD M: **5089**
 AERTS J: 3421
 AERTS L: F014
 AGARD E: F015
 AGUDO M: 2424
 AGUDO-BARRIUSO M: S007, 2243
 AGUIRRE G: 3264
 AHEARNE M: **S014, 1726**
 AHMADI HOSSEINI M: F029, T007
 AHO S: 1731
 AIFA A: 4421
 AJAMIL RODANES S: **F112, S109, 4477**
 AKESBI J: F096
 AKHTAR S: **S022, S051, 3252**
 ALBERT R: 1671, 3252
 ALCALDE I: S054
 ALESSANDRINI L: 4244
 ALI Y: 3446
 ALLENDE-MUÑOZ MJ: 4253
 ALMARAZ A: S101
 ALMENARA C: F031, F036, F063, S035, S107, T098, T099
 ALMENARA MICHELENA C: **F038, S086**, F088
 ALMOALLEM B: **T081**
 ALMUBRAD T: S022, S051, 3252
 AL MUHTASEB H: **F033**
 AL-OBEIDAN S: T081
 ALONSO L: F050
 ALONSO P: S101
 ALVAREZ L: **T075**
 ALVES N: S029, S030, T058, 2433, 2434, 2435, 2648
 AMADIO M: **S008, 3256, 3475**
 AMADO D: 3673, 3674
 AMAOUCHE N: **4772**
 AMARAL A: T051, 1735
 AMATO R: S063, 4457
 AMIRYAN A: S105, 4444
 AMOAKU WM: F075, 4742
 AMORIM A: 2445
 ANDERSSON GRÖNLUND M: 3454
 ANDJELIC S: **S078**, 3253
 ANDONEGUI J: S086
 ANDRE H: **T068**, S002, T067
 ANDRE M: F079
 ANDREEVA T: S104, 4248
 ANDROUDI S: **1642**
 ANG L: **T025**, T024
 ANGIOI K: S001, S090, T085, 4674
 ANITUA E: S053
 ANJOS R: **T058**, S029, S030, T107, **2433, 2648**, 2434, 2435, 3673
 ANSARI E: **T014**
 ANTONIAZZI ER: S087
 APTEL F: **T043, T044**, T038, T042, 3613, 3615
 ARAPI I: 1643, 2251, 3654
 ARAÚJO A: 2443
 ARBOUR JD: F104
 ARCKENS L: 3421
 ARNASON S: F010
 ARNDT C: **F103, 4675**
 ARNOULD S: T064
 ARONSSON M: S002
 ARTAL P: S097, **4255**, 1777

ARVEILER B: **2661, 2663**
 ASATRYAN S: 3664
 ASCASO FJ: **S075, S098**, F031, F038, F063, S018, S086, S088, T098, T105, T106, T114, **3411, 3771**
 ASCASO J: F036, S033, S107
 ASLAM T: T010, **2533**
 ASMUS F: 3471, 3472
 ASOKLIS R: F024, F054, S003, S004
 ASSELAÏN B: 4445
 ATAULLAH S: 3647
 ATHERTON S: **3243**
 AUDENAERT K: 4224
 AUDIO I: **2764, 3764**
 AUGSTEN R: 3718
 AUGUSTIN A: **4534**
 AUGYTE A: S004
 AUMAITRE O: F079
 AUNG T: 3425
 AVADHANAM VS: **4636**, 4432, 4435
 AVILES M: 2424
 AVILES-TRIGUEROS M: S006
 AVILÉS-TRIGUEROS M: 1673
 AVITABILE T: S063, 4457
 AYCHOUA N: **3423**
 AZEVEDO-PINTO S: 3476
 AZIMI A: F029, T001
 AZIZ A: **T091**
 BADAL J: F033
 BADIAN R: **S045, S047**
 BAE HW: T021, T029
 BAGGER M: 4245
 BAGNOLI P: F005, F006
 BAHNERS T: 4631
 BAIER D: F108, 4672
 BAILLIEUL A: **S117**
 BAILLIF S: F094
 BAINBRIDGE J: 3214
 BALDWIN M: F056
 BAO Y: F076, F078, 3441
 BARALE PO: 3764
 BARATZ K: **3632**
 BARBEIRO S: 2443
 BARBIER J: 3647
 BARCATALI MG: **F099**
 BAREILLE M: 4635
 BARILLA' D: T083
 BARNARD A: **3761, 3763**
 BARRAQUER J: **4431**
 BARRAQUER R: **4253, 4655, 4751**, 4251
 BARREAU E: T077
 BARRY P: **4753**
 BARZDZIUKAS V: F089
 BASDEKIDOU C: **2212**, 2211
 BASSON W: T084
 BATTA B: S090
 BAUDONNET R: **T062, 2647**
 BAUDOIN C: T015
 BAUSZ M: S032, 2437
 BAUWENS M: T081, **4661**
 BAZIN L: **F045**
 BEAUJEUUX P: **T085**
 BECHRAKIS N: **3743**
 BEHL C: **2421**
 BEK T: F043, F044, **1611, 3715**, 4744
 BELAHDA A: **F021**
 BELAOUDMOU R: 2475
 BELLA A: T061
 BELMONTE C: S054
 BELTRAN W: 3264
 BELVILLE C: 4423
 BEMELMANS A: F023
 BENALI ABDELLAH M: 4451
 BENCHERIFA F: F082, S111
 BENITEZ DEL CASTILLO JM: S059
 BENLAHBIB M: **F082, S111**
 BEN YAHIA S: 1743

BENZACKEN L: 3426
 BERENDSCHOT TTJM: 4733
 BORGES O: S118, 4449, 4772
 BERGUIGA M: S020, S024, S036, S094
 BERNABEI M: 3615
 BERNARD A: **S040**, S013, S031, S042, S067, **4776**, 1722, 1725, 2436, 4427, 4778
 BERNARDES R: 2443, 2445, 3663
 BERNOTAS G: T102
 BERRAHO A: F082, S111
 BERROD JP: 4674
 BERTAUX AC: 4473
 BERTONE C: T083
 BESOMBES G: **T030**
 BEUERMAN R: **2772, 4454**
 BEUTELSPACHER S: 3474
 BEYTOUT J: F079
 BEZUNARTEA J: 1764
 BHUMIKA S: F002
 BIANCHI PE: T004, T083
 BIARNÉS M: F033
 BIDAUT GARNIER M: **T054**
 BIKBOVA G: **2651**
 BINQUET C: 1664, 4671
 BIRKELDH U: **F060**
 BISCHOFF M: 4735
 BITOUN P: **3426**
 BLANCHON L: 4423
 BLANDAMURA S: 4244
 BLANN A: F046
 BLASETTI F: **F051**, S056
 BLASIAK J: T072, 1765
 BLATTEAU JE: T009
 BLUEML C: 2652
 BLUMEN-OHANA E: F096
 BOCHNIA M: F013
 BODAGHI B: F083, T053, T054, T095, **1745, 3446**, 3443
 BOEY PY: T047
 BOGATYREVA E: **T012**
 BOGDALI A: S102, S103
 BOGNER B: **3431**
 BOLLAERTS I: F002, 4665
 BONNABEL A: F071, 1731, 3661
 BONNEL S: S020
 BONNIN N: **F079**, S025, 4423
 BONSHK R: 3647
 BORDERIE V: **4734**
 BOREL A: S025
 BORGES A: S030, 2435
 BORGES B: T058, T107, 2648
 BORRELLI M: 2674
 BORRI M: S100, 4641, 4642, 4643
 BORRUAT F: T112, **4461, 4463**, 3678, 4464
 BORZENOK SA: 4233
 BOSCHI A: **1653**
 BOSCIA F: F051
 BOSTAN C: 3433
 BOUAFIA K: 3426
 BOUCHE-PILLON J: **4671**
 BOUDRY C: 4241
 BOUHACINA BENMANSOUR A: **T033**
 BOULAGNON C: 4675
 BOULANOUAR A: F082, S111
 BOULZE PANKERT M: 4635
 BOURNIQUEL M: **T087**, T009
 BOYA P: **2422**
 BRACCO S: 4643
 BRANCH MJ: 1721, 3251
 BRANCO P: S030, 2435
 BRASNU E: F083
 BRAUN M: S001
 BRAUTASET R: F030, F060, 1666
 BRÄUTIGAM M: S074
 BREIER M: 1761

- BREMOND-GIGNAC D: S064, **2232**, **2734**, **3453**, **4621**, 4458, 4623
 BRETILLON L: **3723**, 1664, 2223, 3722
 BRON AM: F071, T044, **1731**, **3242**, **4723**, 1664, 2223, 3661, 3722, 4473, 4671
 BROWN D: 4261
 BRUGIER A: T009
 BRUNEL N: 2623
 BRUNETTE I: **3433**, **4635**
 BRUYNS C: T056
 BUCHER M: 3646
 BUCOLO C: 3475
 BURD H: **4651**
 BUSHUYEVA NN: **T090**
 BUSIN M: **4732**
 BUSUTTIL A: 4432
 BUZNYK O: 4634
 BYHR E: 3454
 CABEZON L: F031, F063
 CAHUZAC A: **2215**
 CAINI M: S100, 4641
 CALDIROLA P: 1733
 CALIPPE B: 1754
 CALLIADA F: T035
 CÁMARA R: 1772
 CAMBAZARD F: S057, S072, S114, 2432
 CAMINAL J: S107
 CAMMALLERI M: F005, F006
 CANASTRO M: **F105**, **3665**
 CANDELARIA P: S029, S030, T058, 2433, 2434, 2435, 2648
 CANOVAS-MARTINEZ I: S007
 CARAMELLO C: **F036**, **S033**, F031, F038, F063, F088, S035, S107, T098, T099
 CAMELO F: 2443
 CARAM-LEHAM N: 1733
 CARBONARI G: 2251
 CARDEN D: T010
 CARLU C: 3672
 CASAS P: F031, F036
 CASINI G: F005
 CASPERS L: T056
 CASSOUX N: **3245**, **3742**, 3443, 3645, 4445
 CASTAGNA O: T009
 CASTANHEIRA-DINIS A: 3674
 CASTELO-BRANCO M: T103, 2445, 3671, 3676
 CASU G: F051
 CAUQUIL C: T077
 CEGIELSKI M: F013
 CEJKA C: S038
 CEJKOVA J: S038
 CELLINI M: T028
 CENDRE R: S001
 CHABANE H: **3274**
 CHACÓN M: S053
 CHAINE G: F053, S089, 4474
 CHAMBARD JP: 3426
 CHAMBERLAIN A: S082
 CHAMPION E: F083, 3443
 CHANG HR: **T082**
 CHANG ML: F061
 CHAO J: F076, F078, 3441
 CHAPELLE P: 3426
 CHAPRON T: **T034**, T039
 CHAQUES-ALEPUZ V: F050
 CHARFI H: F018
 CHARRIERE K: S096
 CHATZIRALLI I: **F087**, **F095**, F101, S095
 CHAVEROT D: T043
 CHEBIL A: F018
 CHEMTOB S: F012
 CHEN A: 4452
 CHEN CX: F028
 CHEN X: S045, S047
 CHENTSOVA E: S104, 4248
 CHENY T: **S024**, S094
 CHERNINKOVA S: F022
 CHERNOCK M: 3446
 CHIAMBARETTA F: F066, F079, S025, **3272**, 4423
 CHIQUET C: **2214**, **3613**, 3615
 CHIU CJ: **F061**
 CHLEBDA E: F009
 CHO B: **T027**, **T040**
 CHODOSH J: **4436**, 2644
 CHOI J: F017
 CHOI MINY: T065
 CHUKRAYOV A: 4231
 CHUN Y: F012
 CHUNG SY: F017
 CHYZEWSKI L: T055, 2645
 CIDECIYAN A: 3264
 CIESLIK T: S049
 CIMBALAS A: F054
 CIMBOLINI N: T017
 CINOTTI E: S057, S072, S114, 2432
 CLARK WL: **4261**
 CLOCHE V: T085
 COCA-PRADOS M: T075
 COCHENER B: S096
 COCHEREAU I: 4772
 COHEN SY: F065, F066
 COLCLOUGH T: T070
 COLE ST: **4435**
 COMAN C: T045
 COMPTOUR A: 4423
 CONART JB: 4674
 CONCEIÇÃO G: 3476
 CONSTABLE P: **3261**
 CONWAY RM: S115, S116, 4446, 4447
 COOK A: 3647
 COPIN H: S064, 4458
 COPPARD N: T110, T111, 2658
 COPPIN J: T043
 CORDEIRO M: **2622**, **3721**, 2445
 CORREIA A: **2443**
 COSCAS F: 2414, 2415
 COSCAS G: **2411**, 2413, 2414, 2415, 2416
 COSTA L: T107, 3673
 COULANGEON LM: S025
 COUPLAND SE: 4243
 CRAFT J: F016, T071
 CRAIG JP: **4452**
 CREUZOT-GARCHER C: **F066**, F071, **2615**, 1664, 1731, 2223, 3661, 3722, 4473, 4671
 CRISTOBAL J: F031, F038, F063, S107, T098, T106
 CROUZET E: 4422
 CRUZ N: F031, F063
 C. SILVA AS: **3663**
 CTORI I: F109, **1665**, 1663
 CUNHA JP: T051, T107, **3674**, 1735, 3673
 CUNHA-VAZ J: **4532**
 CURSIEFEN C: **3733**
 CUTHBERTSON F: 3414
 CUTOLO C: T035
 DABASIA P: 3422
 DA CRUZ L: **2254**
 DAI Y: **F032**
 DAIEN V: T115, **2654**
 DAIMON M: F114
 DAL MONTE M: **F005**, **F006**
 DAMATO B: **1622**, 4243
 DAMES C: 2642
 D'AMICO RICCI G: F051
 DAMJI KF: **2724**
 DANIEL E: **S025**, **4423**
 DANIEL F: 4623
 DANIEL S: 1664
 DARUGAR A: 3443
 DASCALU AM: T045
 D'ATHIS P: 4473
 DAVID G: S095
 DAVIES JR: T069, 1767
 DAVIES VJ: T069, 1767
 DE BAERE E: T081, 4661, 4766
 DE BATS F: 2211
 DEBELLEMANIERE G: **1771**, 1667
 DEBICKA-KUMELA M: S102, S103
 DECAUTIN D: 3645
 DE DEYN PP: 4224
 DE FARIA A: T009, T087
 DEFOE D: S067, 4427
 DE FRANCESCO S: **S099**, S100, **4642**, 4641, 4643
 DEGOUMOIS A: **F096**, T093, 2656
 DE GROEF L: 3421
 DE GROOT V: S108, **4224**, 4223
 DE HOZ R: S006, T108, 1673, 2245, 2424, 3675
 DEKARIS I: **3732**
 DE KEIZER RJW: S108
 DEKEYSTER E: **3421**, **4662**
 DE KLEIN JEMM: 4246
 DE LAZZER A: 1731
 DELBARRÉ M: **T038**, T034, T036, T039
 DELBEKE P: T081
 DELBOSC B: F011, 1667, 1771
 DEL BUEY MA: S033, S035
 DELCOURT C: F066
 DE LEENEER K: T081
 DELEMOTTE A: T073
 DELGADO TIRADO S: **T066**
 DELLAFIORE C: T035
 DEL OLMO AGUADO S: **F008**
 DELPORTE C: F110, 4748
 DE LUCA M: S099
 DELUCA MC: 4643
 DENDALE R: 4445
 DENION E: F099, T093, 2656
 DENIS D: F021, T091
 DENIS P: T044
 DE OLIVEIRA MAIA JR O: F019, F084, F085
 DE PLATER L: 3645
 DERAKHSHAN A: S021
 DE ROO A: **4663**
 DE SEZE J: **2262**, **2264**
 DESJARDINS L: **2743**, **4445**
 DESJARDINS M: **F104**
 DESMANGLES PM: F070
 DE SMIT E: T097
 DESPREAUX R: **F083**
 DESSERRE J: **F069**, S117
 DEWISPELAERE R: T056
 DE ZAEYTIJD J: T081
 DICK A: **F078**, F076, **1641**, **1646**, **2253**, **3244**, 3441
 DICKMAN MM: 4733
 DIEBOLD MC: 4675
 DIEP M: 3644
 DIMIER-POISSON I: T059, 2646
 DING J: 2675
 DIRANI A: **2414**
 DIWO E: **T053**
 DOAN S: **2676**, **3271**
 DOBNER B: 2642
 DOBROWOLSKI D: S017, S049, S073, **1634**
 DOLZ-MARCO R: F050
 DOMNGANG NOCHE C: **T061**
 DONALD J: **2441**
 DONATI G: **2412**, 3614
 DOOLEY I: **4475**
 DORÓ Z: 1671
 DOT C: F015, F039, F042
 DOUGLAS RH: T069, 1767
 DOUGLAS CAMERON J: 4635
 DOUMA I: F015
 DOURMAD P: F065
 DRAGO F: 3475
 DRAKOS E: F087
 DRASLAR K: S078
 DROLSUM L: S068, 4428
 DUA A: 1721

- DUA H: **2732, 3624, 3735**, 3251, 3621, 4773
 DUCASSE A: F103, 4675
 DUHAMEL F: F012
 DUMOLLARD JM: S039, S067, S072, S114, 1722, 1724, 2432, 4427, 4775
 DUNCOMBE A: **S041, 4777**
 DUNPHY SE: S055
 DUPUY C: T043
 DUQUESROIX B: **T080**
 DURIEUX P: **T073**
 DUTA S: T045
 DUTESCU M: **S066, 4426**
 DUTESCU R: **S050**
 DUTROW E: 3264
 DZIEWISZEK W: F009, F013
 EBELING M: 2272
 ECKSTEIN A: T055, 2645
 EDGAR D: 3422
 EICHLER WOLFR: **3215**
 EIDET JR: S045, S047
 EKSTROM M: T068
 ELALFY M: **4773**
 EL CHEHAB H: **F023**, F015, T034, T036, T038, T039, 3232
 ELDRED JA: **1773**
 ELENA P: T017
 EL-HUSSEINY M: 3631
 ELIAOU-MALRIEU C: 2654
 ELLIOTT D: **4252**
 EL MATRI L: **F018**
 EMPERADOR S: T114
 EPPIG T: **S092**, S093
 ERB C: **T016**
 ERDIAKOV A: **F077**
 ERIE J: **S082**
 ERNOULD F: S043
 ERRERA MH: **T060**
 ESCRIBANO J: T075
 ESTEBAN O: **S018, T114**, F031, F036, F038, F063, F088, S035, S107, T099
 EYSTEINSSON T: F010
 FACSKO A: F001, 3253
 FADLALLAH A: 4772
 FAGERHOLM P: S068, 4428
 FAGJENBAUM M: T014
 FAJNKUCHEN F: F047, F053, S089, 4474
 FAKHOURY O: T091
 FALLICO M: S063, 4457
 FALLON T: F097
 FARAJ LANA: 4773
 FARDEAU C: F083, F091, 3443
 FARIA M: F105, 3665
 FARKAS J: S058
 FAUCHER C: 3672
 FAUQUERT JL: **3273**
 FAVENNEC L: 4421
 FAZILATI F: F029
 FEIJAO J: S029, 2434
 FEL A: T095
 FELSZEGHY S: S010
 FELTGEN N: 4263
 FENOLLAND JR: S020, T034, T036, T039
 FERAILLE L: T017
 FERETIS E: S119, 4448
 FERNÁNDEZ-ROBREDO P: 1764
 FERNÁNDEZ-VEGA L: T075
 FERREIRA C: 2445
 FERREIRA J: T107, 3673, 3674
 FERREIRA S: **T103, 3676**, 3671
 FERRERO A: **3661**
 FERRINGTON D: **2272**
 FERRIS J: **3223**
 FERTE A: **S090**
 FÉSÜS L: 1671
 FIGUEIRA J: 3663
 FINIS D: **2674**
- FINK W: F062, F067
 FINZI A: **T028**
 FITZGERALD O: 3445
 FLANAGAN JG: 3712
 FLECK O: **1664**
 FLORES M: **1667**, 1771
 FOETS B: 4663
 FONTAINE M: **T086**
 FOREST F: **S039**, S013, S039, S067, S072, S114, **4775**, 1722, 1724, 1725, 2432, 4427, 4775
 FORGET K: 3433
 FORNACIARI I: F005, F006
 FORSTER V: 2623
 FOTI R: S063, 4457
 FOUCAUT V: T056
 FRANCKE M: S026, S027, S028
 FRANCOIS A: 4421
 FRIGERI IA: F006
 FRIOT M: F011
 FRIZZIERO L: 4244, 4442
 FROGER N: T095, 2623
 FROUNTZOU E: 3614
 FROUSSART-MAILLE F: S020, S024, S036, S085, S094
 FRUTOS-BARAJA JM: S109
 FRUTTIGER M: **2244, 2755**
 FSADNI M: 1733
 FUCHS-BUDER T: S090
 FUCHSJAGER-MAYRL G: **F004**
 FUCHSLUGER T: **3432, 4731**, 4631
 FUKUI M: S044
 GABISON E: T064, 4772
 GACEK M: T076
 GAGLIANO C: **S063, 4457**
 GAGYI-PALFFY Z: 3474
 GAIN P: S013, S031, S039, S040, S042, S067, S069, S070, S072, S114, 1722, 1724, 1725, 2432, 2436, 4422, 4427, 4771, 4775, 4776, 4778
 GAJECKA M: T078, **1762**, 1766
 GALATOIRE O: S118, 4449
 GALETTO R: T064
 GALGAUSKAS S: S003, S004
 GALIMBERTI D: S100, 4641
 GALINDO-ROMERO C: 2243, 2424
 GALLAR J: S054, **4632**
 GALLEGRO B: S006, **1673**, 2245, 2424
 GALLEGRO-PINAZO R: F050
 GALLENMÜLLER C: T111, 2658
 GALLICE M: 2214, 3613
 GALLUZZI P: S099, S100, 4641, 4643
 GAMATIKOV B: T092, 2655
 GAN N: T046
 GARCIA M: T075
 GARCIA-ALVAREZ C: S101, S109, 4645
 GARCIA GARCIA L: **1764**
 GARCIA-LAYANA A: 1764
 GARCIA MARTIN ES: **T108, 3675**
 GARHOFER G: F004, S052, T023, **2222**
 GARNIER F: T062, 2647
 GARVEY LH: S062, 4456
 GARWAY-HEATH D: **4721**, 3422
 GASCARD L: 3661
 GASTAUD P: F094
 GAUCHER D: T057, T086
 GAUTHIER AS: **F011**
 GAUTIER E: **1751**
 GAVET Y: S031, S040, S069, 2436, 4776
 GAVRILOVA S: F077
 GEAMANU A: T045
 GEBOES K: 4741
 GEERAERTS E: 4662
 GEERLING G: 2674
 GEISER M: **3615**, 3613, 3614
 GELFI C: 4644
 GENSLER G: F061
 GENTIAN D: 3645
 GEORGIADIS N: S081
- GEORGIADIS O: T037
 GEORGIADOU I: S081
 GEORGIEV R: F022
 GEORGPOULOS V: 1734
 GEROMETTA M: F056
 GERSTNER B: 2652
 GHOUBAY D: 4734
 GICQUEL J: **2231, 2631, 2731**
 GIL P: T108, 3675
 GILLEBERT C: T094, 2657
 GINIS HS: S097, 1777
 GIOCANTI-AUREGAN A: **F065**, F047, F053, S089, 4474
 GIRAUD JM: T009, T038, T087, **3232**
 GIZZI C: T028
 GLACET-BERNARD A: **1712**
 GLEBAUSKIENE B: T102
 GODARD G: **3774**
 GOHLER C: **S028**, S026, S027
 GOLOVIN A: 4232
 GOMES N: 3663
 GONI F: **4533**
 GONZALEZ C: **F064, F072, F073**
 GONZALEZ BUENDIA L: **T074**, T066, **1768**
 GONZÁLEZ-GONZÁLEZ O: S054
 GONZALEZ-IGLESIAS H: T075
 GONZALEZ SANTIAGO R: T066, T074, 1768
 GOTO Y: **T020**
 GOVONI S: S008, 3256, 3475
 GOWEIDA M: **4774**
 GOYER B: 4635
 GRABNER G: 3431
 GRADINARU S: T045
 GRAEFF E: **S110**, S121, **4648**, 3648
 GRALLERT H: 1761
 GRAVANIS A: 1662
 GRAW J: **1761**, 3253
 GREENWOOD J: 3214
 GREINER J: **2673**
 GRESTI G: 3654
 GRIESHABER M: S110, 4648
 GRIFFITH M: **4634**
 GRILL E: 1761
 GRILLO-ANTONELLI S: **T017**
 GRISHINA E: **4646**
 GRIVET D: S057, S072, S114, **2432**
 GROSMAN-DZIEWISZEK P: F013
 GRUENERT A: **3731**
 GRUNEWALD F: T030
 GRUS F: **2423**
 GRZYBOWSKI A: T055, **3413, 3775, 4752, 4754**, 2645
 GUAGLIANO R: **T083**
 GUALINO V: **4412**
 GUDMUNDSSON J: T067
 GUEDIRA TARIGHT G: **S064, 4458**
 GUERRERO P: S069
 GUEUDRY J: S041, T053, **4421**, 4771, 4777
 GUIGOU S: F106, 4472
 GUILHEM M: S070
 GUILLEMOT C: S072
 GUILLOIS B: T093, 2656
 GUILLONNEAU X: **1754**
 GÜMBEL H: **3233**
 GUMBELEVICIUS A: F089
 GUTHOFF R: **3434**
 GUTHOFF RF: **4653**
 GUTMANN J: 4631
 GUYADER V: F096
 GUYTON D: T092, 2655
 GUZIEWICZ K: **3264**
 HADJISTILIANOU T: **S100**, S099, **4641, 4643**, 4642, 4644
 HADOUX X: T003
 HAGIWARA M: F007
 HAJJAR C: F106, 4472
 HAJJI Z: F082, S111

HALFELD FURTADO DE MENDONCA R: **F019, F084, F085**
 HALKJÆR LB: S062, 4456
 HAMAM R: **3442**
 HAMEL C: **2761**, 3263
 HAMMER GP: 1772
 HAMMER M: **3718**
 HAN KE: **S019**
 HANSEN KS: S062, 4456
 HAOUAS M: **S072**, S057, 2432, 4422
 HAOUCHINE B: 3426
 HARDARSON S: **3717**
 HARDCASTLE AJ: T070
 HARDER B: F108, 4672
 HARDY P: F012
 HARJU M: T019
 HAROON M: 3445
 HART-HOLDEN N: T070
 HASEGAWA N: F058
 HASHEMI H: S021, T001
 HA THI B: **1724**
 HAUSWIRTH W: 3264
 HAWLINA M: S078, 3253
 HAYAJNEH J: 2674
 HAYNES R: **3222**
 HE M: 3425
 HE Z: **S067**, S013, S031, S039, S042, S070, **4427**, 1722, 1724, 1725, 2436, 4422, 4771, 4775, 4778
 HEEGAARD S: S015, S016, S062, **4647**, 1727, 1728, 4245, 4441, 4456
 HEGYI P: F001
 HEIER M: 1761
 HEIMANN H: 4243
 HEISSIGEROVA J: F093
 HEITMAR R: **F046, 3716**
 HEITZ A: **T088**
 HEITZ P: **T057**
 HEITZ R: **3773**
 HELISALMI S: T072, 1765
 HERAVIAN J: S021, T001, T007
 HERBORT C: **1645, 1744, 3651**
 HERERRA L: S035
 HERNÁNDEZ M: 1764
 HEROLD J: 4432
 HERON E: T054
 HERRERA L: **S107, T099**, F031, F036, F038, F063, F088, S033, T098
 HERRERO-MARTIN MD: T114
 HEUSSEN FM: **4243**
 HEVE D: 2654
 HILDEBRANDT L: 3444
 HILTUNEN M: T072, 1765
 HIROTA Y: T020
 HJORTDAL J: S068, 4428
 HO H: **3425**
 HÖCK A: 1772
 HODGE C: S023
 HODGE D: S082
 HOFMANN F: F108, 4672
 HØJGAARD-OLSEN K: S016, 1728
 HOLAN V: **S038**
 HOLDER GE: **2664, 3464**
 HOLLANDER DA: 4454
 HOLLANDERS K: **1661, 4664**
 HOLLE R: 1761
 HOLMES JM: **2454**
 HOLOPAINEN J: S061, S068, 4428, 4455
 HOMMER A: **T023**
 HONG S: T021
 HOOGHE S: T081
 HOPKINSON A: S055, **1721, 2733**, 3251
 HOR G: S040, 4776
 HOSOYA T: F007
 HOSSEINI A: T022
 HOUTMAN AC: **2453**
 HOW A: 3425

HOWARD S: S005
 HRARAT L: **F091**
 HSAIRI A: F018
 HTOON HM: T047
 HU S: 1754
 HUBAULT B: F103
 HUBER M: 4735
 HUBERT I: 4674
 HUDSON C: 3712
 HUERVA V: S075, S088, S098, T098
 HUMBERT C: 4421
 HUNTJENS B: **F109, 1663**, 1665
 HUSTER D: S026
 HVALA A: S078
 HWANG HS: S019
 HYSI P: **2462**
 HYTTI M: **1675**
 HYTTINEN J: S012, 3255
 HYUNKYUNG KIM: **T096**
 IAKYMENKO S: 4634
 IANCU R: T045
 IBAÑEZ J: S033, T106
 IDOATE A: S035
 IKUNO Y: 3472
 INGLAVE G: 4636
 IÑIGO PORTUGUÉS A: **S053, S054**
 IONICA V: **T011**
 IRION L: **3647**
 IRSCH K: **T092, 2655**
 ISAICO R: F071, 4473
 ISELI HP: S026, S027, **2715**
 ISLAM M: 4634
 IVANOVA O: S105
 IVKOVIC I: T095, 2623
 IWABE S: 3264
 IYER G: **4433**
 IZSVÁK Z: 1764
 IZUMI S: S058
 J-A SAHEL: 3764
 JACOBS D: **2473**
 JACOBSON S: 3264
 JACOMET PV: S118, 4449
 JAGER M: 3245
 JAKOBSSON G: 3454
 JAKUBOWSKA B: S102, S103, 3641
 JANG HJ: T082
 JANISZEWSKA D: S073, **1631**
 JANSONIUS NM: **F034**, 3423, 3424
 JANSSENS MSA: 3424
 JANUNTS E: 3631
 JANY B: **T084**
 JASIELSKA M: **S074**
 JEFFS N: 3214
 JENSEN PS: **F044**
 JENTSCH S: 3718
 JEPPESEN H: **S015, 1727**
 JIMENEZ DEL RIO B: **T105, T106**
 JIMENEZ-LOPEZ M: S007, 2243
 JIN H: **F100**
 JO S: F035
 JOHANSEN JD: S062, 4456
 JOHNEN S: 1764
 JOHNSON K: T055, 2645
 JONAS J: **F028**, F032, F108, **4724, 4747**, 3474, 4672
 JONQUA F: T084, 4623
 JONVAL L: 4473
 JOO CHOUN: T065
 JØRGENSEN A: **4441**
 JOUROT P: 3426
 JOUSSEN A: **3435**
 JOUSSEN M: S074
 JULIAN HO: **S016**, S015, S062, **1728**, 1727, 4456
 JULIENNE R: **S057, S114**, S031, **4422**, 2432, 2436
 JUMELLE C: **S013, 1725**
 JUNG KI: **T048**
 JUNG S: **S113**

JUNG Y: **T026**
 JUNGHANS B: 3644
 JUNOY MONTOLIO FG: **3424**
 KAARNIRANTA K: **S010**, F052, S008, S011, S012, S022, T072, **2531**, 1675, 1676, 1765, 3254, 3255, 3256
 KABANAROU S: **F020**, F080, F092, S119, **4212**, 4448
 KADZIAUSKIENE A: **S004**
 KAERCHER T: **S059**
 KAESER PF: **4462, 4464**
 KAGMENI G: T061
 KAHLERT CHR: F108, 4672
 KAHLOUN R: 1743, 3655
 KALIRAI H: **3754**, 4243
 KAM WR: 2675
 KAMENAROVA K: F022
 KAMPMANN S: 2652
 KANELLAS D: F080
 KANEVA R: F022
 KANG HB: T008
 KANG JW: T040
 KANG S: **F057**
 KAPOULA Z: **4623**
 KAPSALA Z: **F111**, F113, **4745**, 4746
 KARAGIANNIS D: F101, S095
 KARDON R: **2263**
 KARJALAINEN R: S012, 3255
 KARL A: S026, S027, S028
 KAROLAK JA: T078, 1766
 KARTTUNEN T: **F052**
 KARVELA I: S119, 4448
 KASER-EICHBERGER A: 3431
 KATAMISH T: 4773
 KATO A: F058
 KATO T: F114
 KATONA M: F001
 KAUPPINEN A: S009, **2271**, 1675, 3257
 KAWASAKI A: **1654, 3463**
 KAWASAKI R: **F114**
 KAWASAKI Y: F114
 KAYA M: **F043**
 KAYA S: S052
 KAYAMA T: F114
 KELLY JMF: T010
 KEMAYOU D: T061
 KESTELYN P: T081, **3633, 3772**
 KHABAZKHOOB M: S021, T001
 KHAIRALLAH M: **1743, 3655**
 KHAN A: S022, S051, 3252
 KIEKENS S: **4223**
 KIEL JW: 3431
 KIILGAARD J: **4245**, 4441
 KILIC E: **4246**
 KIM CY: T021, T029
 KIM HJ: F017
 KIM J: T100
 KIM JS: F048, T005
 KIM MS: **F048**, T113
 KIM SY: S076
 KIM YT: **T005**
 KINASZ R: T018
 KING NJC: 2641
 KINNUNEN K: F052
 KIRAT O: 3252
 KISHIMOTO T: S112
 KIVELÄ T: T019, **1621, 1623, 2742, 3623**, 3621, 4242, 4443
 KLARSKOV ANDERSEN M: 4245
 KLIMOVA A: **F093**
 KLONOWSKA A: S106, 4247
 KLOPSTOCK T: T110, T111, 2658
 KLYSIK A: **S060, 1774**
 KNAAPI L: 2444
 KNOP E: **2471**, 2671
 KNOP N: **2671**, 2471
 KO BY: **S076**

- KOCH C: S026, S027, S028
 KOCIOK N: S074
 KODJIKIAN L: **2614**, 4473
 KOEHL A: 1667
 KOEHLER P: F071, 1664, 1731, 4473, 4671
 KOEV K: **F022**, **F081**
 KOLKO M: **1674**
 KOMÁROMY A: 3264
 KÖNIG C: 2674
 KOOPMANS AE: 4246
 KORBER N: **S026**, S027, S028
 KORHONEN E: **S009**, **3257**, 1675
 KOROBELNIK J: **F098**, F066, **2532**, **3472**, **3533**, **4673**, 4471
 KORT F: F018
 KORZYCKA D: 1774
 KOSKAS P: 4772
 KOSKELA A: **S012**, **3255**
 KOTAPATI RAGHUPATHY R: **F016**
 KOTECHA A: **2721**
 KOURENTIS CHR: **4211**
 KOUROUPAKI A: F020, S119, 4448
 KOUSAL B: **T070**
 KOVALEVSKAYA M: F062, F067, T012
 KOVARSKI C: **3672**
 KOVSHUN E: 4232
 KOWAL J: S102, S103
 KRASTEL H: **F108**, **3474**, **4672**
 KREFFT K: 3431
 KREUGER M: F056
 KRIAUCIUNIENE L: **F089**, **T102**
 KRISTÓF E: 1671
 KROMUS M: T023
 KRONSCHLÄGER M: S079, S080, 1775
 KU HC: **F025**
 KUBICKA M: T078, 1762, 1766
 KUCERA T: F093
 KUCHARSKA AZ: F009
 KUDRYAVTSEVA O: **4744**
 KUHN D: **4736**
 KULINSKA K: T078, 1766
 KUMAR A: 3647
 KUOLIENE K: F024, F054
 KURKINEN M: **S068**, **4428**
 KURUMTHOTTICAL M: F074
 KURYSHEVA N: **2621**
 KUZNIAR A: F108, 4672
 KVANTA A: S002, T067, T068
 KWON HJ: **F017**
 LABALETTE P: F069, S043, S117, T073
 LABELLE B: S057, S072, S114, 2432
 LABETOULLE M: **T063**, **T064**, T077, **2233**
 LABIOD D: 3645
 LABREUCHE J: T073
 LAKE S: S081
 LALLOUM F: 2413, 2415
 LAM W: **4755**
 LAMARD M: S096
 LANDI G: 4644
 LANDRÉ C: **F094**
 LANGE C: 3214
 LANGENBUCHER A: **S093**, S092, 3631, 4735
 LANTERI S: T004
 LAPLACE O: F096
 LARSEN L: **4264**
 LASER-JUNGA H: 1772
 LASSEAUX E: 2663
 LATTANZIO F: T022
 LAURENS C: F096
 LAURICHESSE H: F079
 LAURINAVICIUTE G: S003
 LAUWERS N: **F014**, **S108**
 LAVA M: T035
 LAVALETTE S: 1754
 LAVIERS H: 4475
 LAVILLA L: F038, S098
 LAWRENSON J: **3415**, **3422**
 LAZREG S: **S037**, **4451**
 LEABACK R: 4264
 LEATHERBARROW B: 3647
 LE DÙ B: F096
 LEE EK: F025
 LEE HK: S019
 LEE HS: **T065**
 LEE J: **T100**, **T101**, F102
 LEE JH: F017
 LEE JS: 2644, 2644
 LEE JY: T027
 LEE KH: F100
 LEE M: **T097**
 LEE MK: F025
 LEE N: **S046**, **T041**
 LEE S: **F037**, **F049**, **T089**, F035
 LEE SY: **T029**, T021
 LEE T: **T024**, T025
 LEE Y: **T032**, T021, T029
 LEFEVRE S: 4771
 LE GOFF L: 4421
 LEHESJOKI AE: 4242
 LE HOANG P: F083, F091, T053, T054, T095, 3443
 LEHTO VP: S009, 3257
 LEINONEN M: **2444**
 LEITE-MOREIRA AF: 3476
 LEITGEB R: **1613**
 LEMAITRE S: **S118**, **3645**, **4449**
 LEMEE G: **T059**, **2646**
 LE MER Y: **4413**
 LEMIJ H: T015
 LEMMENS K: **F002**, **4665**
 LEONCINI R: 4644
 LEPAPE A: 2654
 LEROY B: **3462**, **4674**
 LEROY BP: T081, **2662**, **2762**, **3262**, **3762**, 4661, 4766
 LESAGE F: F104
 LESENS O: F079
 LEVY C: 4445
 LEVY O: F053
 LEWIN-KOWALIK J: S011, 3254
 LI J: 2441
 LI T: F061
 LIBERT S: **F110**, **4748**
 LIM BA: T046
 LIM HS: F100
 LIM SJ: **T079**
 LIN J: **S084**, S083
 LINDEGAARD J: S015, S016, 1727, 1728
 LINDH S: 4242
 LING Z: F032
 LINKOHR B: 1761
 LIPSKI D: **T056**
 LISBOA M: T051, 1735
 LISCH W: **3634**
 LISKOVA P: T070, **1633**, **2463**, **2763**
 LIU CSC: **4432**, 4435, 4636
 LIU L: **3414**
 LIU X: 4635
 LIU Y: 2675
 LIUTKEVICIENE R: F089, T102
 LLOBET L: T114
 LOB F: T111, 2658
 LOBO C: 3663
 LOEWENSTEIN A: **1715**, **2612**
 LÖFGREN S: **4622**
 LOMBARDO S: **S087**
 LÓPEZ DEL VAL J: T106
 LOPEZ-GALLARDO E: T114
 LÓPEZ GÁLVEZ MI: F112, 4477
 LOPEZ-LARA F: S101, S109, 4645
 LOPIC N: S078
 LORENZ B: **2652**
 LORENZ K: 4262
 LOUKOVAARA S: **4476**
 LOURO C: 3674
 LUBINSKI W: T018
 LUHMANN U: 3214
 LUK S: F074
 LUMBROSO LE ROUIC L: 4445
 LUMI X: 3253
 LUX AL: **T093**, **2656**
 LUZ LEITÃO GUERRA R: F019
 LYONS T: **2752**
 LYTVYNCHUK L: **1672**
 MA Y: T068
 MACAULAY D: 3441
 MACHALINSKA A: **3213**
 MACHIN C: 2446
 MACKENSEN F: **3444**
 MADIGAN M: **S115**, S023, S116, **3644**, **4447**, 2641, 4446
 MADURO V: S029, S030, T051, T058, 1735, 2433, 2434, 2435, 2648
 MAEDA A: **1753**
 MAFFIA A: T083
 MAGAZZINI S: F065
 MAGOURITSAS G: **T037**, **1734**
 MAGRO L: S043
 MAIER AK: S074
 MAIER M: **2714**
 MAIER RF: 2652
 MAJSTEREK I: **T076**
 MAKOWIECKA K: 2446
 MALYSKO K: **F054**
 MALYUGIN B: **4231**, 4235
 MAMMAZADA P: **T067**
 MAMOULAKIS D: F113, 4746
 MAMOURI R: F018
 MAMUNUR R: **4443**
 MANASSEH N: 2213
 MANCZAK H: **2474**
 MANGIORIS G: **F059**, F003
 MANSOUR A: 3442
 MANZANAS LEAL L: F112, 4477
 MARCHESI N: S008, 3256
 MARECHAL M: **T039**, T034, T036
 MARIANI P: 3645
 MARIE C: 1764
 MARILL AF: T034, T036, T039
 MARIOTTI C: **2252**
 MARKIEWICZ A: **S102**, **S103**, 3641
 MARKIEWICZ L: T076
 MARKKINEN S: 4242
 MARKOU C: S081
 MARQUES J: 2445
 MARQUES-NEVES C: F105, 3665
 MARQUINA I: **F030**, **1666**
 MARRAY IJ: T010
 MARSOVSZKY L: **S032**, **2437**
 MARTIANO DH: **S096**
 MARTIN AL: F003
 MARTINEZ M: F031, F038, F063, F088, S033, S035, S107, T099
 MARTINEZ-ROMERO I: T114
 MARTINEZ VELEZ M: **S088**, **T098**
 MARTIN-NAVARRO A: T114
 MASCHI C: **3744**
 MASMALI A: S051
 MASSIN P: **2611**, **4471**, 4473
 MATEO OROBIA AJ: F036, S033
 MATEUS C: T103, 3671, 3676
 MATHIEU B: S041, 4777
 MATONTI F: **F106**, F021, T091, **4472**, 2623
 MATTER MA: F070
 MATYSIAK A: 1762
 MAUGET-FAYSSÉ M: 2211, 2213, 2215
 MAURAGE CA: S117
 MAYA R: S086
 MCALPINE S: S115, 4447

ALL AUTHORS INDEX

- MCCULLOCH D: F016, T071
MCINTOSH OD: 3251
MCKECHNIE C: 4475
MCNAUGHT A: **3224, 3714**
MEANA A: S053
MEENS W: 3424
MEHTA J: **4434**
MEIER T: T110, T111, 2658
MEIER-GIBBONS F: **T052, 1737**
MEILLAT M: 1667
MEILLON C: **F071**
MEIRELES A: 3663
MEKKI MB: **2475**
MELY R: **2472**
MENDRINOS E: F003, F059
MENEY J: **T077**
MENICACCI C: S034
MENICACCI F: **S034**, S100, 4641, 4642, 4644
MENNÉ T: S062, 4456
MENSAH E: F055
MENTEK M: 3615
MERAYO-LLOVES J: S053, S054, S071
MERITE PY: F106, 4472
MERKOUDIS N: 4264
MESSENGER W: 3444
MESSMER EM: T080
METZ G: **T110, T111, 2658**
METZIG C: 4471
METZNER S: 2642
MEUNIER I: **3263**
MEYER F: F106, 4472
MEYER P: **S121**, S110, **3648**, 4648
MICARD E: S001
MICHAEL R: **4251**, 4253, 4655
MICHAU S: **T115**
MICHELI L: S100, **4644**, 4641
MIDENA E: **4442**, 4244
MIDENA G: 4442
MILANO G: T035
MILAZZO S: T084
MILLE C: T084
MILYUTKINA S: **F062, F067**
MINAKAKIS P: F080, F092
MINCHEVA Z: T077
MIOTTI H: 3672
MIRACHTSIS T: **S081**
MIRONOVA I: 4444
MISIUK HOJLO M: **T018**
MITROPOULOS P: F087, F095, F101, S095
MITRY D: F074
MIZOGUCHI T: 3425
MOCKO L: T018
MOGAVERO V: **T004**
MOHAMMAD G: 4741
MOHAMMADIAN M: F029
MOHAND-SAID S: 2446, 3764
MOHNEY B: **2452**
MOKHTARI MA: 2475
MOLEIRO A: 3476
MOLNOS S: 1761
MOMBAERTS I: 3643
MONÉS J: F033
MONNEYRON N: S025
MONTANARI S: T084
MONTARD M: 1771
MONTEIRO-GRILLO M: F105, 3665
MONTENEGRO G: 4253
MONTEZUMA S: 2272
MONTROYA J: T114
MOONS L: F002, 3421, 4662, 4665
MORGADO M: 2443
MORGAN I: **2712**
MORGAN JE: **2722**
MORICE-PICARD F: 2663
MORIGGI M: 4644
MORISSE S: T059, 2646
MORIYUKI K: T020
MORIZE A: 4623
MOROOKA S: **F007**
MOROZ Z: **4232**
MORREALE BUBELLA D: F027, T109
MORREALE BUBELLA R: **F027, T109**
MOSCHANDREAS J: F111, 4745
MOSCHONAS K: F020, T037, 1734
MOSCHOU V: S081
MOSS S: 3214
MOSSER G: 4734
MOUALLEM A: **3443**
MOUINGA A: T034, T036, T039
MOULARD A: S039, 4775
MOULIN A: **3646**
MOUNIER A: **F015**
MOURIAUX F: T093, **4241**, 2656
MOUSAVI M: S021
MOYAL L: **S085**
MUKHERJEE S: 2644
MULAK M: T018
MUMCUOGLU T: **T031, T049**
MUNIER F: **2746**
MUNK SJ: **S062, 4456**
MUNOZ M: S101, 4645
MUNOZ-ERAZO L: **S116, 2641, 4446**
MUONA M: 4242
MURAINÉ M: S041, **4771**, 4421, 4777
MURPHY C: 3445, 4453
MYSLIWIEC J: T055, 2645
NADAL-NICOLAS FM: **S007**
NADIM N: **3412**
NAIGEON N: S013, 1725
NAKAMACHI T: S058
NAKHAEE MA: T001
NAKHJANPOUR N: F029
NANA F: **S120**
NANGOUM-FOSSO T: S013, 1725
NAPORA K: S052
NARBERHAUS B: T114
NAWAZ M: 4741
NEFZAOUI C: **S042, 4778**
NEMATI F: 3645
NÉMETH J: S032, 2437
NERI P: **1643, 2251, 3654**
NETO E: F105, 3665
NEVALAINEN J: F034
NEVEU MM: 2664
NG J: T025
NIAVI S: 1662
NICCHIA GP: F006
NICOLAI M: 2252
NICOLAS M: 3646
NIEPON ML: F023
NIETO-LOPEZ L: S007
NÍ GABHANN J: 4453
NILSSON M: F026, F030, F060, 1666
NONGPIUR M: 3425
NORDMANN JP: F096
NOROUZIRAD R: S021
NORVYDAITE D: **S003**
NOUVEL-JAILLARD C: F023
NOWAK DM: **T078, 1766**
NOWINSKA A: S017, S049, S073, **1632**
NOZAKI M: F058
NUIJTS R: **4733**
NÚÑEZ ÁLVAREZ C: **S071**, F008
NUVOLI E: S056
NYSTRÖM A: **3454**
O'BRIEN C: **2774**
OCHIAI H: **S077**
O'GRADY A: T070
OGURA Y: F058
OHBAYASHI M: F058
OHLENDORF A: **2713**
OIZUMI T: F114
OKALIBE X: F076
OKUNO Y: F007
OLMO-AGUADO S: S071
OMRI S: F012
ONISHENKO NA: 4233
ORBAN GA: T094, 2657
ORGÜL S: T006, T013
ORIVE G: S053
O'ROURKE M: **3445**
ORSSAUD C: 4623
ORSSAUD D: 3672
ORTYL-MARKIEWICZ R: T018
OSBORNE NN: F008, S071, **2241, 3724**
OSHITARI T: **S112**, 2651
OSMAN I: **2431**
OSTADIMOGHADDAM H: **F029, T007**, S021, T001
OTA S: S112
OYE B: F076
OZAKI M: 3425
OZGE G: T031, T049
OZGONUL C: T031
OZONE D: **F058**
PÄÄKKÖNEN A: 1676
PAANANEN RO: **S061, 4455**
PADGETT E: F063
PAETZOLD J: F034
PAIK JISUN: S113
PALACIN M: T105
PALLIKARIS A: F111, 4745
PALLOT C: **4473**
PÄLSSON S: 3454
PANFIL C: S050, S066, 4426
PAPADAKI H: F113, 4746
PAPANDREOU I: **F055, F097**
PAPAPANOS P: F020
PAPAVASILEIOU E: 4475
PAQUES M: **3241**, 2215
PARIDAENS D: 4246
PARIKAKIS E: **F101, S095**, F087, F095
PARK BJ: T040
PARK C: T026, T041
PARK H: T026
PARK J: **F035**, F049, T089
PARK SH: T008, T113
PARK YH: **F102**
PARRAT E: F106, 4472
PARROZZANI R: **4244**, 4442
PARRY NRA: T010
PARSA C: **2653**
PASCALE A: S008, 3256, 3475
PASCHALIDIS T: F092
PASDELOUP D: T064
PASHTAEV A: **4235**
PASHTAYEV NP: 4234
PASTOR JC: T066, T074, 1768
PASTOR IDOATE S: T066, T074, 1768
PASU S: **F074**
PASYECHNIKOVA N: 4634
PATEL SR: 3712
PATERNO JJ: **T072, 1765**
PATNAIK S: T071
PAVESIO C: 3446
PAWLOWSKA M: F090
PAWLOWSKI P: **F090, T055, 2645**
PEAN V: 3426
PEARCE I: **3532, 4262**
PEDERSEN L: F043
PENAUD B: **F053**
PENG XY: F028
PENK A: S026
PENNOS A: **S097, 1777**
PEOC'H M: S013, S039, S067, S072, S114, 1722, 1724, 1725, 2432, 4427, 4775
PEPONIS V: F087, F095, F101, S095
PERARD L: T054
PEREIRA AC: T103, **3671**, 3676

PEREIRA-SILVA P: 3476
 PERERA S: 3425
 PÉREZ D: S033, T099, T105, T106
 PEREZ GARCIA D: F088, S035
 PEREZ NAVARRO I: **F088, S035**, F031, F036, F063, S107, T098, T099
 PERLAT A: T054
 PERNEY P: T115
 PERPETUA C: F105, 3665
 PERRACHE C: S013, 1722, 1724, 1725
 PERRINI P: 4244
 PERRON MC: 4635
 PERROT JL: S057, S072, S114, 2432
 PETERS A: 1761
 PETERS S: 3718
 PETRAKI D: T110
 PETROPOULOS I: **F003, F070**, F059, **1713**
 PETROVIC A: 3642
 PETROVSKI G: **3253, 3751**, 1671, 3252
 PICAUD S: T095, **2623**
 PICCININI P: T004
 PIELEN A: **4263**
 PIERI E: T091
 PIETRUCHA-DUTCZAK M: S011, 3254
 PIIPPO N: 1675
 PILOTTO E: 4442
 PILSON Q: **4453**
 PINAZO-DURAN MD: F050
 PINHEIRO R: S050, S066, 4426
 PINILLA I: F036, S033, S035, T099
 PINILLA-CORTÉ L: 4253
 PINNA A: **S056**, F051
 PINOLI JC: S040, S069, S070, 4776
 PINTO LA: 4676
 PINTO M: T058, 2648
 PINTO-BONILLA I: **2832**
 PIORECKI N: F009
 PIPERNO S: 3645
 PIRANI V: 1643, 2251, 3654
 PIRVULESCU R: T045
 PISANI F: F006
 PISELLA P: T059, **2632**, 2646
 PISELLI S: S042, S067, 1722, 1724, 4427, 4778
 PLANCHER C: 4445
 PLEYER U: S074, **1644, 1742, 3621**, 2642
 PLONKA P: S106, 4247
 POCCIEJ W: S103
 PODBORACZYNSKA-JODKO K: T018
 POJDA-WILCZEK D: **T002, 2442**
 POLAKOWSKI P: T078, 1766
 POLGAR T: 1652
 POMMIER S: **F040**, F106, 4472
 POMORSKA M: T018
 PONTIKOGLOU C: F113, 4746
 PONZIN D: **3734**
 POPA CHERECHEANU A: **T045**
 POPOVIC Z: F026
 PORTALIER S: 3672
 PORTALIOU DM: **S119**, T037, **4448**, 1734
 POSADINU MA: S056
 POURJAVAN S: **4222**
 POURNARAS C: F003, F059, **1711, 2613, 3614, 3711, 4411**, 2412, 3611
 POURNARAS JA: **4214, 4414, 4415**
 POZDEYEVA N: **4234**
 PRAUSE J: S015, 1727, 4441, 4647
 PRÉVOST G: T057
 PRIMAVERA L: 1643
 PROENCA H: F105, 3665
 PRONGUÉ A: F011
 PROST M: T018
 PROST-MAGNIN O: F106, 4472
 PROULX S: 3433, 4635
 PRUSAKIEWICZ J: F056
 PRZYBYŁOWSKA-SYGUT K: T076
 PUCHE N: **1714**

PURSLOW C: **S048, 2672, 2831**
 QIU K: F034
 QU L: **4474**
 QUAH X: S115, 4447
 QUENDERA B: T103, **2445**, 3671, 3676
 QUINONES M: S109
 QURESHI F: 3647
 RÆDER S: S045, S047
 RAIMONDI M: T004
 RAIVIO V: 4242
 RAJAIYA J: **2644**
 RAKONCZAY Z: F001
 RAMASAMY P: 3445
 RAMBAUD C: S020, S024, S036, S094
 RAMIREZ AI: **S006**, T108, 1673, 2245, 2424, 3675
 RAMIREZ JM: S006, T108, 1673, 2245, 2424, 3675
 RAMKE M: 2644
 RAMM L: 3718
 RAMOA R: 4645
 RAMONT L: F103
 RANDON T: S043
 RANNOU K: **S069**, S031, S040, 2436, 4776
 RANTAMÄKI AH: S061, 4455
 RATTUNDE U: **S027**
 RAZAKANDRAINIBE R: 4421
 RECALDE S: 1764
 REICHENBACH A: S026, S027, S028, **2242**
 REINA M: T051, 1735
 REINISALO M: S012, 3255
 REIS A: 2445
 REITSAMER HA: 3431
 REKAS M: T018
 RELPH J: S005
 REMEIJER L: 4733
 REMOND A: **T095**
 RENARD JP: F023, T034, T036, T038, T039, T044, 3232
 RENDU I: F021
 RESCH M: S032, 2437
 RESZEC J: F090, T055, 2645
 REVOL C: 3441
 RHIM WI: F025
 RHO YJ: F057
 RIBEIRO L: 2445
 RICHT M: **S043**, S117
 RIESTRA ANAC: S053
 RIGAL-SASTOURNE JC: S020, S024, S036, S085, S094, **3234**
 RIGOLE H: T115
 RIIKONEN J: S009, 3257
 RIMENSBERGER PC: F003
 RITZ M: T088
 RIVA C: **3611**, 3614
 ROBERT PY: T062, 2647
 ROCHA DE SOUSA A: **3476**
 RODALLEC T: F096
 RODRIGO E: **T010**
 RODRIGUES M: 3645
 RODRIGUEZ A: S086
 RODRIGUEZ JR: 1764
 RODRIGUEZ NA: S018
 RODRIGUEZ-CALVO PP: T075
 RODRIGUEZ HERNANDEZ I: T066, T074, 1768
 ROEHRICH H: 2272
 ROJAS B: S006, T108, **2245**, 1673, 2424, 3675
 ROJAS J: T066, T074, 1768
 ROKICKI D: T018
 ROMANENKO DV: T090
 ROMANIUK W: T018
 ROMANOWSKA DIXON B: **S106**, S102, S103, **3641, 4247**
 ROMAN ROMAN S: 3645
 ROMBACH M: **4654**
 ROSE FRAJ: S055
 ROSE K: **1763**
 ROSÉN R: F026
 ROSENBAUM JT: 3444

ROSENBERG R: **T036**, T034, T039
 ROSSI P: S041, 4777
 ROUFAS A: S023
 ROULAND J: **T042**, T030, T033, T043, T044, T073
 ROUSSEAU A: T064, T077
 ROYER B: F011
 RUBERTO G: T004
 RUIZ HIDALGO I: **4666**
 RUIZ-PESINI E: T114
 RUNGE C: 3431
 RUSSO A: **F042**, F015
 RYABTSEVA ALLA: S091, 1776
 S A: 1672
 SAAB S: 2223
 SAADOUN D: T053, T054
 SAAKYAN S: **S104, S105, 4248, 4444**
 SAHANNE S: 4476
 SAHEL J: T095, T110, 2211, 2213, 2446, 2623
 SAIB N: **S020**
 SAID DG: 4773
 SAITTA A: 2252
 SAKER S: 4742
 SALAZAR JJ: S006, T108, 1673, 2245, 2424, 3675
 SALEH M: 1667, 1771
 SALEHI S: **4631**
 SALIK D: F110, **4667**, 4748
 SALINAS-NAVARRO M: S007, 2424, 3421
 SALMINEN A: 1675
 SAMUDRE S: **T022**
 SANCHEZ A: T099
 SANCHEZ MC: S075, S088
 SANDEMAN S: 4636
 SANTANDER-TRENTINI F: **F050**
 SANTOS A: T051, 1735, 3673, 3674
 SAORNIL ALVAREZ M: **S101**, S109, **4645**
 SAPIN V: 4423
 SARNA T: S106, 4247
 SARNICOLA E: S034
 SARNICOLA V: S034
 SAROSSY M: **T003**, T097, 2441
 SASTRE X: 3645, 4445
 SAUER A: T086, T088
 SAUER L: 3718
 SAUVAN L: T091
 SAWAMURA H: **T094, 2657**
 SCEMAMA TIMSIT C: **2213**
 SCHAEFFEL F: **2711**
 SCHALENBOURG A: **2745**, 3642, 3646
 SCHEIDEMANN-WESP U: 1772
 SCHERMAN D: 1764
 SCHIEFER J: F034
 SCHIEFER U: F034
 SCHLEICHER M: F061
 SCHLICHTENBREDE F: 3474
 SCHLICKEISER S: 2642
 SCHLINGEMANN R: **3531**
 SCHMETTERER L: F004, S052, T023, **2224, 2624, 2833, 3612, 4722**
 SCHMIDL D: S052, T023, **3713**
 SCHMIDT-ERFURTH U: F004
 SCHRADER S: 2674
 SCHRAGE N: S050, S066, 4426
 SCHROEDL F: 3431
 SCHULDT C: S027
 SCHULMEISTER K: S080
 SCHWARTZ C: 1667
 SCOTT ROBER: **3231**
 SECHE E: T059, 2646
 SEDAGHAT M: F029
 SEIDLER STANGOVA P: F093
 SEITZ B: **3631**, 4735
 SEKFALI R: T009
 SEKI T: **S058**
 SELTON J: 4674
 SEMOUN O: **2415**, 2413, 2414
 SENDON D: **S036**, S024, S094

ALL AUTHORS INDEX

- SENGELOEV H: S015, 1727
SENNLAUB F: **1755, 2753, 3211, 1754**
SEO SJ: **T021, T029**
SEONG GJ: T021
SERRANHO P: 2443
SEVE P: T054
SEVESTRE H: S064, 4458
SHAH P: **3221**
SHAHIDI AM: **3712**
SHARIFI F: T007
SHARKAWI E: **3745**
SHIGEYASU C: S044
SHIN J: **F086, F102**
SHIN MC: S019
SHIN SY: T008, T113
SHIODA S: S058
SHOAE-NIA K: F050
SHU X: **T071, F016**
SHUICHI Y: S120
SIDDIQUEI M: 4741
SIDNEY LE: **S055, 3251**
SINAVE D: **4424, 4761**
SIKORAV A: 2413, 2415
SILVA E: T103, 3671, 3676
SILVA N: **S029, T107, 2434**
SILVA R: **3471**
SILVA-GOMES R: 3476
SIMANTIRAKI D: F113, 4746
SIMÃO S: 3663
SIMONUTTI M: T095
SIMONYI S: 4454
SINGER S: 1772
SINHA D: **2273**
SIOULIS C: S081
SJÖDELL L: 3454
SJÖSTRAND J: **F026**
SKALICKA P: T070
SKARPHEDINSDOTTIR S: **F010**
SKOV L: S062, 4456
SKUP M: F076, F078, 3441
SKVARCIANYI I: S003
SLATKEVICIENE G: T102
SLIESORAITYTE I: **2446**
SMEDOWSKI A: **S011, S065, T050, S010, S017, S022, S049, S073, 1736, 3254, 4425**
SMETS RME: F014
SOBRADO-CALVO P: S007, 2243
SÖDERBERG P: S079, S080, **1775**
SOLANAS S: S018, S086
SOLDEVILA J: S088, S098
SONG W: F017
SORG R: F078
SOUBRANE G: **1614, 4216, 4531**
SOUJED E: F066, 2413, 2414, 2415
SOUSA A: S030, T107, 2433, 2435
SOUSA H: S030, 2435
SOZANSKI T: F009
SPALLONE L: T083
SPALTON DJ: 1773
SPEEG-SCHATZ C: T086, T088
SPILEERS W: **3461, 4664, 4761**
STACHON T: 4735
STACHS O: **4652**
STAHL A: **3216**
STALMANS I: 1661, 1732, 1733, 3473, 4424, 4676, 4763, 4764
STALMANS P: 4676
STAM L: 3424
STANA D: T045
STECH S: S003, S004
STECK J: 2652
STEFANSSON E: **3436, 3622, 3621**
STEMPER B: 4261, 4263
STENMAN G: 4647
STEPHAN S: **F047**
STERN ME: 4454
STEVENS A: **4221**
STEWART EA: **F075, 4742**
STIEGER K: 2652
STITT A: **2754**
STOJANOVIC A: S045
STORSBERG J: **4633**
STRANCAR J: S078
STRATOS E: F101, S095
STRELKAUSKAITE E: F024, S004
STROHMAIER C: 3431
STRUBLE C: **F056, S005**
STRUPAITE R: **F024**
SUFFEE N: S013, S039, 1722, 1725, 4775
SUGANO A: F114
SUGITANI M: T020
SUHLER E: 3444
SULLIVAN DA: **2675**
SUN X: F032
SUNARIC MEGEVAND G: **3225**
SURGUCH V: **3664**
SUTTON G: S023
SVELTO M: F006
SVOZILKOVA P: F093
SWIRE M: 3214
SYLVESTRE JP: F104
SZAFLIK J: T076, T078, 1762, 1766
SZALAI E: S010
SZATMARY G: **1652**
SZELAG A: F009, F013
SZENTMARY N: **4735, 3631**
SZUMNY A: F009
SZUMNY D: **F009, F013**
SZYMANEK K: T076
TADAYONI R: F065
TAEYOON LA: T096
TAHIR HJ: T010
TAHIRI H: **F012**
TAKEI A: T068
TALEBI ZADEH N: **S079, S080, 1775**
TÄLL M: 4242
TAMASAUSKAS A: T102
TAN D: 4434
TAN X: 4434
TANG J: T003
TARFAOUI N: T059, 2646
TARIGHT N: S064, 4458
TARKKA I: 1676
TARNAWSKA D: S017, S049, S065, S073, T050, 1736, 4425
TASSI F: T028
TASSIGNON MJ: **3451**
TATSKOV R: S105
TAWK M: T057
TAYLOR A: F061
TAYYARI F: 3712
TEN TUSSCHER M: **2451**
TERLUK M: 2272
TESTER A: F056
THEOCHARIS IP: **3662**
THERIAULT M: 3433
THIEME C: **2642**
THORNE J: **3441**
THORP TAS: 4432
THOUVENIN R: **S094, S024**
THULEAU A: 3645
THUMANN G: 1764
THURAU S: 3446
THURET G: S013, S031, S039, S040, S042, S057, S067, S069, S070, S072, S114, **1722, 1724, 1725, 2432, 2436, 4422, 4427, 4771, 4775, 4776, 4778**
THURET JY: 1724
TIAN J: T024
TIEULIE N: T054
TIFFET T: S040, 4776
TILLEUL J: 2413
TINELLI C: S087, T035
TING M: F055
TISSIER P: **T015**
TODD JT: T094, 2657
TODOROVA MG: T006, T013
TOKARZ P: T072, 1765
TOLD R: F004
TOLSTRUP ANDERSEN M: 4245
TONAEVA H: **4233**
TONG LMG: 4454
TONNELET R: S001
TOPOUZIS F: **2221**
TORNOVIST K: **3455**
TORO M: S063, 4457
TORRICELLI A: 2771
TORVINEN P: **T019**
TOSHIYUKI O: S120
TÓTH M: **1671**
TÓTH-MOLNÁR E: **F001**
TOUBEAU D: S041, 4771, 4777
TOUITOU V: T095, 3443
TRAVERSE A: S075
TRECOT F: **S001, S090, T085**
TRIVINO A: S006, T108, 1673, 2245, 2424, 3675
TRONE M: **S031, S042, S057, 2436, 4422, 4778**
TROSAN P: S038
TROST A: 3431
TRUFFER F: 3613, 3615
TRUSSART R: F104
TSAI A: **T047**
TSAKIRIS K: F020
TSIKA C: F113, **1662, 4746**
TSILIMBARIS M: **F113, F111, 4746, 1662, 4745**
TSIOTRA V: F095, F101
TUGAL-TUTKUN I: **3653**
TUIL E: T080
TUMAHAI P: 1667
TUNDIA N: **F076, F078, 3441**
TUNIK S: **S002**
TÜRKSEVER C: **T006, T013**
TURNBULL PR: 4452
TURUNEN J: **4242**
TUULONEN A: **2723**
TUUMINEN R: 4476
TZOURIO C: 1664, 4671
UTHEIM Ø: S045, S047
UTHEIM TP: S045, S047
UUSITALO H: **2773**
UUSITUPA M: T072, 1765
UZZAN J: **2416**
VAARWATER J: 4246
VADALA M: T109
VAIKOUSIS E: F080, F092
VALERO B: **T009, T087, 3232**
VALESOVA L: T070
VALGAEREN H: **4762**
VALIENTE-SORIANO FJ: S006, 1673, 2243, 2424, 3421
VALLET H: T054
VALTER K: 3644
VAN BERGEN T: **1733, 4763, 1661, 1732, 4424**
VAN CALSTER J: **F041, 2643**
VAN CAUWENBERGH C: T081
VAN DAM D: 4224
VAN DEN BERG T: **2633, 4254**
VANDENBERGHE R: T094, 2657
VAN DEN BIGGELAAR FJHM: 4733
VAN DEN OORD J: 4663
VAN DER LEIJ G: 4733
VANDERMEULEN J: **T104, 3677**
VANDERVEEN D: **3452**
VAN DE VELDE S: **1732, 4764**
VANDEWALLE E: 1661, 1732, 1733, 3473, 4424, 4676
VAN GINDERDEUREN R: **3643, 2643**
VAN HOUCKE J: F002
VAN HOVE I: F002
VAN IJCKEN WJF: 4246
VAN KEER K: **3473**

- VAN LOOVEREN J: **4765**
VAN MARION FW: 4733
VANNONI D: 4644
VAN ROOIJ J: 4733
VAN SCHIL K: **4766**
VASSEUR V: 2211, 2213, 2215
VASSO M: 4644
VATANDOUST S: T007
VÁZQUEZ N: S053
VENGLOVECZ V: F001
VERDIN H: T081
VERÉB Z: 1671
VERTICCHIO VERCELLIN A: **T035**
VICENTE A: T058, T107, **3673**, 2648, 3674
VIDAL-SANZ M: S006, S007, **2424**, 1673, 2243, 3421
VIE A: **F039**, F015
VIEIRA L: **S030, T051, T107**, S029, T058, **1735**, **2435**, 2433, 2434, 2648, 3673
VIENNET A: S025
VIGNAL R: T009, 3232
VILLAIN M: T115, 2654
VILLEGAS PEREZ MP: S006, **2243**, 1673, 2424
VINCENT AL: **2461**
VIREVIALLE C: F096
VIVAR-LLOPIS B: F050
VIZVARI E: F001
VOBMERBÄUMER U: 1772
VOIDE N: **T112, 3678**
VOLK HD: 2642
VON HOLSTEIN S: **3755**, 4647
VON LIVONIUS B: T111, 2658
VOTRUBA M: **T069, 1767**
VOTTONEN P: **1676**
VUJOSEVIC S: 4442
WADT K: 4441
WAHLBERG RAMSAY M: F060
WALCZAK A: T076
WALLACE G: **3753**
WALRAEDT S: T081
WANG N: 4747
WANG X: **3214**
WANG Y: F028, 4747
WASYLUK J: T018
WATANABE J: S058
WEBER M: F066
WEGENER A: **1772**
WEGLARZ B: S049
WEI B: 3666
WEI WB: F028
WEN L: S023
WERKMEISTER R: S052, **1612**
WESCHLER B: T053
WEYMOUTH A: 2441
WIEDEMANN P: S026, S027, S028
WIERZBOWSKA J: T018
WIJDH RJH: 4733
WILLEKENS K: **4676**, 3473
WILLERMAIN F: F110, T056, **1741**, 4748
WILLOUGHBY C: **3752**
WILSKA R: 4242
WILSON S: **2771**
WILSON SL: **1723**
WIRTH M: **S052**
WIRYASAPUTRA S: **F068**
WITTRUP-JENSEN K: 4262
WOLFF B: **2211**, 2213, 2215
WOLZT M: F004
WONG HT: T046
WONG T: T047, 3425, 3471
WONG W: **1752**
WONG TEN YUEN A: T097
WORMSTONE IM: 1773
WOSTIYN P: 4224
WU YK: T092, 2655
WYCISÅ O-GAWRON P: T002
WYLEGALA E: **S017, S049, S073**, S010, S065, T050, **1635, 3635**, 1736, 4425
XIROU T: F020, F080, F092, S119, **4213**, 4212, 4448
XU H: **2274, 2751**
XU JIE: 4747
XU L: F028, 4747
XU Q: S083
XU W: S009, 3257
XU YP: **T046**
YAHIAOUI S: 2475
YAKOUB-AGHA I: S043
YAMADA M: **S044**
YAMAMOTO H: T020
YAMAMOTO S: S112, 2651
YAMANE S: T020
YAMASHITA H: F114
YAN X: 3253
YANG SW: S113
YANG Y: 3446
YASUKAWA T: F058
YAVUZYIGITOGU S: 4246
YAZDANI N: S021
YEKTA AA: **S021, T001**, F029, T007
YEKTA R: S021, T001
YEOM M: F049
YEUNG A: **2234**
YIM H: S046
YIN Y: 4445
YIP L: T024, T025
YIP WLL: T046
YONG KYV: T046
YONG SQ: F068
YOO RM: T027
YOO YS: F102
YOSHIMURA N: F007
YOU J: **S023**
YOU Q: F028, 4747
YOUNIS S: F074
YOUSUF MA: 2644
YU S: T101
YU Z: **S080**, S079, 1775
YUBERO R: T108, 3675
YUGAY MARIA: **S091, 1776**
YUKIHIKO TAKAHASHI W: F019
YUM HR: **T008, T113**
YUNG Y: F086
YU-WAI-MAN P: **1651, 2261**
ZABADANI K: **F031, F063**, F036, F038, S033, S107, T098, T099
ZACHARIAE C: S062, 4456
ZAGORSKI Z: S059
ZAGUIA F: 4635
ZAHN G: 1733
ZAJICOVA A: S038
ZAKARIA N: **4767**
ZALESKA-ZMIJEWSKA A: T018
ZALIUNIENE D: T102
ZAMBARAKJI H: **4215**, 4475
ZANGERL B: 3264
ZANON-MORENO V: F050
ZAOUALI S: 3655
ZAWADA M: 4735
ZEITZ C: 3764
ZERBIB J: **2413**, 2415
ZETTERBERG M: 3454
ZHANG FF: F061
ZHANG S: **3212**
ZHAO C: F078
ZHAO G: **S083**, S084
ZHAO L: **3666**
ZHOU T: 3613
ZHOU X: 2644
ZINCZUK M: F090
ZMUDA M: S118, 4449
ZOGRAFOS L: **2741, 2744, 3642, 3741**
ZOZOLOU M: **F080, F092**

PRESENTING AUTHORS BY COUNTRY

Algeria.....	2
Australia.....	8
Austria.....	10
Belgium.....	34
Bulgaria.....	1
Cameroon.....	1
Canada.....	6
China.....	4
Croatia.....	1
Czech Republic.....	4
Denmark.....	13
Egypt.....	3
Finland.....	18
France.....	150
Germany.....	45
Greece.....	16
Hungary.....	4
Iceland.....	3
India.....	1
Iran.....	2
Ireland.....	5
Israel.....	1
Italy.....	22
Japan.....	11
Lebanon.....	2
Lithuania.....	5
Moldova.....	1
Morocco.....	1
Netherlands.....	9
New Zealand.....	2
Norway.....	1
Poland.....	19
Portugal.....	14
Romania.....	1
Russia.....	12
Saudi Arabia.....	2
Singapore.....	9
Slovenia.....	1
South Korea.....	26
Spain.....	35
Sweden.....	13
Switzerland.....	25
Tunisia.....	2
Turkey.....	2
Ukraine.....	2
United Kingdom.....	58
United States.....	30

Wednesday, October 1, 2014

	HERMES	RHODES 1	RHODES 2	RHODES 3	RHODES 4	GALLIENI 1&2	GALLIENI 5
12:30 - 13:25	Industry-sponsored lunchtime symposium						
13:30 - 15:00	RV: Retinal imaging Leopold SCHMETTERER	PO: Don't panic: a survival course in statistics Tero KIVELÄ	COS: Corneal Dystrophies – from molecular basis to therapeutic approach Edward WYLEGALA Anna NOWINSKA	IM: EBO course: Intraocular inflammation and infection (Part I) Bahram BODAGHI Carl P HERBERT	NSPH: Differential diagnosis and evaluation of acute optic neuropathies and other neuro-ophthalmic causes of acute visual loss Gabriella SZATMARY Aki KAWASAKI	RV 1/6 : Cell biology and macular pigment in AMD Anita LEYS Carl ARNDT	ACB 1/2 : Retinal and glial cell biology Goran PETROVSKI Beatriz I GALLEGO
15:10 - 15:20	Welcome by the President EVER 2014 - Constantin POURNARAS						
15:20 - 15:30	EVER's highlights - Harminder S DUA and Leopold SCHMETTERER						
15:30 - 15:55	EVER Past-President Lecture: AIDS thirty years later, lessons from a pandemic - Philippe KESTELYN						
16:00 - 17:30	RV: Retinal vein occlusion: treatments in 2014 Constantin POURNARAS Agnès GIACET-BERNARD	COS 1/5: Corneal bioengineering Andrew HOPKINSON Gilles THURET	G 1/2 : Surgery Alain BRON K. Sheng LIM	IM: EBO course: Intraocular inflammation and infection (Part II) Bahram BODAGHI Carl P HERBERT	PBP: The role of mononuclear phagocytes in age related macular degeneration (AMD) Florian SENNLAUB	MBGE 1/1 Marzena GAJECKA Marcela VOTRUBA	LC 1/1 Deborah VANDERVEEN AIFNYSTROM
17:40 - 18:15	European Ophthalmology Heritage Lecture: Eye and genes: the new ophthalmology - Daniel SCHORDERET						
18:15 - 19:00	EVER-Acta Lecture: Regulating the body clock – The unrecognised role of the eye - Russell G FOSTER						
19:00 - 21:00	EVER Welcome Reception						

Thursday, October 2, 2014

	Industry-sponsored breakfast: Horus and Innovation						
07:30 - 08:30	Industry-sponsored breakfast: Horus and Innovation						
08:30 - 10:00	RV: Contribution of "en face" SD-OCT in retinal and choroidal pathologies Martine MAUGET-FAYASSE Constantin POURNARAS	G: Ocular blood flow and glaucoma Gerhard GARHOFER Leopold SCHMETTERER	COS: Corneal infectious diseases Jean-Jacques GICQUEL	PBP: Retinal glia in the healthy and unhealthy retina Neville OSBORNE Manuel VIDAL-SANZ	IM: Future of vitreoretinal Surgery in uveitis-diagnosis and management: the next steps Piergiorgio NERI	NSPH: Neuromyelitis optica (NMO) : the expanding spectrum of antibody-mediated optic neuropathy Aki KAWASAKI Jerôme DE SEZE	ACB: Inflammation in the pathogenesis of AMD - Ten years anniversary for EVER RPE SIS Kai KAARNIRANTA Hannu UUSTALO
10:15 - 11:00	Keynote Lecture: Testing vision: one cone at a time - Austin ROORDA						
11:05 - 12:35	Polypoidal choroidal vasculopathies Gabriel COSCAS Constantin POURNARAS	G: Autoimmune mechanisms and neuroinflammation in glaucoma Franz GRUS	COS 2/5 : Corneal Imaging Jean-Jacques GICQUEL	EOVS 1/1 : Visual function and physiology Miguel CASTELO-BRANCO Werner SPILLEERS	NSPH: New developments in paediatric strabismus and amblyopia Marcel TEN TUSSCHER Jonathan M. HOLMES	MBGE: The genetics of keratoconus Petra LISKOVA	ACB: You don't always need a knife ... - scleral lenses in ocular surface disease Nadja KNOP Rene MELY
12:35 - 13:30	Industry-sponsored lunchtime symposium: What's new in micronutrition for AMD patients? - Jean François KOROBELENIK						
13:35 - 14:15	Ophthalmic Research Lecture: Revisiting infectious triggers of chronic intraocular immunity - Bahram BODAGHI						
14:20 - 15:50	RV: Diabetic retinopathy Catherine CREUZOT Pascale MASSIN	G: Neuroprotection in European glaucoma M Francesca CORDEIRO Miriam KOLKO	COS: Why do you need wavefront aberrometry and straylight measurement in your daily practice? Jean-Jacques GICQUEL Pierre Jean PSELLA	IM 1/2 : Advances in pathophysiology and diagnostics of ocular inflammatory diseases Ahmed ABU EL-ASRAR Heping XU	NSPH 1/2 - Pediatric session Dominique BREMOND-GIGNAC Cameron PARSA	MBGE: Clinical & molecular aspects of albinism Bart LEROY Benoit ARVEILLER	ACB: When the oil runs dry - Innovative treatment options for MGD Erich KNOP David A. SULLIVAN
15:50 - 16:30	Poster session 1: Electrophysiology-physiological Optics-Vision Sciences; Glaucoma; Immunology / Microbiology; Molecular Biology / Genetics-Epidemiology; Neuro-ophthalmology / Paediatric Ophthalmology / History of Ophthalmology						
16:30 - 18:00	RV/EOS: Myopia and pathological Myopia - etiology and therapeutic approaches Mike FRANGKE	G: Alternatives to the face-to-face glaucoma specialist consultation Aachal KOTEGHA	COS: New advances in amniotic membrane transplantation Jean-Jacques GICQUEL Harminder S DUA	PO: Radiotherapy in ophthalmology Leonidas ZOGRAFOS Laurence DESJARDINS	IM: Inflammation and retinal angiogenesis Heping XU Ahmed ABU EL-ASRAR	MBGE: Grand rounds in ophthalmic genetics Bart LEROY Christian HAMEL	ACB: Wound healing in health and disease Hannu UUSTALO Roger BEURMAN
18:00 - 19:30	Industry-sponsored evening symposium: What's new in ocular surface disorders? - Leopold SCHMETTERER						

	HERMES	RHODES 1	RHODES 2	RHODES 3	RHODES 4	GALLIENI 1 & 2	GALLIENI 5
Friday, October 3, 2014							
08:30 - 10:00	RV: VEGF antagonists and other sub-specialties: wet lab, virtual reality, and novel technology Andrew MCNAUGHT Gordana SUNARIC MEGEVAND	G: Surgical training in glaucoma, and other sub-specialties: wet lab, virtual reality, and novel technology Andrew MCNAUGHT Gordana SUNARIC MEGEVAND	COS: Ophthalmology in war zones Hermann GÜMBEL Robert SCOTT	PO: Animal models in eye research Martine J. JAGER Nathalie CASSOUX	ACB 2/2 : Corneal and retinal cell biology Goran PETROVSKI Saeed AKHTAR	MBGE: The retinal pigment epithelium in retinal dystrophies Bart LEROY Isabelle MEUNIER	NSPH: Innovation in ocular allergy: pediatric features Dominique BREMOND-GIGNAC Jean-Luc FAUQUERT
10:10 - 10:55	Keynote Lecture: New therapeutic approaches and challenges for the treatment of dry eye disease - David SULLIVAN	G 2/2: Vision & Clinical research	COS: New approaches for unmet needs in ophthalmology Thomas FUCHSLUGER Einar STEFANSSON Antonia JOUSSEN	IM 2/2 : Challenges in uveitis Morcef KHAIRALLAH Andrew DICK	LC/NSPH: Pediatric cataract surgery Stefan LÖFGREN	EOVS: Doctor, I see things that aren't there Graham HOLDER	Hermes PPB 1/1 : Choroidal neovascularisation, optic nerve and diabetic retinopathy Neville OSBORNE Leopold SCHMETTERER
11:00 - 12:30	RV: Drug retinal toxicity Andrzej GRZYBOWSKI Francisco ASCASO	Sajeh POURJAVAN Aachal KOTECHA	COS: Corneal dystrophy & laser keratoplasty: updates Berthold SEITZ Philippe KESTELYN Keith BARATZ	PO: OOG - Ocular Oncology Group 1 Tero KIVELÄ Emine KILIC	IM: The precarious notion of disease phenotype in inflammatory eye conditions Piergiorgio NERI Carl P. HERBORT		Rhodes 2 NSPH 2/2 Francis-Xavier BORRUAT Miguel CASTELO-BRANCO
12:35 - 13:30	Industry-sponsored lunchtime symposium: Aflibercept: Setting its sight on DME - Reinier SCHLINGEMANN, Ian PEARCE, Jean François KOROBELNIK	General: How to get your research published?	COS: Strategies in cornea & ocular surface to improve vision Diego PONZIN Claus CURSIEFFEN Hariminder S. DUA	Business meeting PO Laurence DESJARDINS Leonidas ZOGRAFOS	Business meeting IM / NSPH ARVO @ EVER : Snapshot of what's new in ocular anatomy and pathology Sarah COUPLAND Steffen HEEGAARD	Business meeting ACB	Business meeting MBGE
13:30 - 15:00	RV: Recent developments in laser Doppler flowmetry Christophe CHUQUET Constantin POURNARAS	Uwe PLEYER	Business meeting COS / LC Glaucoma, what should we look at: vitamins, lipids, light? Alain BRON Gordana SUNARIC MEGEVAND	PO: OOG - Ocular Oncology Group 2 Laurence DESJARDINS Eduardo MIDENA	Business meeting IM / NSPH ARVO @ EVER : Snapshot of what's new in ocular anatomy and pathology Sarah COUPLAND Steffen HEEGAARD	RV 2/6 : Retinal surgery Yannick LE MER Catherine CREUZOT	NSPH: The hidden history of ophthalmology from the 16 to the 20 century Andrzej GRZYBOWSKI Francisco ASCASO
15:05 - 15:45	Poster session 2: Physiology / Biochemistry / Pharmacology: Retina / Vitreous						
15:45 - 16:25	Business meeting PPB / RV	Business meeting EOVS / G	Business meeting COS / LC	Business meeting PO	Business meeting IM / NSPH	Business meeting ACB	Business meeting MBGE
16:30 - 18:00	RV: Retinal oximetry Einar STEFANSSON Constantin POURNARAS	Glaucoma, what should we look at: vitamins, lipids, light? Alain BRON Gordana SUNARIC MEGEVAND	COS: Strategies in cornea & ocular surface to improve vision Diego PONZIN Claus CURSIEFFEN Hariminder S. DUA	PO: OOG - Ocular Oncology Group 1 Tero KIVELÄ Emine KILIC	Business meeting IM / NSPH ARVO @ EVER : Snapshot of what's new in ocular anatomy and pathology Sarah COUPLAND Steffen HEEGAARD	MBGE: Retinal gene therapy: an update Bart LEROY Isabelle AUO	NSPH: The hidden history of ophthalmology from the 16 to the 20 century Andrzej GRZYBOWSKI Francisco ASCASO
20:00 - 23:00	Congress dinner: in Negresco - Registration required						
Saturday, October 4, 2014							
08:30 - 10:00	RV: Myopic macular disease Hadi ZAMBARAKJI Tina XROU	G: Glaucoma progression despite good pressure control Sajeh POURJAVAN Aachal KOTECHA	COS: S.Fyodorov Eye Microsurgery Complex symposium: new trends in corneal transplantation Boris MALYUGIN Zhiqida MOROZ	PO: OOG - Ocular Oncology Group 1 Tero KIVELÄ Emine KILIC	LC: Optical effects of cataracts Ralph MICHAEL Rafael I. BARRAQUER	RV 3/6 : Vein occlusion Jost B. JONAS Stephanie BAILLIF	quartett diagnostica Research Award Session Thomas FUCHSLUGER Jean-Jacques GICQUEL
10:15 - 10:55	Keynote Lecture: Lessons learned from gene therapy for color blindness in primates - Jay MEITZ	Keynote Lecture: Lessons learned from gene therapy for color blindness in primates - Jay MEITZ	COS: Keratoprosthesis I Christopher LIU Jodhbir Singh MEHTA Thomas FUCHSLUGER	PO: OOG - Ocular Oncology Group 2 Laurence DESJARDINS Eduardo MIDENA	COS 4/5 : Ocular surface inflammation Dominique BREMOND-GIGNAC Jennifer CRAIG	NSPH: Examination of eye movements and common peripheral and central oculomotority disorders Francis-Xavier BORRUAT Pierre-François KAESER	Hermes RV 4/6 : Diabetes Pascale MASSIN Stephanie BAILLIF
11:00 - 12:30	RV: Vitreoretinal interface disorders Jean - Antoine C POURNARAS Yannick LE MER	COS 3/5 : Corneal infections and wound healing Philippe KESTELYN Marc MURARINE	COS: Keratoprosthesis II: Artificial Corneas May GRIFITH Thomas FUCHSLUGER Christopher LIU	PO: OOG - Ocular Oncology Group 3 Francis MUNIER Maria Antonia SAORNIL ALVAREZ	LC: Accommodation Rafael I. BARRAQUER Ralph MICHAEL		Rhodes 2 Rhodes 3
12:35 - 13:30	Industry-sponsored lunchtime symposium: Changing Perspectives in DME: Recognising & Understanding Chronic DME	Industry-sponsored lunchtime symposium: Changing Perspectives in DME: Recognising & Understanding Chronic DME	EEBA symposium: Innovative approaches in the treatment of corneal & ocular surface diseases Rudy NUIJTS Vincent BORDERIE	RV 6/6 : Cell biology and physiology in retinal disease Ahmed ABU EL ASRAR Catherine CREUZOT	LC: Controversies on antibiotic use in ocular surgery Andrzej GRZYBOWSKI Rafael I. BARRAQUER	RV 5/6 : Vitreo macular interface Jean François KOROBELNIK Constantin POURNARAS	COS 5/5 : Corneal grafting Marc MURARINE Mohamed GOWEIDA
12:35 - 13:30	PO: OOG : Business meeting: Sarah COUPLAND, Nathalie CASSOUX	NSPH: What's new in visual development and binocular vision Dominique BREMOND-GIGNAC Stefan LÖFGREN	EEBA symposium: Innovative approaches in the treatment of corneal & ocular surface diseases Rudy NUIJTS Vincent BORDERIE	RV 6/6 : Cell biology and physiology in retinal disease Ahmed ABU EL ASRAR Catherine CREUZOT	LC: Accommodation Rafael I. BARRAQUER Ralph MICHAEL	RV 5/6 : Vitreo macular interface Jean François KOROBELNIK Constantin POURNARAS	COS 5/5 : Corneal grafting Marc MURARINE Mohamed GOWEIDA
13:35 - 15:05	RV: FAN : Fluorescein Angiography Club 1 Mary VAN SCHOONEVELD	NSPH: What's new in visual development and binocular vision Dominique BREMOND-GIGNAC Stefan LÖFGREN	EEBA symposium: Innovative approaches in the treatment of corneal & ocular surface diseases Rudy NUIJTS Vincent BORDERIE	RV 6/6 : Cell biology and physiology in retinal disease Ahmed ABU EL ASRAR Catherine CREUZOT	LC: Accommodation Rafael I. BARRAQUER Ralph MICHAEL	RV 5/6 : Vitreo macular interface Jean François KOROBELNIK Constantin POURNARAS	COS 5/5 : Corneal grafting Marc MURARINE Mohamed GOWEIDA
15:10 - 15:50	Poster session 3: Anatomy-Cell Biology/Cornea-Ocular Surface / Lens and Cataract / Pathology-Oncology						
16:00 - 17:30	RV: FAN : Fluorescein Angiography Club 2 Mary VAN SCHOONEVELD	G: Aspects in the pathogenesis of glaucomatous optic neuropathy Jost B. JONAS	EEBA symposium: Innovative approaches in the treatment of corneal & ocular surface diseases Rudy NUIJTS Vincent BORDERIE	RV 6/6 : Cell biology and physiology in retinal disease Ahmed ABU EL ASRAR Catherine CREUZOT	LC: Controversies on antibiotic use in ocular surgery Andrzej GRZYBOWSKI Rafael I. BARRAQUER	RV 5/6 : Vitreo macular interface Jean François KOROBELNIK Constantin POURNARAS	COS 5/5 : Corneal grafting Marc MURARINE Mohamed GOWEIDA
17:45 - 19:15	EVER General Assembly and Prize Giving						Hermes

SPONSORS AND EXHIBITORS

EVER would like to thank all of its past and present sponsors. We would especially like to thank the following companies, many of which are our long-term supporters, for their generous sponsorship in 2014. Thanks to their kind support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

MAIN



MAJOR



CIS



SIS



EXHIBITORS



MARKETING



NON PROFIT

